US20100076280A1 - Health Monitor - Google Patents
Health Monitor Download PDFInfo
- Publication number
- US20100076280A1 US20100076280A1 US12/628,201 US62820109A US2010076280A1 US 20100076280 A1 US20100076280 A1 US 20100076280A1 US 62820109 A US62820109 A US 62820109A US 2010076280 A1 US2010076280 A1 US 2010076280A1
- Authority
- US
- United States
- Prior art keywords
- data
- analyte
- sensor
- analyte level
- transfer module
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
- A61B5/002—Monitoring the patient using a local or closed circuit, e.g. in a room or building
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
- A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1495—Calibrating or testing of in-vivo probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0223—Operational features of calibration, e.g. protocols for calibrating sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0266—Operational features for monitoring or limiting apparatus function
- A61B2560/0276—Determining malfunction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/04—Constructional details of apparatus
- A61B2560/0443—Modular apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/04—Constructional details of apparatus
- A61B2560/0443—Modular apparatus
- A61B2560/045—Modular apparatus with a separable interface unit, e.g. for communication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/04—Constructional details of apparatus
- A61B2560/0456—Apparatus provided with a docking unit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/04—Constructional details of apparatus
- A61B2560/0475—Special features of memory means, e.g. removable memory cards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
- A61B5/0017—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system transmitting optical signals
Definitions
- the detection of the level of analytes, such as glucose, lactate, oxygen, and the like, in certain individuals is vitally important to their health.
- the monitoring of glucose is particularly important to individuals with diabetes.
- Diabetics may need to monitor glucose levels to determine when insulin is needed to reduce glucose levels in their bodies or when additional glucose is needed to raise the level of glucose in their bodies.
- Embodiments include enhanced in vitro analyte meters and systems which are enhanced with in vivo continuous analyte monitoring functionality.
- the descriptions herein describe in vitro analyte glucose meters primarily as in vitro blood glucose (“BG”) meters and in vivo continuous analyte system primarily as in vivo continuous glucose (“CG”) monitoring devices and systems, for convenience only. Such descriptions are in no way intended to limit the scope of the disclosure in any way.
- BG meters and systems having high levels of functionality are provided.
- Each BG or CG system may accept and process data from its own respective system and/or from another system, e.g., a BG system may accept and process CG system data, or vice versa.
- Embodiments enable CG data to be provided to a user by way of a BG meter.
- Embodiments may be useful to users who may require conventional blood glucose BG data most of the time, but who may have a periodic need for CG data.
- One way this problem has been addressed in the past is to provide the user with both a BG meter and a CG system.
- this has the disadvantage of cost because a CG system may be more expensive than a BG meter, and increased training as the user must learn how to use two meters a BG meter for normal use and a CG meter for those times when CG data is required.
- Embodiments herein may be appropriate for Type I and Type II diabetics, other patients experiencing diabetic conditions, or patients in post surgery recovery period.
- FIG. 1 shows a block diagram of an embodiment of a data monitoring and management system according to the present disclosure
- FIG. 2 shows a block diagram of an embodiment of the transmitter unit of the data monitoring and management system of FIG. 1 ;
- FIG. 3 shows a block diagram of an embodiment of the receiver/monitor unit of the data monitoring and management system of FIG. 1 ;
- FIG. 4 shows a schematic diagram of an embodiment of an analyte sensor according to the present disclosure
- FIGS. 5A-5B show a perspective view and a cross sectional view, respectively of another embodiment an analyte sensor
- FIG. 6 shows an exemplary embodiment of a system that includes a CG Data Logger (for example, including a data storage device or memory) and an enhanced BG meter, in which the CG Data Logger is capable of transferring CG data obtained by a CG analyte sensor positioned at least partially beneath a skin surface of a user to the enhanced BG meter;
- a CG Data Logger for example, including a data storage device or memory
- an enhanced BG meter in which the CG Data Logger is capable of transferring CG data obtained by a CG analyte sensor positioned at least partially beneath a skin surface of a user to the enhanced BG meter;
- FIG. 7 shows an exemplary embodiment of a Modular System that includes a CG unit having a transmitter, data transfer module and enhanced BG meter, in which the CG unit is capable of wirelessly transferring data obtained by a CG analyte sensor positioned at least partially beneath a skin surface of a user to the enhanced BG meter by way of the data transfer module;
- FIG. 8 shows an exemplary embodiment of an integrated system that includes an enhanced BG meter and a CG unit having a transmitter, in which the CG unit is capable of transferring CG data obtained by a CG analyte sensor positioned at least partially beneath a skin surface of a user to the enhanced BG meter in real time;
- FIG. 9 shows an exemplary embodiment of a system which includes a BG meter and a docking unit, herein shown configured as a belt holster;
- FIGS. 10A-10C show exemplary embodiments of glucose test strips that may be used with the enhanced systems described herein;
- FIGS. 11A-11C show exemplary BG meters.
- Embodiments include devices which allow diabetic patients to measure the blood (or other bodily fluid) glucose levels, e.g., hand-held electronic meters (blood glucose meters), e.g., such as Freestyle® or Precision® blood glucose monitoring systems available from Abbott Diabetes Care, Inc., of Alameda, Calif. (and the like) which receives blood samples via enzyme-based test strips.
- blood glucose meters e.g., hand-held electronic meters
- a test strip into a meter and lances a finger or alternate body site to obtain a blood sample.
- the drawn sample is applied to the test strip and the meter reads the strip and determines analyte concentration, which is then conveyed to the user.
- the blood glucose meter converts a current generated by the enzymatic reaction in the test strip to a corresponding blood glucose value which is displayed or otherwise provided to the patient to show the level of glucose at the time of testing.
- Test strips may be adapted to measure the concentration of an analyte in any volume of sample, including but not limited to small volumes of sample, e.g., about 1 microliter or less sample, for example about 0.5 microliters or less, for example about 0.3 microliters or less, for example about 0.1 microliters or less.
- the volume of sample may be as low as about 0.05 microliters or as low as about 0.03 microliters.
- Strips may be configures so that an accurate analyte measurement may be obtained using a volume of sample that wholly or partially fills a sample chamber of a strip.
- a test may only start when sufficient sample has been applied to a strip, e.g., as detected by a detector such as an electrode.
- a system may be programmed to allow re-application of additional sample if insufficient sample is firstly applied, e.g., the time to reapply sample may range from about 10 seconds to about 2 minutes, e.g., from about 30 seconds to about 60 seconds.
- Test strips may be side fill, front fill, top fill or corner fill, or any combination thereof.
- Test strips may be calibration-free, e.g., minimal input (if any) is required of a user to calibrate. In certain embodiments, no calibration test strips may be employed. In such embodiments, the user need not take any action for calibration, i.e., calibration is invisible to a user.
- meters may be integrated meters, i.e., a device which has at least one strip and at least a second element, such as a meter and/or a skin piercing element such as a lancet or the like, in the device.
- a strip may be integrated with both a meter and a lancet, e.g., in a single housing. Having multiple elements together in one device reduces the number of devices needed to obtain an analyte level and facilitates the sampling process.
- embodiments may include a housing that includes one or more analyte test strips, a skin piercing element and a processor for determining the concentration of an analyte in a sample applied to the strip.
- a plurality of strips may be retained in a magazine in the housing interior and, upon actuation by a user, a single strip may be dispensed from the magazine so that at least a portion extends out of the housing for use.
- Test strips may be short test time test strips.
- test times may range from about 1 second to about 20 seconds, e.g., from about 3 seconds to about 10 seconds, e.g., from about 3 seconds to about 7 seconds, e.g., about 5 seconds or about 3 seconds.
- FIGS. 10A-10C and 11 A- 11 C Exemplary meters and test strips and using the same are shown in FIGS. 10A-10C and 11 A- 11 C.
- Embodiments include analyte monitoring devices and systems that include an analyte sensor—at least a portion of which is positionable beneath the skin of the user—for the in vivo detection, of at least one analyte, such as glucose, lactate, and the like, in a body fluid.
- analyte sensor at least a portion of which is positionable beneath the skin of the user—for the in vivo detection, of at least one analyte, such as glucose, lactate, and the like, in a body fluid.
- Such in vivo sensors are generally referred to herein as in vivo sensors/systems and/or continuous sensors/systems, where such are used interchangeably unless indicated otherwise.
- Embodiments include wholly implantable analyte sensors and analyte sensors in which only a portion of the sensor is positioned under the skin and a portion of the sensor resides above the skin, e.g., for contact to a transmitter, receiver, transceiver, processor,
- the sensor may be, for example, subcutaneously positionable in a patient for the continuous or periodic monitoring of a level of an analyte in a patient's interstitial fluid.
- continuous monitoring and periodic monitoring will be used interchangeably, unless noted otherwise.
- the sensor response may be correlated and/or converted to analyte levels in blood or other fluids.
- an analyte sensor may be positioned in contact with interstitial fluid to detect the level of glucose, which detected glucose may be used to infer the glucose level in the patient's bloodstream.
- Analyte sensors may be insertable into a vein, artery, or other portion of the body containing fluid.
- Embodiments of the analyte sensors of the subject disclosure may be configured for monitoring the level of the analyte over a time period which may range from minutes, hours, days, weeks, or longer. Analyte sensors that do not require contact with bodily fluid are also contemplated.
- analyte sensors such as glucose sensors, that are capable of in vivo detection of an analyte for about one hour or more, e.g., about a few hours or more, e.g., about a few days of more, e.g., about three or more days, e.g., about five days or more, e.g., about seven days or more, e.g., about several weeks or at least one month.
- Future analyte levels may be predicted based on information obtained, e.g., the current analyte level at time t 0 , the rate of change of the analyte, etc.
- Predictive alarms may notify the user of a predicted analyte levels that may be of concern in advance of the user's analyte level reaching the future level. This provides the user an opportunity to take corrective action.
- FIG. 1 shows a data monitoring and management system such as, for example, an analyte (e.g., glucose) monitoring system 100 in accordance with certain embodiments.
- an analyte e.g., glucose
- FIG. 1 shows a data monitoring and management system such as, for example, an analyte (e.g., glucose) monitoring system 100 in accordance with certain embodiments.
- analyte e.g., glucose
- the analyte monitoring system may be configured to monitor a variety of analytes at the same time or at different times.
- Analytes that may be monitored include, but are not limited to, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, creatinine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketone bodies, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin.
- concentration of drugs such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be monitored. In those embodiments that monitor more than one analyte, the analytes may be monitored at the same or different times.
- the analyte monitoring system 100 includes a sensor 101 , a data processing unit 102 connectable to the sensor 101 , and a primary receiver unit 104 which is configured to communicate with the data processing unit 102 via a communication link 103 .
- the primary receiver unit 104 may be further configured to transmit data to a data processing terminal 105 to evaluate or otherwise process or format data received by the primary receiver unit 104 .
- the data processing terminal 105 may be configured to receive data directly from the data processing unit 102 via a communication link which may optionally be configured for bi-directional communication.
- the data processing unit 102 may include a transmitter or a transceiver to transmit and/or receive data to and/or from the primary receiver unit 104 and/or the data processing terminal 105 and/or optionally the secondary receiver unit 106 .
- an optional secondary receiver unit 106 which is operatively coupled to the communication link and configured to receive data transmitted from the data processing unit 102 .
- the secondary receiver unit 106 may be configured to communicate with the primary receiver unit 104 , as well as the data processing terminal 105 .
- the secondary receiver unit 106 may be configured for bi-directional wireless communication with each of the primary receiver unit 104 and the data processing terminal 105 .
- the secondary receiver unit 106 may be a de-featured receiver as compared to the primary receiver, i.e., the secondary receiver may include a limited or minimal number of functions and features as compared with the primary receiver unit 104 .
- the secondary receiver unit 106 may include a smaller (in one or more, including all, dimensions), compact housing or embodied in a device such as a wrist watch, arm band, etc., for example.
- the secondary receiver unit 106 may be configured with the same or substantially similar functions and features as the primary receiver unit 104 .
- the secondary receiver unit 106 may include a docking portion to be mated with a docking cradle unit for placement by, e.g., the bedside for night time monitoring, and/or a bi-directional communication device.
- a docking cradle may recharge a powers supply.
- the analyte monitoring system 100 may include more than one sensor 101 and/or more than one data processing unit 102 , and/or more than one data processing terminal 105 .
- Multiple sensors may be positioned in a patient for analyte monitoring at the same or different times.
- analyte information obtained by a first positioned sensor may be employed as a comparison to analyte information obtained by a second sensor. This may be useful to confirm or validate analyte information obtained from one or both of the sensors. Such redundancy may be useful if analyte information is contemplated in critical therapy-related decisions.
- a first sensor may be used to calibrate a second sensor.
- the analyte monitoring system 100 may be a continuous monitoring system, or semi-continuous, or a discrete monitoring system.
- each component may be configured to be uniquely identified by one or more of the other components in the system so that communication conflict may be readily resolved between the various components within the analyte monitoring system 100 .
- unique IDs, communication channels, and the like may be used.
- the senor 101 is physically positioned in or on the body of a user whose analyte level is being monitored.
- the sensor 101 may be configured to at least periodically sample the analyte level of the user and convert the sampled analyte level into a corresponding signal for transmission by the data processing unit 102 .
- the data processing unit 102 is coupleable to the sensor 101 so that both devices are positioned in or on the user's body, with at least a portion of the analyte sensor 101 positioned transcutaneously.
- the data processing unit may include a fixation element such as adhesive or the like to secure it to the user's body.
- a mount (not shown) attachable to the user and mateable with the unit 102 may be used.
- a mount may include an adhesive surface.
- the data processing unit 102 performs data processing functions, where such functions may include but are not limited to, amplification, filtering and encoding of data signals, each of which corresponds to a sampled analyte level of the user, for transmission to the primary receiver unit 104 via the communication link 103 .
- the sensor 101 or the data processing unit 102 or a combined sensor/data processing unit may be wholly implantable under the skin layer of the user.
- the primary receiver unit 104 may include an analog interface section including an RF receiver and an antenna that is configured to communicate with the data processing unit 102 via the communication link 103 , and a data processing section for processing the received data from the data processing unit 102 such as data decoding, error detection and correction, data clock generation, data bit recovery, etc., or any combination thereof.
- the primary receiver unit 104 in certain embodiments is configured to synchronize with the data processing unit 102 to uniquely identify the data processing unit 102 , based on, for example, an identification information of the data processing unit 102 , and thereafter, to periodically receive signals transmitted from the data processing unit 102 associated with the monitored analyte levels detected by the sensor 101 .
- the data processing terminal 105 may include a personal computer, a portable computer such as a laptop or a handheld device (e.g., personal digital assistants (PDAs), telephone such as a cellular phone (e.g., a multimedia and Internet-enabled mobile phone such as an iPhone or similar phone), mp3 player, pager, and the like), drug delivery device, each of which may be configured for data communication with the receiver via a wired or a wireless connection. Additionally, the data processing terminal 105 may further be connected to a data network (not shown) for storing, retrieving, updating, and/or analyzing data corresponding to the detected analyte level of the user.
- a data network not shown
- the data processing terminal 105 may include an infusion device such as an insulin infusion pump or the like, which may be configured to administer insulin to patients, and which may be configured to communicate with the primary receiver unit 104 for receiving, among others, the measured analyte level.
- the primary receiver unit 104 may be configured to integrate an infusion device therein so that the primary receiver unit 104 is configured to administer insulin (or other appropriate drug) therapy to patients, for example, for administering and modifying basal profiles, as well as for determining appropriate boluses for administration based on, among others, the detected analyte levels received from the data processing unit 102 .
- An infusion device may be an external device or an internal device (wholly implantable in a user).
- the data processing terminal 105 which may include an insulin pump, may be configured to receive the analyte signals from the data processing unit 102 , and thus, incorporate the functions of the primary receiver unit 104 including data processing for managing the patient's insulin therapy and analyte monitoring.
- the communication link 103 as well as one or more of the other communication interfaces shown in FIG. 1 , may use one or more of: an RF communication protocol, an infrared communication protocol, a Bluetooth enabled communication protocol, an 802.11x wireless communication protocol, or an equivalent wireless communication protocol which would allow secure, wireless communication of several units (for example, per HIPPA requirements), while avoiding potential data collision and interference.
- FIG. 2 shows a block diagram of an embodiment of a data processing unit of the data monitoring and detection system shown in FIG. 1 .
- User input and/or interface components may be included or a data processing unit may be free of user input and/or interface components.
- one or more application-specific integrated circuits may be used to implement one or more functions or routines associated with the operations of the data processing unit (and/or receiver unit) using for example one or more state machines and buffers.
- the processor shown in FIG. 2 may be equipped with sufficient memory to store the data of interest (such as analyte data) for extended periods of time ranging from one to several samples to the number of samples obtained for an entire wear period of several days to weeks.
- the memory may be included as part of the processor 204 .
- a separate memory unit such as a memory chip, random access memory (RAM) or any other storage device for storing for subsequent retrieval data.
- the data processing unit may include a storage unit 215 operative coupled to the processor 204 , and configured to store the analyte data received, for example, from the sensor 101 ( FIG. 1 ).
- the storage unit 215 may be configured to store a large volume of data received over a predetermined time period from the sensor, and, the processor 204 may be configured to, for example, transmit the stored analyte sensor data in a batch mode, for example, after collecting and storing over a defined time period in a single or multiple data transmission.
- the processor 204 may be configured such that the received analyte sensor data is e transmitted in real time, when received from the analyte sensor.
- the processor 204 may be configured to anticipate or wait for a receipt confirmation signal from the recipient of the data transmission (for example, the receiver unit 104 FIG. 1 ), where when the signal receipt confirmation signal is not received, the processor 204 of the data processing unit 102 may be configured to retrieve the stored analyte sensor data and retransmit it to the receiver unit 104 , for example.
- the sensor unit 101 ( FIG. 1 ) includes four contacts, three of which are electrodes—work electrode (W) 210 , reference electrode (R) 212 , and counter electrode (C) 213 , each operatively coupled to the analog interface 201 of the data processing unit 102 .
- This embodiment also shows optional guard contact (G) 211 . Fewer or greater electrodes may be employed.
- the counter and reference electrode functions may be served by a single counter/reference electrode, there may be more than one working electrode and/or reference electrode and/or counter electrode, etc.
- FIG. 3 is a block diagram of an embodiment of a receiver/monitor unit such as the primary receiver unit 104 of the data monitoring and management system shown in FIG. 1 .
- the primary receiver unit 104 includes one or more of: a blood glucose test strip interface 301 , an RF receiver 302 , an input 303 , a temperature detection section 304 , and a clock 305 , each of which is operatively coupled to a processing and storage section 307 .
- the primary receiver unit 104 also includes a power supply 306 operatively coupled to a power conversion and monitoring section 308 . Further, the power conversion and monitoring section 308 is also coupled to the receiver processor 307 .
- a receiver serial communication section 309 and an output 310 , each operatively coupled to the processing and storage unit 307 .
- the receiver may include user input and/or interface components or may be free of user input and/or interface components.
- the test strip interface 301 includes a glucose level testing portion to receive a blood (or other body fluid sample) glucose test or information related thereto.
- the interface may include a test strip port to receive a glucose test strip.
- the device may determine the glucose level of the test strip, and optionally display (or otherwise notice) the glucose level on the output 310 of the primary receiver unit 104 .
- Any suitable test strip may be employed, e.g., test strips that only require a very small amount (e.g., one microliter or less, e.g., 0.5 microliter or less, e.g., 0.1 microliter or less), of applied sample to the strip in order to obtain accurate glucose information, e.g. FreeStyle® blood glucose test strips from Abbott Diabetes Care Inc.
- Glucose information obtained by the in vitro glucose testing device may be used for a variety of purposes, computations, etc.
- the information may be used to calibrate sensor 101 , confirm results of the sensor 101 to increase the confidence thereof (e.g., in instances in which information obtained by sensor 101 is employed in therapy related decisions), etc.
- the data processing unit 102 and/or the primary receiver unit 104 and/or the secondary receiver unit 105 , and/or the data processing terminal/infusion section 105 may be configured to receive the blood glucose value wirelessly over a communication link from, for example, a blood glucose meter.
- a user manipulating or using the analyte monitoring system 100 may manually input the blood glucose value using, for example, a user interface (for example, a keyboard, keypad, voice commands, and the like) incorporated in the one or more of the data processing unit 102 , the primary receiver unit 104 , secondary receiver unit 105 , or the data processing terminal/infusion section 105 .
- test strips, blood glucose (BG) meters and continuous monitoring systems and data management systems that may be employed are provided in but not limited to: U.S. Pat. No. 6,175,752; U.S. Pat. No. 6,560,471; U.S. Pat. No. 5,262,035; U.S. Pat. No. 6,881,551; U.S. Pat. No. 6,121,009; U.S. Pat. No. 7,167,818; U.S. Pat. No. 6,270,455; U.S. Pat. No. 6,161,095; U.S. Pat. No. 5,918,603; U.S. Pat. No. 6,144,837; U.S. Pat. No.
- FIG. 4 schematically shows an embodiment of an analyte sensor in accordance with the present disclosure.
- This sensor embodiment includes electrodes 401 , 402 and 403 on a base 404 .
- Electrodes (and/or other features) may be applied or otherwise processed using any suitable technology, e.g., chemical vapor deposition (CVD), physical vapor deposition, sputtering, reactive sputtering, printing, coating, ablating (e.g., laser ablation), painting, dip coating, etching, and the like.
- CVD chemical vapor deposition
- sputtering e.g., reactive sputtering
- printing e.g., coating
- ablating e.g., laser ablation
- Materials include but are not limited to aluminum, carbon (such as graphite), cobalt, copper, gallium, gold, indium, iridium, iron, lead, magnesium, mercury (as an amalgam), nickel, niobium, osmium, palladium, platinum, rhenium, rhodium, selenium, silicon (e.g., doped polycrystalline silicon), silver, tantalum, tin, titanium, tungsten, uranium, vanadium, zinc, zirconium, mixtures thereof, and alloys, oxides, or metallic compounds of these elements.
- the sensor may be wholly implantable in a user or may be configured so that only a portion is positioned within (internal) a user and another portion outside (external) a user.
- the sensor 400 may include a portion positionable above a surface of the skin 410 , and a portion positioned below the skin.
- the external portion may include contacts (connected to respective electrodes of the second portion by traces) to connect to another device also external to the user such as a transmitter unit. While the embodiment of FIG.
- FIG. 4 shows three electrodes side-by-side on the same surface of base 404 , other configurations are contemplated, e.g., fewer or greater electrodes, some or all electrodes on different surfaces of the base or present on another base, some or all electrodes stacked together, electrodes of differing materials and dimensions, etc.
- FIG. 5A shows a perspective view of an embodiment of an electrochemical analyte sensor 500 having a first portion (which in this embodiment may be characterized as a major portion) positionable above a surface of the skin 510 , and a second portion (which in this embodiment may be characterized as a minor portion) that includes an insertion tip 530 positionable below the skin, e.g., penetrating through the skin and into, e.g., the subcutaneous space 520 , in contact with the user's biofluid such as interstitial fluid.
- Contact portions of a working electrode 501 , a reference electrode 502 , and a counter electrode 503 are positioned on the portion of the sensor 500 situated above the skin surface 510 .
- Working electrode 501 a reference electrode 502 , and a counter electrode 503 are shown at the second section and particularly at the insertion tip 530 . Traces may be provided from the electrode at the tip to the contact, as shown in FIG. 5A . It is to be understood that greater or fewer electrodes may be provided on a sensor.
- a sensor may include more than one working electrode and/or the counter and reference electrodes may be a single counter/reference electrode, etc.
- FIG. 5B shows a cross sectional view of a portion of the sensor 500 of FIG. 5A .
- the electrodes 510 , 502 and 503 , of the sensor 500 as well as the substrate and the dielectric layers are provided in a layered configuration or construction.
- the sensor 500 (such as the sensor unit 101 FIG. 1 ), includes a substrate layer 504 , and a first conducting layer 501 such as carbon, gold, etc., disposed on at least a portion of the substrate layer 504 , and which may provide the working electrode. Also shown disposed on at least a portion of the first conducting layer 501 is a sensing layer 508 .
- a first insulation layer such as a first dielectric layer 505 is disposed or layered on at least a portion of the first conducting layer 501 , and further, a second conducting layer 509 may be disposed or stacked on top of at least a portion of the first insulation layer (or dielectric layer) 505 .
- the second conducting layer 509 may provide the reference electrode 502 , and in one aspect, may include a layer of silver/silver chloride (Ag/AgCl), gold, etc.
- a second insulation layer 506 such as a dielectric layer in one embodiment may be disposed or layered on at least a portion of the second conducting layer 509 .
- a third conducting layer 503 may provide the counter electrode 503 . It may be disposed on at least a portion of the second insulation layer 506 .
- a third insulation layer may be disposed or layered on at least a portion of the third conducting layer 503 .
- the sensor 500 may be layered such that at least a portion of each of the conducting layers is separated by a respective insulation layer (for example, a dielectric layer).
- the embodiment of FIGS. 5A and 5B show the layers having different lengths. Some or all of the layers may have the same or different lengths and/or widths.
- some or all of the electrodes 501 , 502 , 503 may be provided on the same side of the substrate 504 in the layered construction as described above, or alternatively, may be provided in a co-planar manner such that two or more electrodes may be positioned on the same plane (e.g., side-by side (e.g., parallel) or angled relative to each other) on the substrate 504 .
- co-planar electrodes may include a suitable spacing there between and/or include dielectric material or insulation material disposed between the conducting layers/electrodes.
- one or more of the electrodes 501 , 502 , 503 may be disposed on opposing sides of the substrate 504 .
- contact pads may be one the same or different sides of the substrate.
- an electrode may be on a first side and its respective contact may be on a second side, e.g., a trace connecting the electrode and the contact may traverse through the substrate.
- analyte sensors may include an analyte-responsive enzyme to provide a sensing component or sensing layer.
- Some analytes such as oxygen, can be directly electrooxidized or electroreduced on a sensor, and more specifically at least on a working electrode of a sensor.
- Other analytes such as glucose and lactate, require the presence of at least one electron transfer agent and/or at least one catalyst to facilitate the electrooxidation or electroreduction of the analyte.
- Catalysts may also be used for those analyte, such as oxygen, that can be directly electrooxidized or electroreduced on the working electrode.
- each working electrode includes a sensing layer (see for example sensing layer 408 of FIG. 5B ) proximate to or on a surface of a working electrode.
- a sensing layer is formed near or on only a small portion of at least a working electrode.
- the sensing layer includes one or more components designed to facilitate the electrochemical oxidation or reduction of the analyte.
- the sensing layer may include, for example, a catalyst to catalyze a reaction of the analyte and produce a response at the working electrode, an electron transfer agent to transfer electrons between the analyte and the working electrode (or other component), or both.
- the sensing layer is deposited on the conductive material of a working electrode.
- the sensing layer may extend beyond the conductive material of the working electrode.
- the sensing layer may also extend over other electrodes, e.g., over the counter electrode and/or reference electrode (or counter/reference is provided).
- a sensing layer that is in direct contact with the working electrode may contain an electron transfer agent to transfer electrons directly or indirectly between the analyte and the working electrode, and/or a catalyst to facilitate a reaction of the analyte.
- a glucose, lactate, or oxygen electrode may be formed having a sensing layer which contains a catalyst, such as glucose oxidase, lactate oxidase, or laccase, respectively, and an electron transfer agent that facilitates the electrooxidation of the glucose, lactate, or oxygen, respectively.
- the sensing layer is not deposited directly on the working electrode.
- the sensing layer 64 may be spaced apart from the working electrode, and separated from the working electrode, e.g., by a separation layer.
- a separation layer may include one or more membranes or films or a physical distance.
- the separation layer may also act as a mass transport limiting layer and/or an interferent eliminating layer and/or a biocompatible layer.
- one or more of the working electrodes may not have a corresponding sensing layer, or may have a sensing layer which does not contain one or more components (e.g., an electron transfer agent and/or catalyst) needed to electrolyze the analyte.
- the signal at this working electrode may correspond to background signal which may be removed from the analyte signal obtained from one or more other working electrodes that are associated with fully-functional sensing layers by, for example, subtracting the signal.
- the sensing layer includes one or more electron transfer agents.
- Electron transfer agents that may be employed are electroreducible and electrooxidizable ions or molecules having redox potentials that are a few hundred millivolts above or below the redox potential of the standard calomel electrode (SCE).
- the electron transfer agent may be organic, organometallic, or inorganic. Examples of organic redox species are quinones and species that in their oxidized state have quinoid structures, such as Nile blue and indophenol. Examples of organometallic redox species are metallocenes such as ferrocene. Examples of inorganic redox species are hexacyanoferrate (III), ruthenium hexamine etc.
- electron transfer agents have structures or charges which prevent or substantially reduce the diffusional loss of the electron transfer agent during the period of time that the sample is being analyzed.
- electron transfer agents include but are not limited to a redox species, e.g., bound to a polymer which can in turn be disposed on or near the working electrode.
- the bond between the redox species and the polymer may be covalent, coordinative, or ionic.
- the redox species is a transition metal compound or complex, e.g., osmium, ruthenium, iron, and cobalt compounds or complexes. It will be recognized that many redox species described for use with a polymeric component may also be used, without a polymeric component.
- polymeric electron transfer agent contains a redox species covalently bound in a polymeric composition.
- An example of this type of mediator is poly(vinylferrocene).
- Another type of electron transfer agent contains an ionically-bound redox species.
- This type of mediator may include a charged polymer coupled to an oppositely charged redox species.
- Examples of this type of mediator include a negatively charged polymer coupled to a positively charged redox species such as an osmium or ruthenium polypyridyl cation.
- an ionically-bound mediator is a positively charged polymer such as quaternized poly(4-vinyl pyridine) or poly(1-vinyl imidazole) coupled to a negatively charged redox species such as ferricyanide or ferrocyanide.
- electron transfer agents include a redox species coordinatively bound to a polymer.
- the mediator may be formed by coordination of an osmium or cobalt 2,2′-bipyridyl complex to poly(1-vinyl imidazole) or poly(4-vinyl pyridine).
- Suitable electron transfer agents are osmium transition metal complexes with one or more ligands, each ligand having a nitrogen-containing heterocycle such as 2,2′-bipyridine, 1,10-phenanthroline, 1-methyl, 2-pyridyl biimidazole, or derivatives thereof.
- the electron transfer agents may also have one or more ligands covalently bound in a polymer, each ligand having at least one nitrogen-containing heterocycle, such as pyridine, imidazole, or derivatives thereof.
- an electron transfer agent includes (a) a polymer or copolymer having pyridine or imidazole functional groups and (b) osmium cations complexed with two ligands, each ligand containing 2,2′-bipyridine, 1,10-phenanthroline, or derivatives thereof, the two ligands not necessarily being the same.
- Some derivatives of 2,2′-bipyridine for complexation with the osmium cation include but are not limited to 4,4′-dimethyl-2,2′-bipyridine and mono-, di-, and polyalkoxy-2,2′-bipyridines, such as 4,4′-dimethoxy-2,2′-bipyridine.
- 1,10-phenanthroline for complexation with the osmium cation include but are not limited to 4,7-dimethyl-1,10-phenanthroline and mono, di-, and polyalkoxy-1,10-phenanthrolines, such as 4,7-dimethoxy-1,10-phenanthroline.
- Polymers for complexation with the osmium cation include but are not limited to polymers and copolymers of poly(1-vinyl imidazole) (referred to as “PVI”) and poly(4-vinyl pyridine) (referred to as “PVP”).
- Suitable copolymer substituents of poly(1-vinyl imidazole) include acrylonitrile, acrylamide, and substituted or quaternized N-vinyl imidazole, e.g., electron transfer agents with osmium complexed to a polymer or copolymer of poly(1-vinyl imidazole).
- Embodiments may employ electron transfer agents having a redox potential ranging from about ⁇ 200 mV to about +200 mV versus the standard calomel electrode (SCE).
- the sensing layer may also include a catalyst which is capable of catalyzing a reaction of the analyte.
- the catalyst may also, in some embodiments, act as an electron transfer agent.
- One example of a suitable catalyst is an enzyme which catalyzes a reaction of the analyte.
- a catalyst such as a glucose oxidase, glucose dehydrogenase (e.g., pyrroloquinoline quinone (PQQ), dependent glucose dehydrogenase, flavine adenine dinucleotide (FAD) dependent glucose dehydrogenase, or nicotinamide adenine dinucleotide (NAD) dependent glucose dehydrogenase), may be used when the analyte of interest is glucose.
- PQQ pyrroloquinoline quinone
- FAD flavine adenine dinucleotide
- NAD nicotinamide adenine dinucleotide dependent glucose dehydrogenase
- a lactate oxidase or lactate dehydrogenase may be used when the analyte of interest is lactate.
- Laccase may be used when the analyte of interest is oxygen or when oxygen is generated or consumed in response to a reaction of the analyte.
- the sensing layer may also include a catalyst which is capable of catalyzing a reaction of the analyte.
- the catalyst may also, in some embodiments, act as an electron transfer agent.
- One example of a suitable catalyst is an enzyme which catalyzes a reaction of the analyte.
- a catalyst such as a glucose oxidase, glucose dehydrogenase (e.g., pyrroloquinoline quinone (PQQ), dependent glucose dehydrogenase or oligosaccharide dehydrogenase, flavine adenine dinucleotide (FAD) dependent glucose dehydrogenase, nicotinamide adenine dinucleotide (NAD) dependent glucose dehydrogenase), may be used when the analyte of interest is glucose.
- PQQ glucose dehydrogenase
- FAD flavine adenine dinucleotide
- NAD nicotinamide adenine dinucleotide dependent glucose dehydrogenase
- a lactate oxidase or lactate dehydrogenase may be used when the analyte of interest is lactate.
- Laccase may be used when the analyte of interest is oxygen or when oxygen is generated or consumed in response to a
- a catalyst may be attached to a polymer, cross linking the catalyst with another electron transfer agent (which, as described above, may be polymeric.
- a second catalyst may also be used in certain embodiments. This second catalyst may be used to catalyze a reaction of a product compound resulting from the catalyzed reaction of the analyte. The second catalyst may operate with an electron transfer agent to electrolyze the product compound to generate a signal at the working electrode.
- a second catalyst may be provided in an interferent-eliminating layer to catalyze reactions that remove interferents.
- Certain embodiments include a Wired EnzymeTM sensing layer (Abbott Diabetes Care, Inc.) that works at a gentle oxidizing potential, e.g., a potential of about +40 mV.
- This sensing layer uses an osmium (Os)-based mediator designed for low potential operation and is stably anchored in a polymeric layer.
- the sensing element is redox active component that includes (1) Osmium-based mediator molecules attached by stable (bidente) ligands anchored to a polymeric backbone, and (2) glucose oxidase enzyme molecules. These two constituents are crosslinked together.
- a mass transport limiting layer (not shown), e.g., an analyte flux modulating layer, may be included with the sensor to act as a diffusion-limiting barrier to reduce the rate of mass transport of the analyte, for example, glucose or lactate, into the region around the working electrodes.
- the mass transport limiting layers are useful in limiting the flux of an analyte to a working electrode in an electrochemical sensor so that the sensor is linearly responsive over a large range of analyte concentrations and is easily calibrated.
- Mass transport limiting layers may include polymers and may be biocompatible.
- a mass transport limiting layer may provide many functions, e.g., biocompatibility and/or interferent-eliminating, etc.
- a mass transport limiting layer is a membrane composed of crosslinked polymers containing heterocyclic nitrogen groups, such as polymers of polyvinylpyridine and polyvinylimidazole.
- Embodiments also include membranes that are made of a polyurethane, or polyether urethane, or chemically related material, or membranes that are made of silicone, and the like.
- a membrane may be formed by crosslinking in situ a polymer, modified with a zwitterionic moiety, a non-pyridine copolymer component, and optionally another moiety that is either hydrophilic or hydrophobic, and/or has other desirable properties, in an alcohol-buffer solution.
- the modified polymer may be made from a precursor polymer containing heterocyclic nitrogen groups.
- a precursor polymer may be polyvinylpyridine or polyvinylimidazole.
- hydrophilic or hydrophobic modifiers may be used to “fine-tune” the permeability of the resulting membrane to an analyte of interest.
- Optional hydrophilic modifiers such as poly(ethylene glycol), hydroxyl or polyhydroxyl modifiers, may be used to enhance the biocompatibility of the polymer or the resulting membrane.
- a membrane may be formed in situ by applying an alcohol-buffer solution of a crosslinker and a modified polymer over an enzyme-containing sensing layer and allowing the solution to cure for about one to two days or other appropriate time period.
- the crosslinker-polymer solution may be applied to the sensing layer by placing a droplet or droplets of the solution on the sensor, by dipping the sensor into the solution, or the like.
- the thickness of the membrane is controlled by the concentration of the solution, by the number of droplets of the solution applied, by the number of times the sensor is dipped in the solution, or by any combination of these factors.
- a membrane applied in this manner may have any combination of the following functions: (1) mass transport limitation, i.e. reduction of the flux of analyte that can reach the sensing layer, (2) biocompatibility enhancement, or (3) interferent reduction.
- a hydrogen peroxide-detecting sensor may be constructed in which a sensing layer includes enzyme such as glucose oxides, glucose dehydrogensae, or the like, and is positioned proximate to the working electrode.
- the sending layer may be covered by a membrane that is selectively permeable to glucose. Once the glucose passes through the membrane, it is oxidized by the enzyme and reduced glucose oxidase can then be oxidized by reacting with molecular oxygen to produce hydrogen peroxide.
- Certain embodiments include a hydrogen peroxide-detecting sensor constructed from a sensing layer prepared by crosslinking two components together, for example: (1) a redox compound such as a redox polymer containing pendent Os polypyridyl complexes with oxidation potentials of about +200 mV vs. SCE, and (2) periodate oxidized horseradish peroxidase (HRP).
- a redox compound such as a redox polymer containing pendent Os polypyridyl complexes with oxidation potentials of about +200 mV vs. SCE
- HRP horseradish peroxidase
- a potentiometric sensor can be constructed as follows.
- a glucose-sensing layer is constructed by crosslinking together (1) a redox polymer containing pendent Os polypyridyl complexes with oxidation potentials from about ⁇ 200 mV to +200 mV vs. SCE, and (2) glucose oxidase.
- This sensor can then be used in a potentiometric mode, by exposing the sensor to a glucose containing solution, under conditions of zero current flow, and allowing the ratio of reduced/oxidized Os to reach an equilibrium value.
- the reduced/oxidized Os ratio varies in a reproducible way with the glucose concentration, and will cause the electrode's potential to vary in a similar way.
- a sensor may also include an active agent such as an anticlotting and/or antiglycolytic agent(s) disposed on at least a portion a sensor that is positioned in a user.
- An anticlotting agent may reduce or eliminate the clotting of blood or other body fluid around the sensor, particularly after insertion of the sensor.
- useful anticlotting agents include heparin and tissue plasminogen activator (TPA), as well as other known anticlotting agents.
- Embodiments may include an antiglycolytic agent or precursor thereof. Examples of antiglycolytic agents are glyceraldehyde, fluoride ion, and mannose.
- Sensors may be configured to require no system calibration or no user calibration.
- a sensor may be factory calibrated and need not require further calibrating.
- calibration may be required, but may be done without user intervention, i.e., may be automatic.
- the calibration may be according to a predetermined schedule or may be dynamic, i.e., the time for which may be determined by the system on a real-time basis according to various factors, such as but not limited to glucose concentration and/or temperature and/or rate of change of glucose, etc.
- Calibration may be accomplished using an in vitro test strip (or other reference), e.g., a small sample test strip such as a test strip that requires less than about 1 microliter of sample (for example FreeStyle® blood glucose monitoring test strips from Abbott Diabetes Care). For example, test strips that require less than about 1 nanoliter of sample may be used.
- a sensor may be calibrated using only one sample of body fluid per calibration event. For example, a user need only lance a body part one time to obtain sample for a calibration event (e.g., for a test strip), or may lance more than one time within a short period of time if an insufficient volume of sample is firstly obtained.
- Embodiments include obtaining and using multiple samples of body fluid for a given calibration event, where glucose values of each sample are substantially similar. Data obtained from a given calibration event may be used independently to calibrate or combined with data obtained from previous calibration events, e.g., averaged including weighted averaged, etc., to calibrate. In certain embodiments, a system need only be calibrated once by a user, where recalibration of the system is not required.
- Analyte systems may include an optional alarm system that, e.g., based on information from a processor, warns the patient of a potentially detrimental condition of the analyte. For example, if glucose is the analyte, an alarm system may warn a user of conditions such as hypoglycemia and/or hyperglycemia and/or impending hypoglycemia, and/or impending hyperglycemia. An alarm system may be triggered when analyte levels approach, reach or exceed a threshold value. An alarm system may also, or alternatively, be activated when the rate of change, or acceleration of the rate of change, in analyte level increase or decrease approaches, reaches or exceeds a threshold rate or acceleration.
- an alarm system may also, or alternatively, be activated when the rate of change, or acceleration of the rate of change, in analyte level increase or decrease approaches, reaches or exceeds a threshold rate or acceleration.
- a system may also include system alarms that notify a user of system information such as battery condition, calibration, sensor dislodgment, sensor malfunction, etc.
- Alarms may be, for example, auditory and/or visual.
- Other sensory-stimulating alarm systems may be used including alarm systems which heat, cool, vibrate, or produce a mild electrical shock when activated.
- the subject disclosure also includes sensors used in sensor-based drug delivery systems.
- the system may provide a drug to counteract the high or low level of the analyte in response to the signals from one or more sensors. Alternatively, the system may monitor the drug concentration to ensure that the drug remains within a desired therapeutic range.
- the drug delivery system may include one or more (e.g., two or more) sensors, a processing unit such as a transmitter, a receiver/display unit, and a drug administration system. In some cases, some or all components may be integrated in a single unit.
- a sensor-based drug delivery system may use data from the one or more sensors to provide necessary input for a control algorithm/mechanism to adjust the administration of drugs, e.g., automatically or semi-automatically.
- a glucose sensor may be used to control and adjust the administration of insulin from an external or implanted insulin pump.
- Embodiments relate to methods and devices for detecting at least one analyte such as glucose in body fluid.
- Embodiments relate to the continuous and/or automatic in vivo monitoring of the level of one or more analytes using a continuous analyte monitoring system that includes an analyte sensor at least a portion of which is to be positioned beneath a skin surface of a user for a period of time and/or the discrete monitoring of one or more analytes using an in vitro blood glucose (“BG”) meter in conjunction with an analyte test strip.
- BG in vitro blood glucose
- Embodiments include combined or combinable devices, systems and methods and/or transferring data between an in vivo continuous system and a BG meter system, and include integrated systems.
- Embodiments include “Data Logger” systems which include a continuous glucose monitoring system (at least an analyte sensor and control unit (e.g., an on body unit)).
- the continuous glucose monitoring (“CG”) system may have limited real-time connectivity with a BG meter.
- real time connectivity may be limited to communicating calibration data (e.g., a BG value) to the CG system or it may have the ability to receive data from the CG system on demand (as compared to a CG system continuously broadcasting such data).
- the data processing unit ( 102 ) may be an on-body unit that is configured to operate in several transmission modes.
- analyte related data may be transmitted when a new data value (e.g., sensor data) is available (for example, when received from the analyte sensor).
- a new data value e.g., sensor data
- This mode of operation may result in “lost data” because the data processing unit 102 does not get confirmation that the data was successfully received by the receiver unit 104 , and in some embodiments, this data may not be resent.
- data may be transmitted when the new data is available and the data processing unit 102 may receive an acknowledgement that such data has been successfully received, or if the transmission was unsuccessful the data would be stored (“buffered”) for another attempt. This mode reduces the likelihood of “lost data”.
- data logging mode the data processing unit 102 may be configured to retain or store all data (i.e.; not attempt to transmit it when it becomes available) until the receiver unit ( 104 ) requests the data, or based upon a scheduled data transmission.
- CG data obtained by the CG Data Logger may be processed by the Data Logger system or by the BG meter and/or by a data management system (“DMS”) which may includes a computer such as a PC and an optional server.
- DMS data management system
- the CoPilotTM data management system from Abbott Diabetes Care, Inc., or the like, may be employed.
- neither the CG system nor the BG meter are capable of (or have such capability, but the capability is selectively turned off) supporting continuous real time CG data communication, thereby substantially reducing power requirements.
- Such embodiments are CG Data Loggers in which CG data resides (i.e., is logged) in a CG control unit (e.g., on-body unit) until it is retrieved by a BG meter.
- a CG Data Logger buffers the CG data and stores it in memory until the CG data is downloaded or transferred to the BG meter, e.g., a user initiates data transfer or transfer may occur at set times.
- the CG component logs continuous glucose data, but only gives up this data to the on-request to a BG meter.
- Retrieval may be by any suitable methodology, including but not limited to wireless communication protocols such as for example RF, optical means (such as an IR link), Bluetooth, or a direct connection (such as a USB, or the like), etc.
- a given BG meter and CG data Logger may be synchronized, e.g., by one or more unique identifiers, thereby ensuring preventing inadvertent data exchange between devices.
- FIG. 6 shows an exemplary embodiment of a system that includes a CG Data Logger and an enhanced BG meter.
- the enhanced BG meter may communicate with the CG Data Logger by a wired connection and/or by IR or RF.
- the CG data logger may be configured to collect and store monitored analyte data over a predetermined time period (for example, from a transcutaneous, subcutaneous or implanted analyte sensor), and transmit the collected and stored analyte data to the BG meter either continuously in real time, or periodically (for example, when the CG data logger is in signal communication with the BG meter (either cabled or wireless), or in a single data transfer mode, for example, at the end of the predetermined time period.
- a predetermined time period for example, from a transcutaneous, subcutaneous or implanted analyte sensor
- Modular embodiments are also provided. Modular systems may be used in conjunction with the Data Logger system in certain embodiments.
- a separable CG data transfer module may be configured for wireless communication with the CG data logger and further configured to removably mate with a BG meter to transfer CG information to the BG meter (see for example FIG. 7 ).
- Modular embodiments include all the necessary hardware (and software) to support either (or both) continuous (real time) or “batched” (data logged) CG data collection in a snap-on or otherwise mateable module that provides CG data to a BG meter.
- Alarm functionality may be included in the BG meter, as well as features to support CG data processing and communication to a user, e.g., hardware and software to process CG data and/or calibrate CG data, enhanced user interface to communicate CG information to a user (in addition to BG information), e.g., may include CG calibration information, CG trend information, rate of change indicators to indicate the rate of change of glucose, and the like.
- Modules may be re-usable by a plurality of users.
- User privacy features may be included, e.g., a module may not permanently store patient data (user data may be automatically deleted or expunged after a certain time period), data may be encrypted, password protected, or otherwise provided with one or more security features that will limit access to only the intended users.
- the CG data logger may be configured to collect and store the monitored analyte data received from an analyte sensor, and upon establishing data communication with the BG meter via the data transfer module, communicate the received analyte data in one or more batch transfer, or continuously in real time as the analyte sensor data is received from the sensor.
- FIG. 7 shows an exemplary embodiment of a modular system that includes a CG control unit/transmitter, a mateable module and an enhanced BG meter.
- the CG data logger/transmitter is shown communicating with the module via RF where the module is mateably coupled to the BG meter.
- RF radio frequency
- FIG. 8 shows an integrated or continuous system that includes an enhanced BG meter and a CG data logger/transmitter, where the CG data logger is capable of transferring CG data to the enhanced BG meter directly and in real time, in this embodiment shown via a wireless protocol.
- the enhanced BG meter may include an RF communication module or chipset that allows for wireless communication with the CG data logger. Accordingly, as the continuous analyte sensor data is received by the CG data logger, the data is substantially contemporaneously transferred or communicated in real time to the enhanced BG meter over the RF communication link.
- FIG. 9 shows an exemplary embodiment of a system which includes a BG meter and a docking unit, herein shown configured as a belt holster.
- the BG meter couples to the holster via contacts of the holster, which correspond to contacts of the BG meter.
- the BG meter displays information to the user when electronically coupled to the holster, i.e., when docked or when in wireless signal communication with the belt holster (for example, when removed from the holster).
- the holster may include some or all functionality of a primary receiver unit as described below for CG monitoring.
- the holster may contain some or all of a FreeStyle Navigator® system, e.g., the receiver functionality as described above.
- the belt holster may integrate the CG data logger such that the collected and stored analyte data may be transferred to the BG meter when docked in the holster (or when wirelessly synchronized with the belt holster).
- the CG system may be calibrated using the BG meter, e.g., when the BG meter is docked. Such as system may be useful in a variety of instances, e.g., for gestational diabetes, assessing/diagnosing diabetes, and the like.
- the CG system may be configured with reduced set of functionalities. For example, it may not include alarms (audible and/or vibratory and/or visual) and/or glucose rate of change indicators and/or a visual or user interface display such as a dot matrix display and/or additional processing power and/or miniaturized, or it may not include a test strip port.
- FIG. 10 illustrates features which may be included in an exemplary full-featured CG system, and exemplary integrated real time system and an exemplary Data Logger system.
- synchronization between a BG and CG systems is provided to calibrate the CG sensor using a BG strip measurement as a reference data point.
- the enhanced BG meters may be used by those who require more intensive (i.e., continuous) glucose monitoring, by temporarily or periodically allowing a user's BG meter to capture CG data without the user having to obtain another meter.
- HCP health care provider
- a Data Logger includes providing molded electrical contacts that allow for electrical connections thru the on-body case without compromising the watertight seal of the case.
- Embodiments herein may provide increased value of a BG meter to the patient by adding CG functionality to a base BG meter, a low learning curve such that the user does not need to become familiar with two different user interfaces (one for the BG unit and another for the CG system), reduction in cost of the overall system, and substantial immunity to environments where continuous wireless communication may be prohibited such as during flight on an airplane, within hospital or other settings that have sensitive instrumentation that may interfere with RF or other wireless signals.
- an analyte monitoring system in one embodiment includes an analyte sensor for transcutaneous positioning under a skin layer of a subject, a data processing device operatively coupled to the analyte sensor, the device comprising: a control unit, a memory operatively coupled to the control unit and configured to store a plurality of data associated with the monitored analyte level received from the sensor, and a communication unit operatively coupled to the control unit; and a blood glucose meter configured for signal communication with the data processing device, where when the control unit of the data processing device detects a communication link with the blood glucose meter, the control unit is further configured to retrieve the stored plurality of data from the memory and to transmit the retrieved data to the blood glucose meter.
- the blood glucose meter includes a strip port for receiving a blood glucose test strip.
- the communication unit may be configured to communicate with the blood glucose meter using one or more of a wired connection, a USB cable connection, a serial cable connection, an RF communication protocol, an infrared communication protocol, a Bluetooth communication protocol, or an 802.11x communication protocol.
- data processing device does not include a user output component, where the user output component includes a display.
- the control unit may detect the communication link with the blood glucose meter based on detection of a wired connection to the meter.
- the retrieved stored plurality of data may correspond to glucose data of the subject collected over a predetermined time period.
- the glucose data may be uncalibrated or calibrated.
- the analyte sensor may be a glucose sensor.
- the blood glucose meter may include an output unit configured to output one or more of the received retrieved data.
- the output unit may include a display unit operatively coupled to a housing of the blood glucose meter.
- the output of one or more received data may include a graphical output, a numerical output, or a text output.
- the blood glucose meter may be configured to calibrate the received data.
- the blood glucose meter may include a storage unit configured to store the calibrated data.
- the blood glucose meter may include a storage unit configured to store the received data.
- the system may include a holster device for receiving the blood glucose meter, and the data processing unit may be integrated in the holster device.
- the control unit may be configured to detect the communication link with the blood glucose meter when the meter is coupled to the holster.
- the holster device may include a belt clip.
- a method in another embodiment may include transcutaneously positioning an analyte sensor under a skin layer of a subject, coupling a data processing device to the analyte sensor, storing in a memory of the data processing device a plurality of data associated with the monitored analyte level received from the sensor, operatively coupling a communication unit to the control unit, detecting a communication link with the blood glucose meter, retrieving the stored plurality of data from the memory, and commanding the communication unit to transmit the retrieved data to the blood glucose meter.
- the communication link may be established based on one or more of a wired connection, a USB cable connection, a serial cable connection, an RF communication protocol, an infrared communication protocol, a Bluetooth communication protocol, or an 802.11x communication protocol.
- the method may include displaying on the blood glucose meter the received analyte data.
- the retrieved data may correspond to glucose data of the subject collected over a predetermined time period.
- the method may include calibrating the received data.
- the method may include storing the received data in a memory of the blood glucose meter.
- the method may include encrypting the retrieved data prior to transmitting to the blood glucose meter.
Abstract
Methods and devices to detect analyte in body fluid are provided. Embodiments include enhanced analyte monitoring devices and systems.
Description
- The present application is a continuation of U.S. patent application Ser. No. 12/143,734 filed Jun. 20, 2008, entitled “Health Monitor”, which claims priority to U.S. provisional application No. 60/945,581 filed Jun. 21, 2007, entitled “Health Monitor” and assigned to the assignee of the present application, Abbott Diabetes Care Inc., the disclosure of which is incorporated herein by reference for all purposes.
- The detection of the level of analytes, such as glucose, lactate, oxygen, and the like, in certain individuals is vitally important to their health. For example, the monitoring of glucose is particularly important to individuals with diabetes. Diabetics may need to monitor glucose levels to determine when insulin is needed to reduce glucose levels in their bodies or when additional glucose is needed to raise the level of glucose in their bodies.
- Accordingly, of interest are devices, system and methods that allow a user to test for one or more analytes.
- Embodiments include enhanced in vitro analyte meters and systems which are enhanced with in vivo continuous analyte monitoring functionality. The descriptions herein describe in vitro analyte glucose meters primarily as in vitro blood glucose (“BG”) meters and in vivo continuous analyte system primarily as in vivo continuous glucose (“CG”) monitoring devices and systems, for convenience only. Such descriptions are in no way intended to limit the scope of the disclosure in any way.
- Accordingly, BG meters and systems having high levels of functionality are provided. Each BG or CG system may accept and process data from its own respective system and/or from another system, e.g., a BG system may accept and process CG system data, or vice versa. Embodiments enable CG data to be provided to a user by way of a BG meter.
- Embodiments may be useful to users who may require conventional blood glucose BG data most of the time, but who may have a periodic need for CG data. One way this problem has been addressed in the past is to provide the user with both a BG meter and a CG system. However, this has the disadvantage of cost because a CG system may be more expensive than a BG meter, and increased training as the user must learn how to use two meters a BG meter for normal use and a CG meter for those times when CG data is required.
- Embodiments herein may be appropriate for Type I and Type II diabetics, other patients experiencing diabetic conditions, or patients in post surgery recovery period.
- Also provided are devices, methods and kits.
-
FIG. 1 shows a block diagram of an embodiment of a data monitoring and management system according to the present disclosure; -
FIG. 2 shows a block diagram of an embodiment of the transmitter unit of the data monitoring and management system ofFIG. 1 ; -
FIG. 3 shows a block diagram of an embodiment of the receiver/monitor unit of the data monitoring and management system ofFIG. 1 ; -
FIG. 4 shows a schematic diagram of an embodiment of an analyte sensor according to the present disclosure; -
FIGS. 5A-5B show a perspective view and a cross sectional view, respectively of another embodiment an analyte sensor; -
FIG. 6 shows an exemplary embodiment of a system that includes a CG Data Logger (for example, including a data storage device or memory) and an enhanced BG meter, in which the CG Data Logger is capable of transferring CG data obtained by a CG analyte sensor positioned at least partially beneath a skin surface of a user to the enhanced BG meter; -
FIG. 7 shows an exemplary embodiment of a Modular System that includes a CG unit having a transmitter, data transfer module and enhanced BG meter, in which the CG unit is capable of wirelessly transferring data obtained by a CG analyte sensor positioned at least partially beneath a skin surface of a user to the enhanced BG meter by way of the data transfer module; -
FIG. 8 shows an exemplary embodiment of an integrated system that includes an enhanced BG meter and a CG unit having a transmitter, in which the CG unit is capable of transferring CG data obtained by a CG analyte sensor positioned at least partially beneath a skin surface of a user to the enhanced BG meter in real time; -
FIG. 9 shows an exemplary embodiment of a system which includes a BG meter and a docking unit, herein shown configured as a belt holster; -
FIGS. 10A-10C show exemplary embodiments of glucose test strips that may be used with the enhanced systems described herein; and -
FIGS. 11A-11C show exemplary BG meters. - Before the present disclosure is described, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.
- Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
- It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.
- As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure.
- The figures shown herein are not necessarily drawn to scale, with some components and features being exaggerated for clarity.
- Embodiments include devices which allow diabetic patients to measure the blood (or other bodily fluid) glucose levels, e.g., hand-held electronic meters (blood glucose meters), e.g., such as Freestyle® or Precision® blood glucose monitoring systems available from Abbott Diabetes Care, Inc., of Alameda, Calif. (and the like) which receives blood samples via enzyme-based test strips. Typically, a user inserts a test strip into a meter and lances a finger or alternate body site to obtain a blood sample. The drawn sample is applied to the test strip and the meter reads the strip and determines analyte concentration, which is then conveyed to the user. For example, the blood glucose meter converts a current generated by the enzymatic reaction in the test strip to a corresponding blood glucose value which is displayed or otherwise provided to the patient to show the level of glucose at the time of testing.
- Such periodic discrete glucose testing helps diabetic patients to take any necessary corrective actions to better manage diabetic conditions.
- Test strips may be adapted to measure the concentration of an analyte in any volume of sample, including but not limited to small volumes of sample, e.g., about 1 microliter or less sample, for example about 0.5 microliters or less, for example about 0.3 microliters or less, for example about 0.1 microliters or less. In some embodiments, the volume of sample may be as low as about 0.05 microliters or as low as about 0.03 microliters. Strips may be configures so that an accurate analyte measurement may be obtained using a volume of sample that wholly or partially fills a sample chamber of a strip. In certain embodiments, a test may only start when sufficient sample has been applied to a strip, e.g., as detected by a detector such as an electrode. A system may be programmed to allow re-application of additional sample if insufficient sample is firstly applied, e.g., the time to reapply sample may range from about 10 seconds to about 2 minutes, e.g., from about 30 seconds to about 60 seconds.
- Strips may be side fill, front fill, top fill or corner fill, or any combination thereof. Test strips may be calibration-free, e.g., minimal input (if any) is required of a user to calibrate. In certain embodiments, no calibration test strips may be employed. In such embodiments, the user need not take any action for calibration, i.e., calibration is invisible to a user.
- As noted above, strips are used with meters. In certain embodiments, meters may be integrated meters, i.e., a device which has at least one strip and at least a second element, such as a meter and/or a skin piercing element such as a lancet or the like, in the device. In some embodiments, a strip may be integrated with both a meter and a lancet, e.g., in a single housing. Having multiple elements together in one device reduces the number of devices needed to obtain an analyte level and facilitates the sampling process. For example, embodiments may include a housing that includes one or more analyte test strips, a skin piercing element and a processor for determining the concentration of an analyte in a sample applied to the strip. A plurality of strips may be retained in a magazine in the housing interior and, upon actuation by a user, a single strip may be dispensed from the magazine so that at least a portion extends out of the housing for use.
- Test strips may be short test time test strips. For example, test times may range from about 1 second to about 20 seconds, e.g., from about 3 seconds to about 10 seconds, e.g., from about 3 seconds to about 7 seconds, e.g., about 5 seconds or about 3 seconds.
- Exemplary meters and test strips and using the same are shown in
FIGS. 10A-10C and 11A-11C. - Embodiments include analyte monitoring devices and systems that include an analyte sensor—at least a portion of which is positionable beneath the skin of the user—for the in vivo detection, of at least one analyte, such as glucose, lactate, and the like, in a body fluid. Such in vivo sensors are generally referred to herein as in vivo sensors/systems and/or continuous sensors/systems, where such are used interchangeably unless indicated otherwise. Embodiments include wholly implantable analyte sensors and analyte sensors in which only a portion of the sensor is positioned under the skin and a portion of the sensor resides above the skin, e.g., for contact to a transmitter, receiver, transceiver, processor, etc. The sensor may be, for example, subcutaneously positionable in a patient for the continuous or periodic monitoring of a level of an analyte in a patient's interstitial fluid. For the purposes of this description, continuous monitoring and periodic monitoring will be used interchangeably, unless noted otherwise. The sensor response may be correlated and/or converted to analyte levels in blood or other fluids. In certain embodiments, an analyte sensor may be positioned in contact with interstitial fluid to detect the level of glucose, which detected glucose may be used to infer the glucose level in the patient's bloodstream. Analyte sensors may be insertable into a vein, artery, or other portion of the body containing fluid. Embodiments of the analyte sensors of the subject disclosure may be configured for monitoring the level of the analyte over a time period which may range from minutes, hours, days, weeks, or longer. Analyte sensors that do not require contact with bodily fluid are also contemplated.
- Of interest are analyte sensors, such as glucose sensors, that are capable of in vivo detection of an analyte for about one hour or more, e.g., about a few hours or more, e.g., about a few days of more, e.g., about three or more days, e.g., about five days or more, e.g., about seven days or more, e.g., about several weeks or at least one month. Future analyte levels may be predicted based on information obtained, e.g., the current analyte level at time t0, the rate of change of the analyte, etc. Predictive alarms may notify the user of a predicted analyte levels that may be of concern in advance of the user's analyte level reaching the future level. This provides the user an opportunity to take corrective action.
-
FIG. 1 shows a data monitoring and management system such as, for example, an analyte (e.g., glucose)monitoring system 100 in accordance with certain embodiments. Embodiments of the subject disclosure are further described primarily with respect to glucose monitoring devices and systems, and methods of glucose detection, for convenience only and such description is in no way intended to limit the scope of the disclosure. It is to be understood that the analyte monitoring system may be configured to monitor a variety of analytes at the same time or at different times. - Analytes that may be monitored include, but are not limited to, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, creatinine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketone bodies, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be monitored. In those embodiments that monitor more than one analyte, the analytes may be monitored at the same or different times.
- The
analyte monitoring system 100 includes asensor 101, adata processing unit 102 connectable to thesensor 101, and aprimary receiver unit 104 which is configured to communicate with thedata processing unit 102 via acommunication link 103. In certain embodiments, theprimary receiver unit 104 may be further configured to transmit data to adata processing terminal 105 to evaluate or otherwise process or format data received by theprimary receiver unit 104. Thedata processing terminal 105 may be configured to receive data directly from thedata processing unit 102 via a communication link which may optionally be configured for bi-directional communication. Further, thedata processing unit 102 may include a transmitter or a transceiver to transmit and/or receive data to and/or from theprimary receiver unit 104 and/or thedata processing terminal 105 and/or optionally thesecondary receiver unit 106. - Also shown in
FIG. 1 is an optionalsecondary receiver unit 106 which is operatively coupled to the communication link and configured to receive data transmitted from thedata processing unit 102. Thesecondary receiver unit 106 may be configured to communicate with theprimary receiver unit 104, as well as thedata processing terminal 105. Thesecondary receiver unit 106 may be configured for bi-directional wireless communication with each of theprimary receiver unit 104 and thedata processing terminal 105. As discussed in further detail below, in certain embodiments thesecondary receiver unit 106 may be a de-featured receiver as compared to the primary receiver, i.e., the secondary receiver may include a limited or minimal number of functions and features as compared with theprimary receiver unit 104. As such, thesecondary receiver unit 106 may include a smaller (in one or more, including all, dimensions), compact housing or embodied in a device such as a wrist watch, arm band, etc., for example. Alternatively, thesecondary receiver unit 106 may be configured with the same or substantially similar functions and features as theprimary receiver unit 104. Thesecondary receiver unit 106 may include a docking portion to be mated with a docking cradle unit for placement by, e.g., the bedside for night time monitoring, and/or a bi-directional communication device. A docking cradle may recharge a powers supply. - Only one
sensor 101, data processing unit orcontrol unit 102 anddata processing terminal 105 are shown in the embodiment of theanalyte monitoring system 100 illustrated inFIG. 1 . However, it will be appreciated by one of ordinary skill in the art that theanalyte monitoring system 100 may include more than onesensor 101 and/or more than onedata processing unit 102, and/or more than onedata processing terminal 105. Multiple sensors may be positioned in a patient for analyte monitoring at the same or different times. In certain embodiments, analyte information obtained by a first positioned sensor may be employed as a comparison to analyte information obtained by a second sensor. This may be useful to confirm or validate analyte information obtained from one or both of the sensors. Such redundancy may be useful if analyte information is contemplated in critical therapy-related decisions. In certain embodiments, a first sensor may be used to calibrate a second sensor. - The
analyte monitoring system 100 may be a continuous monitoring system, or semi-continuous, or a discrete monitoring system. In a multi-component environment, each component may be configured to be uniquely identified by one or more of the other components in the system so that communication conflict may be readily resolved between the various components within theanalyte monitoring system 100. For example, unique IDs, communication channels, and the like, may be used. - In certain embodiments, the
sensor 101 is physically positioned in or on the body of a user whose analyte level is being monitored. Thesensor 101 may be configured to at least periodically sample the analyte level of the user and convert the sampled analyte level into a corresponding signal for transmission by thedata processing unit 102. Thedata processing unit 102 is coupleable to thesensor 101 so that both devices are positioned in or on the user's body, with at least a portion of theanalyte sensor 101 positioned transcutaneously. The data processing unit may include a fixation element such as adhesive or the like to secure it to the user's body. A mount (not shown) attachable to the user and mateable with theunit 102 may be used. For example, a mount may include an adhesive surface. Thedata processing unit 102 performs data processing functions, where such functions may include but are not limited to, amplification, filtering and encoding of data signals, each of which corresponds to a sampled analyte level of the user, for transmission to theprimary receiver unit 104 via thecommunication link 103. In one embodiment, thesensor 101 or thedata processing unit 102 or a combined sensor/data processing unit may be wholly implantable under the skin layer of the user. - In certain embodiments, the
primary receiver unit 104 may include an analog interface section including an RF receiver and an antenna that is configured to communicate with thedata processing unit 102 via thecommunication link 103, and a data processing section for processing the received data from thedata processing unit 102 such as data decoding, error detection and correction, data clock generation, data bit recovery, etc., or any combination thereof. - In operation, the
primary receiver unit 104 in certain embodiments is configured to synchronize with thedata processing unit 102 to uniquely identify thedata processing unit 102, based on, for example, an identification information of thedata processing unit 102, and thereafter, to periodically receive signals transmitted from thedata processing unit 102 associated with the monitored analyte levels detected by thesensor 101. - Referring again to
FIG. 1 , thedata processing terminal 105 may include a personal computer, a portable computer such as a laptop or a handheld device (e.g., personal digital assistants (PDAs), telephone such as a cellular phone (e.g., a multimedia and Internet-enabled mobile phone such as an iPhone or similar phone), mp3 player, pager, and the like), drug delivery device, each of which may be configured for data communication with the receiver via a wired or a wireless connection. Additionally, thedata processing terminal 105 may further be connected to a data network (not shown) for storing, retrieving, updating, and/or analyzing data corresponding to the detected analyte level of the user. - The
data processing terminal 105 may include an infusion device such as an insulin infusion pump or the like, which may be configured to administer insulin to patients, and which may be configured to communicate with theprimary receiver unit 104 for receiving, among others, the measured analyte level. Alternatively, theprimary receiver unit 104 may be configured to integrate an infusion device therein so that theprimary receiver unit 104 is configured to administer insulin (or other appropriate drug) therapy to patients, for example, for administering and modifying basal profiles, as well as for determining appropriate boluses for administration based on, among others, the detected analyte levels received from thedata processing unit 102. An infusion device may be an external device or an internal device (wholly implantable in a user). - In certain embodiments, the
data processing terminal 105, which may include an insulin pump, may be configured to receive the analyte signals from thedata processing unit 102, and thus, incorporate the functions of theprimary receiver unit 104 including data processing for managing the patient's insulin therapy and analyte monitoring. In certain embodiments, thecommunication link 103 as well as one or more of the other communication interfaces shown inFIG. 1 , may use one or more of: an RF communication protocol, an infrared communication protocol, a Bluetooth enabled communication protocol, an 802.11x wireless communication protocol, or an equivalent wireless communication protocol which would allow secure, wireless communication of several units (for example, per HIPPA requirements), while avoiding potential data collision and interference. -
FIG. 2 shows a block diagram of an embodiment of a data processing unit of the data monitoring and detection system shown inFIG. 1 . User input and/or interface components may be included or a data processing unit may be free of user input and/or interface components. In certain embodiments, one or more application-specific integrated circuits (ASIC) may be used to implement one or more functions or routines associated with the operations of the data processing unit (and/or receiver unit) using for example one or more state machines and buffers. The processor shown inFIG. 2 may be equipped with sufficient memory to store the data of interest (such as analyte data) for extended periods of time ranging from one to several samples to the number of samples obtained for an entire wear period of several days to weeks. In one aspect, the memory may be included as part of theprocessor 204. In another embodiment, a separate memory unit such as a memory chip, random access memory (RAM) or any other storage device for storing for subsequent retrieval data. For example, as shown, the data processing unit may include astorage unit 215 operative coupled to theprocessor 204, and configured to store the analyte data received, for example, from the sensor 101 (FIG. 1 ). In one aspect, thestorage unit 215 may be configured to store a large volume of data received over a predetermined time period from the sensor, and, theprocessor 204 may be configured to, for example, transmit the stored analyte sensor data in a batch mode, for example, after collecting and storing over a defined time period in a single or multiple data transmission. In another aspect, theprocessor 204 may be configured such that the received analyte sensor data is e transmitted in real time, when received from the analyte sensor. - Also, the
processor 204 may be configured to anticipate or wait for a receipt confirmation signal from the recipient of the data transmission (for example, thereceiver unit 104FIG. 1 ), where when the signal receipt confirmation signal is not received, theprocessor 204 of thedata processing unit 102 may be configured to retrieve the stored analyte sensor data and retransmit it to thereceiver unit 104, for example. - As can be seen in the embodiment of
FIG. 2 , the sensor unit 101 (FIG. 1 ) includes four contacts, three of which are electrodes—work electrode (W) 210, reference electrode (R) 212, and counter electrode (C) 213, each operatively coupled to theanalog interface 201 of thedata processing unit 102. This embodiment also shows optional guard contact (G) 211. Fewer or greater electrodes may be employed. For example, the counter and reference electrode functions may be served by a single counter/reference electrode, there may be more than one working electrode and/or reference electrode and/or counter electrode, etc. -
FIG. 3 is a block diagram of an embodiment of a receiver/monitor unit such as theprimary receiver unit 104 of the data monitoring and management system shown inFIG. 1 . Theprimary receiver unit 104 includes one or more of: a blood glucosetest strip interface 301, anRF receiver 302, aninput 303, atemperature detection section 304, and aclock 305, each of which is operatively coupled to a processing andstorage section 307. Theprimary receiver unit 104 also includes apower supply 306 operatively coupled to a power conversion andmonitoring section 308. Further, the power conversion andmonitoring section 308 is also coupled to thereceiver processor 307. Moreover, also shown are a receiverserial communication section 309, and anoutput 310, each operatively coupled to the processing andstorage unit 307. The receiver may include user input and/or interface components or may be free of user input and/or interface components. - In certain embodiments, the
test strip interface 301 includes a glucose level testing portion to receive a blood (or other body fluid sample) glucose test or information related thereto. For example, the interface may include a test strip port to receive a glucose test strip. The device may determine the glucose level of the test strip, and optionally display (or otherwise notice) the glucose level on theoutput 310 of theprimary receiver unit 104. Any suitable test strip may be employed, e.g., test strips that only require a very small amount (e.g., one microliter or less, e.g., 0.5 microliter or less, e.g., 0.1 microliter or less), of applied sample to the strip in order to obtain accurate glucose information, e.g. FreeStyle® blood glucose test strips from Abbott Diabetes Care Inc. Glucose information obtained by the in vitro glucose testing device may be used for a variety of purposes, computations, etc. For example, the information may be used to calibratesensor 101, confirm results of thesensor 101 to increase the confidence thereof (e.g., in instances in which information obtained bysensor 101 is employed in therapy related decisions), etc. - In further embodiments, the
data processing unit 102 and/or theprimary receiver unit 104 and/or thesecondary receiver unit 105, and/or the data processing terminal/infusion section 105 may be configured to receive the blood glucose value wirelessly over a communication link from, for example, a blood glucose meter. In further embodiments, a user manipulating or using the analyte monitoring system 100 (FIG. 1 ) may manually input the blood glucose value using, for example, a user interface (for example, a keyboard, keypad, voice commands, and the like) incorporated in the one or more of thedata processing unit 102, theprimary receiver unit 104,secondary receiver unit 105, or the data processing terminal/infusion section 105. - Additional detailed description of embodiments of test strips, blood glucose (BG) meters and continuous monitoring systems and data management systems that may be employed are provided in but not limited to: U.S. Pat. No. 6,175,752; U.S. Pat. No. 6,560,471; U.S. Pat. No. 5,262,035; U.S. Pat. No. 6,881,551; U.S. Pat. No. 6,121,009; U.S. Pat. No. 7,167,818; U.S. Pat. No. 6,270,455; U.S. Pat. No. 6,161,095; U.S. Pat. No. 5,918,603; U.S. Pat. No. 6,144,837; U.S. Pat. No. 5,601,435; U.S. Pat. No. 5,822,715; U.S. Pat. No. 5,899,855; U.S. Pat. No. 6,071,391; U.S. Pat. No. 6,120,676; U.S. Pat. No. 6,143,164; U.S. Pat. No. 6,299,757; U.S. Pat. No. 6,338,790; U.S. Pat. No. 6,377,894; U.S. Pat. No. 6,600,997; U.S. Pat. No. 6,773,671; U.S. Pat. No. 6,514,460; U.S. Pat. No. 6,592,745; U.S. Pat. No. 5,628,890; U.S. Pat. No. 5,820,551; U.S. Pat. No. 6,736,957; U.S. Pat. No. 4,545,382; U.S. Pat. No. 4,711,245; U.S. Pat. No. 5,509,410; U.S. Pat. No. 6,540,891; U.S. Pat. No. 6,730,200; U.S. Pat. No. 6,764,581; U.S. Pat. No. 6,299,757; U.S. Pat. No. 6,461,496; U.S. Pat. No. 6,503,381; U.S. Pat. No. 6,591,125; U.S. Pat. No. 6,616,819; U.S. Pat. No. 6,618,934; U.S. Pat. No. 6,676,816; U.S. Pat. No. 6,749,740; U.S. Pat. No. 6,893,545; U.S. Pat. No. 6,942,518; U.S. Pat. No. 6,514,718; U.S. patent application Ser. No. 10/745,878 filed Dec. 26, 2003 entitled “Continuous Glucose Monitoring System and Methods of Use”, and elsewhere, the disclosures of each which are incorporated herein by reference for all purposes.
-
FIG. 4 schematically shows an embodiment of an analyte sensor in accordance with the present disclosure. This sensor embodiment includeselectrodes base 404. Electrodes (and/or other features) may be applied or otherwise processed using any suitable technology, e.g., chemical vapor deposition (CVD), physical vapor deposition, sputtering, reactive sputtering, printing, coating, ablating (e.g., laser ablation), painting, dip coating, etching, and the like. Materials include but are not limited to aluminum, carbon (such as graphite), cobalt, copper, gallium, gold, indium, iridium, iron, lead, magnesium, mercury (as an amalgam), nickel, niobium, osmium, palladium, platinum, rhenium, rhodium, selenium, silicon (e.g., doped polycrystalline silicon), silver, tantalum, tin, titanium, tungsten, uranium, vanadium, zinc, zirconium, mixtures thereof, and alloys, oxides, or metallic compounds of these elements. - The sensor may be wholly implantable in a user or may be configured so that only a portion is positioned within (internal) a user and another portion outside (external) a user. For example, the
sensor 400 may include a portion positionable above a surface of theskin 410, and a portion positioned below the skin. In such embodiments, the external portion may include contacts (connected to respective electrodes of the second portion by traces) to connect to another device also external to the user such as a transmitter unit. While the embodiment ofFIG. 4 shows three electrodes side-by-side on the same surface ofbase 404, other configurations are contemplated, e.g., fewer or greater electrodes, some or all electrodes on different surfaces of the base or present on another base, some or all electrodes stacked together, electrodes of differing materials and dimensions, etc. -
FIG. 5A shows a perspective view of an embodiment of anelectrochemical analyte sensor 500 having a first portion (which in this embodiment may be characterized as a major portion) positionable above a surface of theskin 510, and a second portion (which in this embodiment may be characterized as a minor portion) that includes aninsertion tip 530 positionable below the skin, e.g., penetrating through the skin and into, e.g., the subcutaneous space 520, in contact with the user's biofluid such as interstitial fluid. Contact portions of a workingelectrode 501, areference electrode 502, and acounter electrode 503 are positioned on the portion of thesensor 500 situated above theskin surface 510. Workingelectrode 501, areference electrode 502, and acounter electrode 503 are shown at the second section and particularly at theinsertion tip 530. Traces may be provided from the electrode at the tip to the contact, as shown inFIG. 5A . It is to be understood that greater or fewer electrodes may be provided on a sensor. For example, a sensor may include more than one working electrode and/or the counter and reference electrodes may be a single counter/reference electrode, etc. -
FIG. 5B shows a cross sectional view of a portion of thesensor 500 ofFIG. 5A . Theelectrodes sensor 500 as well as the substrate and the dielectric layers are provided in a layered configuration or construction. For example, as shown inFIG. 5B , in one aspect, the sensor 500 (such as thesensor unit 101FIG. 1 ), includes asubstrate layer 504, and afirst conducting layer 501 such as carbon, gold, etc., disposed on at least a portion of thesubstrate layer 504, and which may provide the working electrode. Also shown disposed on at least a portion of thefirst conducting layer 501 is asensing layer 508. - A first insulation layer such as a first
dielectric layer 505 is disposed or layered on at least a portion of thefirst conducting layer 501, and further, asecond conducting layer 509 may be disposed or stacked on top of at least a portion of the first insulation layer (or dielectric layer) 505. As shown inFIG. 5B , thesecond conducting layer 509 may provide thereference electrode 502, and in one aspect, may include a layer of silver/silver chloride (Ag/AgCl), gold, etc. - A
second insulation layer 506 such as a dielectric layer in one embodiment may be disposed or layered on at least a portion of thesecond conducting layer 509. Further, athird conducting layer 503 may provide thecounter electrode 503. It may be disposed on at least a portion of thesecond insulation layer 506. Finally, a third insulation layer may be disposed or layered on at least a portion of thethird conducting layer 503. In this manner, thesensor 500 may be layered such that at least a portion of each of the conducting layers is separated by a respective insulation layer (for example, a dielectric layer). The embodiment ofFIGS. 5A and 5B show the layers having different lengths. Some or all of the layers may have the same or different lengths and/or widths. - In certain embodiments, some or all of the
electrodes substrate 504 in the layered construction as described above, or alternatively, may be provided in a co-planar manner such that two or more electrodes may be positioned on the same plane (e.g., side-by side (e.g., parallel) or angled relative to each other) on thesubstrate 504. For example, co-planar electrodes may include a suitable spacing there between and/or include dielectric material or insulation material disposed between the conducting layers/electrodes. Furthermore, in certain embodiments one or more of theelectrodes substrate 504. In such embodiments, contact pads may be one the same or different sides of the substrate. For example, an electrode may be on a first side and its respective contact may be on a second side, e.g., a trace connecting the electrode and the contact may traverse through the substrate. - As noted above, analyte sensors may include an analyte-responsive enzyme to provide a sensing component or sensing layer. Some analytes, such as oxygen, can be directly electrooxidized or electroreduced on a sensor, and more specifically at least on a working electrode of a sensor. Other analytes, such as glucose and lactate, require the presence of at least one electron transfer agent and/or at least one catalyst to facilitate the electrooxidation or electroreduction of the analyte. Catalysts may also be used for those analyte, such as oxygen, that can be directly electrooxidized or electroreduced on the working electrode. For these analytes, each working electrode includes a sensing layer (see for example sensing layer 408 of
FIG. 5B ) proximate to or on a surface of a working electrode. In many embodiments, a sensing layer is formed near or on only a small portion of at least a working electrode. - The sensing layer includes one or more components designed to facilitate the electrochemical oxidation or reduction of the analyte. The sensing layer may include, for example, a catalyst to catalyze a reaction of the analyte and produce a response at the working electrode, an electron transfer agent to transfer electrons between the analyte and the working electrode (or other component), or both.
- A variety of different sensing layer configurations may be used. In certain embodiments, the sensing layer is deposited on the conductive material of a working electrode. The sensing layer may extend beyond the conductive material of the working electrode. In some cases, the sensing layer may also extend over other electrodes, e.g., over the counter electrode and/or reference electrode (or counter/reference is provided).
- A sensing layer that is in direct contact with the working electrode may contain an electron transfer agent to transfer electrons directly or indirectly between the analyte and the working electrode, and/or a catalyst to facilitate a reaction of the analyte. For example, a glucose, lactate, or oxygen electrode may be formed having a sensing layer which contains a catalyst, such as glucose oxidase, lactate oxidase, or laccase, respectively, and an electron transfer agent that facilitates the electrooxidation of the glucose, lactate, or oxygen, respectively.
- In other embodiments the sensing layer is not deposited directly on the working electrode. Instead, the sensing layer 64 may be spaced apart from the working electrode, and separated from the working electrode, e.g., by a separation layer. A separation layer may include one or more membranes or films or a physical distance. In addition to separating the working electrode from the sensing layer the separation layer may also act as a mass transport limiting layer and/or an interferent eliminating layer and/or a biocompatible layer.
- In certain embodiments which include more than one working electrode, one or more of the working electrodes may not have a corresponding sensing layer, or may have a sensing layer which does not contain one or more components (e.g., an electron transfer agent and/or catalyst) needed to electrolyze the analyte. Thus, the signal at this working electrode may correspond to background signal which may be removed from the analyte signal obtained from one or more other working electrodes that are associated with fully-functional sensing layers by, for example, subtracting the signal.
- In certain embodiments, the sensing layer includes one or more electron transfer agents. Electron transfer agents that may be employed are electroreducible and electrooxidizable ions or molecules having redox potentials that are a few hundred millivolts above or below the redox potential of the standard calomel electrode (SCE). The electron transfer agent may be organic, organometallic, or inorganic. Examples of organic redox species are quinones and species that in their oxidized state have quinoid structures, such as Nile blue and indophenol. Examples of organometallic redox species are metallocenes such as ferrocene. Examples of inorganic redox species are hexacyanoferrate (III), ruthenium hexamine etc.
- In certain embodiments, electron transfer agents have structures or charges which prevent or substantially reduce the diffusional loss of the electron transfer agent during the period of time that the sample is being analyzed. For example, electron transfer agents include but are not limited to a redox species, e.g., bound to a polymer which can in turn be disposed on or near the working electrode. The bond between the redox species and the polymer may be covalent, coordinative, or ionic. Although any organic, organometallic or inorganic redox species may be bound to a polymer and used as an electron transfer agent, in certain embodiments the redox species is a transition metal compound or complex, e.g., osmium, ruthenium, iron, and cobalt compounds or complexes. It will be recognized that many redox species described for use with a polymeric component may also be used, without a polymeric component.
- One type of polymeric electron transfer agent contains a redox species covalently bound in a polymeric composition. An example of this type of mediator is poly(vinylferrocene). Another type of electron transfer agent contains an ionically-bound redox species. This type of mediator may include a charged polymer coupled to an oppositely charged redox species. Examples of this type of mediator include a negatively charged polymer coupled to a positively charged redox species such as an osmium or ruthenium polypyridyl cation. Another example of an ionically-bound mediator is a positively charged polymer such as quaternized poly(4-vinyl pyridine) or poly(1-vinyl imidazole) coupled to a negatively charged redox species such as ferricyanide or ferrocyanide. In other embodiments, electron transfer agents include a redox species coordinatively bound to a polymer. For example, the mediator may be formed by coordination of an osmium or cobalt 2,2′-bipyridyl complex to poly(1-vinyl imidazole) or poly(4-vinyl pyridine).
- Suitable electron transfer agents are osmium transition metal complexes with one or more ligands, each ligand having a nitrogen-containing heterocycle such as 2,2′-bipyridine, 1,10-phenanthroline, 1-methyl, 2-pyridyl biimidazole, or derivatives thereof. The electron transfer agents may also have one or more ligands covalently bound in a polymer, each ligand having at least one nitrogen-containing heterocycle, such as pyridine, imidazole, or derivatives thereof. One example of an electron transfer agent includes (a) a polymer or copolymer having pyridine or imidazole functional groups and (b) osmium cations complexed with two ligands, each ligand containing 2,2′-bipyridine, 1,10-phenanthroline, or derivatives thereof, the two ligands not necessarily being the same. Some derivatives of 2,2′-bipyridine for complexation with the osmium cation include but are not limited to 4,4′-dimethyl-2,2′-bipyridine and mono-, di-, and polyalkoxy-2,2′-bipyridines, such as 4,4′-dimethoxy-2,2′-bipyridine. Derivatives of 1,10-phenanthroline for complexation with the osmium cation include but are not limited to 4,7-dimethyl-1,10-phenanthroline and mono, di-, and polyalkoxy-1,10-phenanthrolines, such as 4,7-dimethoxy-1,10-phenanthroline. Polymers for complexation with the osmium cation include but are not limited to polymers and copolymers of poly(1-vinyl imidazole) (referred to as “PVI”) and poly(4-vinyl pyridine) (referred to as “PVP”). Suitable copolymer substituents of poly(1-vinyl imidazole) include acrylonitrile, acrylamide, and substituted or quaternized N-vinyl imidazole, e.g., electron transfer agents with osmium complexed to a polymer or copolymer of poly(1-vinyl imidazole).
- Embodiments may employ electron transfer agents having a redox potential ranging from about −200 mV to about +200 mV versus the standard calomel electrode (SCE). The sensing layer may also include a catalyst which is capable of catalyzing a reaction of the analyte. The catalyst may also, in some embodiments, act as an electron transfer agent. One example of a suitable catalyst is an enzyme which catalyzes a reaction of the analyte. For example, a catalyst, such as a glucose oxidase, glucose dehydrogenase (e.g., pyrroloquinoline quinone (PQQ), dependent glucose dehydrogenase, flavine adenine dinucleotide (FAD) dependent glucose dehydrogenase, or nicotinamide adenine dinucleotide (NAD) dependent glucose dehydrogenase), may be used when the analyte of interest is glucose. A lactate oxidase or lactate dehydrogenase may be used when the analyte of interest is lactate. Laccase may be used when the analyte of interest is oxygen or when oxygen is generated or consumed in response to a reaction of the analyte.
- The sensing layer may also include a catalyst which is capable of catalyzing a reaction of the analyte. The catalyst may also, in some embodiments, act as an electron transfer agent. One example of a suitable catalyst is an enzyme which catalyzes a reaction of the analyte. For example, a catalyst, such as a glucose oxidase, glucose dehydrogenase (e.g., pyrroloquinoline quinone (PQQ), dependent glucose dehydrogenase or oligosaccharide dehydrogenase, flavine adenine dinucleotide (FAD) dependent glucose dehydrogenase, nicotinamide adenine dinucleotide (NAD) dependent glucose dehydrogenase), may be used when the analyte of interest is glucose. A lactate oxidase or lactate dehydrogenase may be used when the analyte of interest is lactate. Laccase may be used when the analyte of interest is oxygen or when oxygen is generated or consumed in response to a reaction of the analyte.
- In certain embodiments, a catalyst may be attached to a polymer, cross linking the catalyst with another electron transfer agent (which, as described above, may be polymeric. A second catalyst may also be used in certain embodiments. This second catalyst may be used to catalyze a reaction of a product compound resulting from the catalyzed reaction of the analyte. The second catalyst may operate with an electron transfer agent to electrolyze the product compound to generate a signal at the working electrode. Alternatively, a second catalyst may be provided in an interferent-eliminating layer to catalyze reactions that remove interferents.
- Certain embodiments include a Wired Enzyme™ sensing layer (Abbott Diabetes Care, Inc.) that works at a gentle oxidizing potential, e.g., a potential of about +40 mV. This sensing layer uses an osmium (Os)-based mediator designed for low potential operation and is stably anchored in a polymeric layer. Accordingly, in certain embodiments the sensing element is redox active component that includes (1) Osmium-based mediator molecules attached by stable (bidente) ligands anchored to a polymeric backbone, and (2) glucose oxidase enzyme molecules. These two constituents are crosslinked together.
- A mass transport limiting layer (not shown), e.g., an analyte flux modulating layer, may be included with the sensor to act as a diffusion-limiting barrier to reduce the rate of mass transport of the analyte, for example, glucose or lactate, into the region around the working electrodes. The mass transport limiting layers are useful in limiting the flux of an analyte to a working electrode in an electrochemical sensor so that the sensor is linearly responsive over a large range of analyte concentrations and is easily calibrated. Mass transport limiting layers may include polymers and may be biocompatible. A mass transport limiting layer may provide many functions, e.g., biocompatibility and/or interferent-eliminating, etc.
- In certain embodiments, a mass transport limiting layer is a membrane composed of crosslinked polymers containing heterocyclic nitrogen groups, such as polymers of polyvinylpyridine and polyvinylimidazole. Embodiments also include membranes that are made of a polyurethane, or polyether urethane, or chemically related material, or membranes that are made of silicone, and the like.
- A membrane may be formed by crosslinking in situ a polymer, modified with a zwitterionic moiety, a non-pyridine copolymer component, and optionally another moiety that is either hydrophilic or hydrophobic, and/or has other desirable properties, in an alcohol-buffer solution. The modified polymer may be made from a precursor polymer containing heterocyclic nitrogen groups. For example, a precursor polymer may be polyvinylpyridine or polyvinylimidazole. Optionally, hydrophilic or hydrophobic modifiers may be used to “fine-tune” the permeability of the resulting membrane to an analyte of interest. Optional hydrophilic modifiers, such as poly(ethylene glycol), hydroxyl or polyhydroxyl modifiers, may be used to enhance the biocompatibility of the polymer or the resulting membrane.
- A membrane may be formed in situ by applying an alcohol-buffer solution of a crosslinker and a modified polymer over an enzyme-containing sensing layer and allowing the solution to cure for about one to two days or other appropriate time period. The crosslinker-polymer solution may be applied to the sensing layer by placing a droplet or droplets of the solution on the sensor, by dipping the sensor into the solution, or the like. Generally, the thickness of the membrane is controlled by the concentration of the solution, by the number of droplets of the solution applied, by the number of times the sensor is dipped in the solution, or by any combination of these factors. A membrane applied in this manner may have any combination of the following functions: (1) mass transport limitation, i.e. reduction of the flux of analyte that can reach the sensing layer, (2) biocompatibility enhancement, or (3) interferent reduction.
- The description herein is directed primarily to electrochemical sensors for convenience only and is in no way intended to limit the scope of the disclosure. Other sensors and sensor systems are contemplated. Such include, but are not limited to, optical sensors, colorimetric sensors, potentiometric sensors, coulometric sensors and sensors that detect hydrogen peroxide to infer glucose levels, for example. For example, a hydrogen peroxide-detecting sensor may be constructed in which a sensing layer includes enzyme such as glucose oxides, glucose dehydrogensae, or the like, and is positioned proximate to the working electrode. The sending layer may be covered by a membrane that is selectively permeable to glucose. Once the glucose passes through the membrane, it is oxidized by the enzyme and reduced glucose oxidase can then be oxidized by reacting with molecular oxygen to produce hydrogen peroxide.
- Certain embodiments include a hydrogen peroxide-detecting sensor constructed from a sensing layer prepared by crosslinking two components together, for example: (1) a redox compound such as a redox polymer containing pendent Os polypyridyl complexes with oxidation potentials of about +200 mV vs. SCE, and (2) periodate oxidized horseradish peroxidase (HRP). Such a sensor functions in a reductive mode; the working electrode is controlled at a potential negative to that of the Os complex, resulting in mediated reduction of hydrogen peroxide through the HRP catalyst.
- In another example, a potentiometric sensor can be constructed as follows. A glucose-sensing layer is constructed by crosslinking together (1) a redox polymer containing pendent Os polypyridyl complexes with oxidation potentials from about −200 mV to +200 mV vs. SCE, and (2) glucose oxidase. This sensor can then be used in a potentiometric mode, by exposing the sensor to a glucose containing solution, under conditions of zero current flow, and allowing the ratio of reduced/oxidized Os to reach an equilibrium value. The reduced/oxidized Os ratio varies in a reproducible way with the glucose concentration, and will cause the electrode's potential to vary in a similar way.
- A sensor may also include an active agent such as an anticlotting and/or antiglycolytic agent(s) disposed on at least a portion a sensor that is positioned in a user. An anticlotting agent may reduce or eliminate the clotting of blood or other body fluid around the sensor, particularly after insertion of the sensor. Examples of useful anticlotting agents include heparin and tissue plasminogen activator (TPA), as well as other known anticlotting agents. Embodiments may include an antiglycolytic agent or precursor thereof. Examples of antiglycolytic agents are glyceraldehyde, fluoride ion, and mannose.
- Sensors may be configured to require no system calibration or no user calibration. For example, a sensor may be factory calibrated and need not require further calibrating. In certain embodiments, calibration may be required, but may be done without user intervention, i.e., may be automatic. In those embodiments in which calibration by the user is required, the calibration may be according to a predetermined schedule or may be dynamic, i.e., the time for which may be determined by the system on a real-time basis according to various factors, such as but not limited to glucose concentration and/or temperature and/or rate of change of glucose, etc.
- Calibration may be accomplished using an in vitro test strip (or other reference), e.g., a small sample test strip such as a test strip that requires less than about 1 microliter of sample (for example FreeStyle® blood glucose monitoring test strips from Abbott Diabetes Care). For example, test strips that require less than about 1 nanoliter of sample may be used. In certain embodiments, a sensor may be calibrated using only one sample of body fluid per calibration event. For example, a user need only lance a body part one time to obtain sample for a calibration event (e.g., for a test strip), or may lance more than one time within a short period of time if an insufficient volume of sample is firstly obtained. Embodiments include obtaining and using multiple samples of body fluid for a given calibration event, where glucose values of each sample are substantially similar. Data obtained from a given calibration event may be used independently to calibrate or combined with data obtained from previous calibration events, e.g., averaged including weighted averaged, etc., to calibrate. In certain embodiments, a system need only be calibrated once by a user, where recalibration of the system is not required.
- Analyte systems may include an optional alarm system that, e.g., based on information from a processor, warns the patient of a potentially detrimental condition of the analyte. For example, if glucose is the analyte, an alarm system may warn a user of conditions such as hypoglycemia and/or hyperglycemia and/or impending hypoglycemia, and/or impending hyperglycemia. An alarm system may be triggered when analyte levels approach, reach or exceed a threshold value. An alarm system may also, or alternatively, be activated when the rate of change, or acceleration of the rate of change, in analyte level increase or decrease approaches, reaches or exceeds a threshold rate or acceleration. A system may also include system alarms that notify a user of system information such as battery condition, calibration, sensor dislodgment, sensor malfunction, etc. Alarms may be, for example, auditory and/or visual. Other sensory-stimulating alarm systems may be used including alarm systems which heat, cool, vibrate, or produce a mild electrical shock when activated.
- The subject disclosure also includes sensors used in sensor-based drug delivery systems. The system may provide a drug to counteract the high or low level of the analyte in response to the signals from one or more sensors. Alternatively, the system may monitor the drug concentration to ensure that the drug remains within a desired therapeutic range. The drug delivery system may include one or more (e.g., two or more) sensors, a processing unit such as a transmitter, a receiver/display unit, and a drug administration system. In some cases, some or all components may be integrated in a single unit. A sensor-based drug delivery system may use data from the one or more sensors to provide necessary input for a control algorithm/mechanism to adjust the administration of drugs, e.g., automatically or semi-automatically. As an example, a glucose sensor may be used to control and adjust the administration of insulin from an external or implanted insulin pump.
- As discussed above, embodiments of the present disclosure relate to methods and devices for detecting at least one analyte such as glucose in body fluid. Embodiments relate to the continuous and/or automatic in vivo monitoring of the level of one or more analytes using a continuous analyte monitoring system that includes an analyte sensor at least a portion of which is to be positioned beneath a skin surface of a user for a period of time and/or the discrete monitoring of one or more analytes using an in vitro blood glucose (“BG”) meter in conjunction with an analyte test strip. Embodiments include combined or combinable devices, systems and methods and/or transferring data between an in vivo continuous system and a BG meter system, and include integrated systems.
- Embodiments include “Data Logger” systems which include a continuous glucose monitoring system (at least an analyte sensor and control unit (e.g., an on body unit)). The continuous glucose monitoring (“CG”) system may have limited real-time connectivity with a BG meter. For example, real time connectivity may be limited to communicating calibration data (e.g., a BG value) to the CG system or it may have the ability to receive data from the CG system on demand (as compared to a CG system continuously broadcasting such data). In one embodiment, the data processing unit (102) may be an on-body unit that is configured to operate in several transmission modes. In a first mode, analyte related data may be transmitted when a new data value (e.g., sensor data) is available (for example, when received from the analyte sensor). This mode of operation may result in “lost data” because the
data processing unit 102 does not get confirmation that the data was successfully received by thereceiver unit 104, and in some embodiments, this data may not be resent. - In a second transmission mode, data may be transmitted when the new data is available and the
data processing unit 102 may receive an acknowledgement that such data has been successfully received, or if the transmission was unsuccessful the data would be stored (“buffered”) for another attempt. This mode reduces the likelihood of “lost data”. In a third mode (“data logging mode”), thedata processing unit 102 may be configured to retain or store all data (i.e.; not attempt to transmit it when it becomes available) until the receiver unit (104) requests the data, or based upon a scheduled data transmission. - CG data obtained by the CG Data Logger may be processed by the Data Logger system or by the BG meter and/or by a data management system (“DMS”) which may includes a computer such as a PC and an optional server. For example, the CoPilot™ data management system from Abbott Diabetes Care, Inc., or the like, may be employed. In certain embodiments neither the CG system nor the BG meter are capable of (or have such capability, but the capability is selectively turned off) supporting continuous real time CG data communication, thereby substantially reducing power requirements. Such embodiments are CG Data Loggers in which CG data resides (i.e., is logged) in a CG control unit (e.g., on-body unit) until it is retrieved by a BG meter. In other words, a CG Data Logger buffers the CG data and stores it in memory until the CG data is downloaded or transferred to the BG meter, e.g., a user initiates data transfer or transfer may occur at set times. The CG component logs continuous glucose data, but only gives up this data to the on-request to a BG meter. Retrieval may be by any suitable methodology, including but not limited to wireless communication protocols such as for example RF, optical means (such as an IR link), Bluetooth, or a direct connection (such as a USB, or the like), etc. A given BG meter and CG data Logger may be synchronized, e.g., by one or more unique identifiers, thereby ensuring preventing inadvertent data exchange between devices.
-
FIG. 6 shows an exemplary embodiment of a system that includes a CG Data Logger and an enhanced BG meter. As shown, the enhanced BG meter may communicate with the CG Data Logger by a wired connection and/or by IR or RF. Referring to the Figure, in one aspect, the CG data logger may be configured to collect and store monitored analyte data over a predetermined time period (for example, from a transcutaneous, subcutaneous or implanted analyte sensor), and transmit the collected and stored analyte data to the BG meter either continuously in real time, or periodically (for example, when the CG data logger is in signal communication with the BG meter (either cabled or wireless), or in a single data transfer mode, for example, at the end of the predetermined time period. - “Modular” embodiments are also provided. Modular systems may be used in conjunction with the Data Logger system in certain embodiments. For example, a separable CG data transfer module may be configured for wireless communication with the CG data logger and further configured to removably mate with a BG meter to transfer CG information to the BG meter (see for example
FIG. 7 ). Modular embodiments include all the necessary hardware (and software) to support either (or both) continuous (real time) or “batched” (data logged) CG data collection in a snap-on or otherwise mateable module that provides CG data to a BG meter. Alarm functionality may be included in the BG meter, as well as features to support CG data processing and communication to a user, e.g., hardware and software to process CG data and/or calibrate CG data, enhanced user interface to communicate CG information to a user (in addition to BG information), e.g., may include CG calibration information, CG trend information, rate of change indicators to indicate the rate of change of glucose, and the like. - Modules may be re-usable by a plurality of users. User privacy features may be included, e.g., a module may not permanently store patient data (user data may be automatically deleted or expunged after a certain time period), data may be encrypted, password protected, or otherwise provided with one or more security features that will limit access to only the intended users. In one aspect, the CG data logger may be configured to collect and store the monitored analyte data received from an analyte sensor, and upon establishing data communication with the BG meter via the data transfer module, communicate the received analyte data in one or more batch transfer, or continuously in real time as the analyte sensor data is received from the sensor.
-
FIG. 7 shows an exemplary embodiment of a modular system that includes a CG control unit/transmitter, a mateable module and an enhanced BG meter. In this embodiment, the CG data logger/transmitter is shown communicating with the module via RF where the module is mateably coupled to the BG meter. However, other suitable data communication approaches may be used including IR, Bluetooth, Zigbee communication, and the like. -
FIG. 8 shows an integrated or continuous system that includes an enhanced BG meter and a CG data logger/transmitter, where the CG data logger is capable of transferring CG data to the enhanced BG meter directly and in real time, in this embodiment shown via a wireless protocol. For example, as shown, the enhanced BG meter may include an RF communication module or chipset that allows for wireless communication with the CG data logger. Accordingly, as the continuous analyte sensor data is received by the CG data logger, the data is substantially contemporaneously transferred or communicated in real time to the enhanced BG meter over the RF communication link. -
FIG. 9 shows an exemplary embodiment of a system which includes a BG meter and a docking unit, herein shown configured as a belt holster. The BG meter couples to the holster via contacts of the holster, which correspond to contacts of the BG meter. The BG meter displays information to the user when electronically coupled to the holster, i.e., when docked or when in wireless signal communication with the belt holster (for example, when removed from the holster). The holster may include some or all functionality of a primary receiver unit as described below for CG monitoring. For example, the holster may contain some or all of a FreeStyle Navigator® system, e.g., the receiver functionality as described above. In one aspect, the belt holster may integrate the CG data logger such that the collected and stored analyte data may be transferred to the BG meter when docked in the holster (or when wirelessly synchronized with the belt holster). - The CG system may be calibrated using the BG meter, e.g., when the BG meter is docked. Such as system may be useful in a variety of instances, e.g., for gestational diabetes, assessing/diagnosing diabetes, and the like.
- In certain embodiments, the CG system (whether it be modular or includes a data logger) may be configured with reduced set of functionalities. For example, it may not include alarms (audible and/or vibratory and/or visual) and/or glucose rate of change indicators and/or a visual or user interface display such as a dot matrix display and/or additional processing power and/or miniaturized, or it may not include a test strip port. For example,
FIG. 10 illustrates features which may be included in an exemplary full-featured CG system, and exemplary integrated real time system and an exemplary Data Logger system. - In certain embodiments, synchronization between a BG and CG systems is provided to calibrate the CG sensor using a BG strip measurement as a reference data point.
- In certain applications, the enhanced BG meters may be used by those who require more intensive (i.e., continuous) glucose monitoring, by temporarily or periodically allowing a user's BG meter to capture CG data without the user having to obtain another meter. Likewise, the added value to a health care provider (“HCP”) is gained by patients periodically obtaining more detailed blood glucose information (e.g., prior to regular check up), thus allowing the HCP to make more informed and suited therapy adjustments for the patient.
- Various embodiments have extensive applicability. For example, indwelling or external sensors other than CG sensors may be included. Data from indwelling or external sensors other than a CG sensor may be captured by the systems described herein (such as temperature data, ketone data, and the like). Furthermore, functions such as weigh management, enhanced data management or insulin pump control may also be added to a BG meter via the modular approach to further enhance the meter. In certain embodiments, a Data Logger includes providing molded electrical contacts that allow for electrical connections thru the on-body case without compromising the watertight seal of the case.
- Embodiments herein may provide increased value of a BG meter to the patient by adding CG functionality to a base BG meter, a low learning curve such that the user does not need to become familiar with two different user interfaces (one for the BG unit and another for the CG system), reduction in cost of the overall system, and substantial immunity to environments where continuous wireless communication may be prohibited such as during flight on an airplane, within hospital or other settings that have sensitive instrumentation that may interfere with RF or other wireless signals.
- Accordingly, an analyte monitoring system in one embodiment includes an analyte sensor for transcutaneous positioning under a skin layer of a subject, a data processing device operatively coupled to the analyte sensor, the device comprising: a control unit, a memory operatively coupled to the control unit and configured to store a plurality of data associated with the monitored analyte level received from the sensor, and a communication unit operatively coupled to the control unit; and a blood glucose meter configured for signal communication with the data processing device, where when the control unit of the data processing device detects a communication link with the blood glucose meter, the control unit is further configured to retrieve the stored plurality of data from the memory and to transmit the retrieved data to the blood glucose meter.
- The blood glucose meter includes a strip port for receiving a blood glucose test strip.
- The communication unit may be configured to communicate with the blood glucose meter using one or more of a wired connection, a USB cable connection, a serial cable connection, an RF communication protocol, an infrared communication protocol, a Bluetooth communication protocol, or an 802.11x communication protocol.
- In one embodiment, data processing device does not include a user output component, where the user output component includes a display.
- The control unit may detect the communication link with the blood glucose meter based on detection of a wired connection to the meter.
- The retrieved stored plurality of data may correspond to glucose data of the subject collected over a predetermined time period.
- The glucose data may be uncalibrated or calibrated.
- The analyte sensor may be a glucose sensor.
- In one aspect, the blood glucose meter may include an output unit configured to output one or more of the received retrieved data.
- The output unit may include a display unit operatively coupled to a housing of the blood glucose meter.
- The output of one or more received data may include a graphical output, a numerical output, or a text output.
- The blood glucose meter may be configured to calibrate the received data.
- The blood glucose meter may include a storage unit configured to store the calibrated data.
- The blood glucose meter may include a storage unit configured to store the received data.
- In another aspect, the system may include a holster device for receiving the blood glucose meter, and the data processing unit may be integrated in the holster device.
- The control unit may be configured to detect the communication link with the blood glucose meter when the meter is coupled to the holster.
- The holster device may include a belt clip.
- A method in another embodiment may include transcutaneously positioning an analyte sensor under a skin layer of a subject, coupling a data processing device to the analyte sensor, storing in a memory of the data processing device a plurality of data associated with the monitored analyte level received from the sensor, operatively coupling a communication unit to the control unit, detecting a communication link with the blood glucose meter, retrieving the stored plurality of data from the memory, and commanding the communication unit to transmit the retrieved data to the blood glucose meter.
- The communication link may be established based on one or more of a wired connection, a USB cable connection, a serial cable connection, an RF communication protocol, an infrared communication protocol, a Bluetooth communication protocol, or an 802.11x communication protocol.
- The method may include displaying on the blood glucose meter the received analyte data.
- The retrieved data may correspond to glucose data of the subject collected over a predetermined time period.
- The method may include calibrating the received data.
- In another aspect, the method may include storing the received data in a memory of the blood glucose meter.
- In still a further aspect, the method may include encrypting the retrieved data prior to transmitting to the blood glucose meter.
- Various other modifications and alterations in the structure and method of operation of the present disclosure will be apparent to those skilled in the art without departing from the scope and spirit of the present disclosure. Although the present disclosure has been described in connection with specific embodiments, it should be understood that the present disclosure as claimed should not be unduly limited to such specific embodiments. It is intended that the following claims define the scope of the present disclosure and that structures and methods within the scope of these claims and their equivalents be covered thereby.
Claims (19)
1. A health monitoring device, comprising:
a housing;
an analyte sensor operatively coupled to the housing, the analyte sensor monitoring an analyte level; and
a data transfer module coupled to the housing and in signal communication with the analyte sensor, the data transfer module receiving one or more signals related to a monitored analyte level and transmitting data related to the monitored analyte level in response to a request for the data, the data transfer module including a memory for storing the data related to the monitored analyte level.
2. The device of claim 1 wherein the data transfer module transmits the stored data related to the monitored analyte level only upon receiving the request.
3. The device of claim 1 wherein upon request the data transfer module transmits the data stored in the memory related to the monitored analyte level, or data related to a substantially real time analyte level, or both the data stored in the memory related to the monitored analyte level and the data related to the substantially real time analyte level.
4. The device of claim 1 wherein the analyte sensor is a glucose sensor.
5. The device of claim 1 wherein the data transfer module transmits a unique identifier with the transmitted data related to the monitored analyte level.
6. The device of claim 5 wherein the data transfer module is synchronized with an external device based at least in part on the transmitted unique identifier.
7. The device of claim 1 wherein the data related to the monitored analyte level is transmitted based on one or more of a wireless communication protocol or a wired connection.
8. The device of claim 7 wherein the wireless communication protocol includes a radio frequency (RF) communication protocol, optical communication protocol, Bluetooth communication protocol, or Zigbee communication protocol.
9. The device of claim 7 wherein the wired connection includes a universal serial bus (USB) connection or a cable connection.
10. The device of claim 1 wherein the memory of the data transfer module buffers the data related to the monitored analyte level.
11. The device of claim 10 wherein the data transfer module includes a processing unit configured to transmit the buffered data related to the monitored analyte level only on request.
12. The device of claim 1 wherein the data transfer module operates in one or more of a first data transmission mode, a second data transmission mode, or a third data transmission mode.
13. The device of claim 12 wherein the first data transmission mode includes transmitting the data related to the monitored analyte level in response to the request when a new sensor data is available.
14. The device of claim 12 wherein the second data transmission mode includes transmitting the data related to the monitored analyte level in response to the request when a new sensor data is available and storing the data related to the monitored analyte level for retransmission.
15. The device of claim 12 wherein the third transmission mode includes storing data related to the monitored analyte level and transmitting the stored data related to the monitored analyte level in response to the request.
16. The device of claim 1 wherein the data transfer module performs one or more of a prospective analysis or a retrospective analysis on the monitored analyte level.
17. The device of claim 1 wherein the analyte sensor requires no system calibration.
18. The device of claim 1 wherein the analyte sensor requires no user calibration.
19. The device of claim 1 wherein the analyte sensor is automatically calibrated.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/628,201 US20100076280A1 (en) | 2007-06-21 | 2009-11-30 | Health Monitor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94558107P | 2007-06-21 | 2007-06-21 | |
US12/143,734 US8617069B2 (en) | 2007-06-21 | 2008-06-20 | Health monitor |
US12/628,201 US20100076280A1 (en) | 2007-06-21 | 2009-11-30 | Health Monitor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/143,734 Continuation US8617069B2 (en) | 2007-06-21 | 2008-06-20 | Health monitor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100076280A1 true US20100076280A1 (en) | 2010-03-25 |
Family
ID=40137215
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/143,734 Active 2032-03-22 US8617069B2 (en) | 2007-06-21 | 2008-06-20 | Health monitor |
US12/625,510 Abandoned US20100076290A1 (en) | 2007-06-21 | 2009-11-24 | Health Monitor |
US12/628,201 Abandoned US20100076280A1 (en) | 2007-06-21 | 2009-11-30 | Health Monitor |
US12/628,210 Abandoned US20100076293A1 (en) | 2007-06-21 | 2009-11-30 | Health Monitor |
US12/628,198 Abandoned US20100076291A1 (en) | 2007-06-21 | 2009-11-30 | Health Monitor |
US12/628,203 Abandoned US20100076292A1 (en) | 2007-06-21 | 2009-11-30 | Health Monitor |
US12/628,177 Abandoned US20100076289A1 (en) | 2007-06-21 | 2009-11-30 | Health Monitor |
US13/292,074 Abandoned US20120053428A1 (en) | 2007-06-21 | 2011-11-08 | Health Monitor |
US14/133,635 Abandoned US20140107436A1 (en) | 2007-06-21 | 2013-12-18 | Health Monitor |
US15/985,615 Abandoned US20180271419A1 (en) | 2007-06-21 | 2018-05-21 | Health Monitor |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/143,734 Active 2032-03-22 US8617069B2 (en) | 2007-06-21 | 2008-06-20 | Health monitor |
US12/625,510 Abandoned US20100076290A1 (en) | 2007-06-21 | 2009-11-24 | Health Monitor |
Family Applications After (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/628,210 Abandoned US20100076293A1 (en) | 2007-06-21 | 2009-11-30 | Health Monitor |
US12/628,198 Abandoned US20100076291A1 (en) | 2007-06-21 | 2009-11-30 | Health Monitor |
US12/628,203 Abandoned US20100076292A1 (en) | 2007-06-21 | 2009-11-30 | Health Monitor |
US12/628,177 Abandoned US20100076289A1 (en) | 2007-06-21 | 2009-11-30 | Health Monitor |
US13/292,074 Abandoned US20120053428A1 (en) | 2007-06-21 | 2011-11-08 | Health Monitor |
US14/133,635 Abandoned US20140107436A1 (en) | 2007-06-21 | 2013-12-18 | Health Monitor |
US15/985,615 Abandoned US20180271419A1 (en) | 2007-06-21 | 2018-05-21 | Health Monitor |
Country Status (7)
Country | Link |
---|---|
US (10) | US8617069B2 (en) |
EP (2) | EP3473167A1 (en) |
JP (4) | JP2010531169A (en) |
CN (2) | CN101686804B (en) |
AU (1) | AU2008265542B2 (en) |
CA (1) | CA2690870C (en) |
WO (1) | WO2008157821A1 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012138431A1 (en) | 2011-04-08 | 2012-10-11 | Praxair Technology, Inc. | Oxygen separation module and apparatus |
US8844007B2 (en) | 2011-04-08 | 2014-09-23 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US8852409B2 (en) | 2012-09-19 | 2014-10-07 | Praxair Technology, Inc. | High purity ceramic oxygen generator |
US9386522B2 (en) | 2011-09-23 | 2016-07-05 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US9452388B2 (en) | 2013-10-08 | 2016-09-27 | Praxair Technology, Inc. | System and method for air temperature control in an oxygen transport membrane based reactor |
US9452401B2 (en) | 2013-10-07 | 2016-09-27 | Praxair Technology, Inc. | Ceramic oxygen transport membrane array reactor and reforming method |
US9453644B2 (en) | 2012-12-28 | 2016-09-27 | Praxair Technology, Inc. | Oxygen transport membrane based advanced power cycle with low pressure synthesis gas slip stream |
US9486735B2 (en) | 2011-12-15 | 2016-11-08 | Praxair Technology, Inc. | Composite oxygen transport membrane |
US9492784B2 (en) | 2011-12-15 | 2016-11-15 | Praxair Technology, Inc. | Composite oxygen transport membrane |
US9556027B2 (en) | 2013-12-02 | 2017-01-31 | Praxair Technology, Inc. | Method and system for producing hydrogen using an oxygen transport membrane based reforming system with secondary reforming |
US9561476B2 (en) | 2010-12-15 | 2017-02-07 | Praxair Technology, Inc. | Catalyst containing oxygen transport membrane |
US9562472B2 (en) | 2014-02-12 | 2017-02-07 | Praxair Technology, Inc. | Oxygen transport membrane reactor based method and system for generating electric power |
US9611144B2 (en) | 2013-04-26 | 2017-04-04 | Praxair Technology, Inc. | Method and system for producing a synthesis gas in an oxygen transport membrane based reforming system that is free of metal dusting corrosion |
US9789445B2 (en) | 2014-10-07 | 2017-10-17 | Praxair Technology, Inc. | Composite oxygen ion transport membrane |
US9839899B2 (en) | 2013-04-26 | 2017-12-12 | Praxair Technology, Inc. | Method and system for producing methanol using an integrated oxygen transport membrane based reforming system |
US9901292B2 (en) | 2013-11-07 | 2018-02-27 | Dexcom, Inc. | Systems and methods for a continuous monitoring of analyte values |
US9938145B2 (en) | 2013-04-26 | 2018-04-10 | Praxair Technology, Inc. | Method and system for adjusting synthesis gas module in an oxygen transport membrane based reforming system |
US9938146B2 (en) | 2015-12-28 | 2018-04-10 | Praxair Technology, Inc. | High aspect ratio catalytic reactor and catalyst inserts therefor |
US9969645B2 (en) | 2012-12-19 | 2018-05-15 | Praxair Technology, Inc. | Method for sealing an oxygen transport membrane assembly |
US10005664B2 (en) | 2013-04-26 | 2018-06-26 | Praxair Technology, Inc. | Method and system for producing a synthesis gas using an oxygen transport membrane based reforming system with secondary reforming and auxiliary heat source |
US10118823B2 (en) | 2015-12-15 | 2018-11-06 | Praxair Technology, Inc. | Method of thermally-stabilizing an oxygen transport membrane-based reforming system |
US10441922B2 (en) | 2015-06-29 | 2019-10-15 | Praxair Technology, Inc. | Dual function composite oxygen transport membrane |
US10822234B2 (en) | 2014-04-16 | 2020-11-03 | Praxair Technology, Inc. | Method and system for oxygen transport membrane enhanced integrated gasifier combined cycle (IGCC) |
US11052353B2 (en) | 2016-04-01 | 2021-07-06 | Praxair Technology, Inc. | Catalyst-containing oxygen transport membrane |
US11136238B2 (en) | 2018-05-21 | 2021-10-05 | Praxair Technology, Inc. | OTM syngas panel with gas heated reformer |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
EP1718198A4 (en) | 2004-02-17 | 2008-06-04 | Therasense Inc | Method and system for providing data communication in continuous glucose monitoring and management system |
US8515518B2 (en) * | 2005-12-28 | 2013-08-20 | Abbott Diabetes Care Inc. | Analyte monitoring |
US8160670B2 (en) * | 2005-12-28 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent |
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
US8346335B2 (en) | 2008-03-28 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US8374668B1 (en) | 2007-10-23 | 2013-02-12 | Abbott Diabetes Care Inc. | Analyte sensor with lag compensation |
US8478557B2 (en) | 2009-07-31 | 2013-07-02 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte monitoring system calibration accuracy |
US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US9392969B2 (en) | 2008-08-31 | 2016-07-19 | Abbott Diabetes Care Inc. | Closed loop control and signal attenuation detection |
US8224415B2 (en) | 2009-01-29 | 2012-07-17 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US7653425B2 (en) | 2006-08-09 | 2010-01-26 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US8473022B2 (en) | 2008-01-31 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte sensor with time lag compensation |
US7630748B2 (en) | 2006-10-25 | 2009-12-08 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US20080199894A1 (en) | 2007-02-15 | 2008-08-21 | Abbott Diabetes Care, Inc. | Device and method for automatic data acquisition and/or detection |
US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
DE202007003159U1 (en) * | 2007-03-01 | 2007-05-10 | Schunk Kohlenstofftechnik Gmbh | Brush contact picking up current from conductive guide rail, comprises sliding contact, carrier and contact pin, all forming parts of a single molded unit |
CA2683721C (en) | 2007-04-14 | 2017-05-23 | Abbott Diabetes Care Inc. | Method and apparatus for providing dynamic multi-stage signal amplification in a medical device |
US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8103471B2 (en) | 2007-05-14 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9125548B2 (en) | 2007-05-14 | 2015-09-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
AU2008265542B2 (en) * | 2007-06-21 | 2014-07-24 | Abbott Diabetes Care Inc. | Health monitor |
US8597188B2 (en) | 2007-06-21 | 2013-12-03 | Abbott Diabetes Care Inc. | Health management devices and methods |
US8160900B2 (en) | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US8834366B2 (en) | 2007-07-31 | 2014-09-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor calibration |
US20090085768A1 (en) * | 2007-10-02 | 2009-04-02 | Medtronic Minimed, Inc. | Glucose sensor transceiver |
US8377031B2 (en) | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US8409093B2 (en) | 2007-10-23 | 2013-04-02 | Abbott Diabetes Care Inc. | Assessing measures of glycemic variability |
US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
US8924159B2 (en) | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8591410B2 (en) | 2008-05-30 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8734422B2 (en) | 2008-08-31 | 2014-05-27 | Abbott Diabetes Care Inc. | Closed loop control with improved alarm functions |
US9943644B2 (en) | 2008-08-31 | 2018-04-17 | Abbott Diabetes Care Inc. | Closed loop control with reference measurement and methods thereof |
US20100057040A1 (en) | 2008-08-31 | 2010-03-04 | Abbott Diabetes Care, Inc. | Robust Closed Loop Control And Methods |
US8986208B2 (en) | 2008-09-30 | 2015-03-24 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US9402544B2 (en) | 2009-02-03 | 2016-08-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
CN102300501B (en) * | 2009-02-04 | 2015-04-08 | 艾伯特糖尿病护理公司 | Multi-function analyte test device and methods therefor |
EP4252639A3 (en) * | 2009-02-26 | 2024-01-03 | Abbott Diabetes Care Inc. | Method of calibrating an analyte sensor |
EP2409253B1 (en) * | 2009-03-16 | 2018-12-05 | Roche Diabetes Care GmbH | Method for automated creation of a user-specific measurement data creation regime for non-continuous blood sugar measurement, data processing device and blood sugar measuring device |
EP2233067A1 (en) * | 2009-03-23 | 2010-09-29 | Roche Diagnostics GmbH | Medicinal system with plug-and-play function |
WO2010127050A1 (en) | 2009-04-28 | 2010-11-04 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
WO2010138856A1 (en) | 2009-05-29 | 2010-12-02 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
EP2438527B1 (en) * | 2009-06-04 | 2018-05-02 | Abbott Diabetes Care, Inc. | Method and system for updating a medical device |
US8613892B2 (en) * | 2009-06-30 | 2013-12-24 | Abbott Diabetes Care Inc. | Analyte meter with a moveable head and methods of using the same |
EP3173014B1 (en) | 2009-07-23 | 2021-08-18 | Abbott Diabetes Care, Inc. | Real time management of data relating to physiological control of glucose levels |
US8993331B2 (en) | 2009-08-31 | 2015-03-31 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
US9314195B2 (en) | 2009-08-31 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
BR112012000220A2 (en) | 2009-08-31 | 2020-12-22 | Abbott Diabetes Care Inc. | METHODS AND MEDICAL DEVICES |
WO2011026053A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Displays for a medical device |
EP2482720A4 (en) | 2009-09-29 | 2014-04-23 | Abbott Diabetes Care Inc | Method and apparatus for providing notification function in analyte monitoring systems |
US8185181B2 (en) | 2009-10-30 | 2012-05-22 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
US8661895B2 (en) * | 2009-12-29 | 2014-03-04 | Abbott Diabetes Care Inc. | Carrying cases for medical devices that use analyte test strips and methods of using the same |
WO2011081678A1 (en) * | 2009-12-31 | 2011-07-07 | Turner Richard W | Blood glucose measurement devices and methods of using the same |
US8828330B2 (en) * | 2010-01-28 | 2014-09-09 | Abbott Diabetes Care Inc. | Universal test strip port |
LT3766408T (en) | 2010-03-24 | 2022-07-11 | Abbott Diabetes Care, Inc. | Medical device inserters |
CN102843969B (en) | 2010-04-16 | 2015-05-13 | 爱科来株式会社 | Sensor and method for removal of interfering substance |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
EP2436311A1 (en) * | 2010-10-04 | 2012-04-04 | PharmaSens AG | Diagnostic device |
US20130248695A1 (en) * | 2010-10-29 | 2013-09-26 | Duncan MacIntyre | Method and apparatus for analyte detection |
EP3583901A3 (en) | 2011-02-28 | 2020-01-15 | Abbott Diabetes Care, Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US10010273B2 (en) | 2011-03-10 | 2018-07-03 | Abbott Diabetes Care, Inc. | Multi-function analyte monitor device and methods of use |
ES2847578T3 (en) | 2011-04-15 | 2021-08-03 | Dexcom Inc | Advanced analyte sensor calibration and error detection |
EP2699175A4 (en) | 2011-04-20 | 2014-08-13 | Abbott Diabetes Care Inc | Analyte monitoring devices and methods |
US9069536B2 (en) | 2011-10-31 | 2015-06-30 | Abbott Diabetes Care Inc. | Electronic devices having integrated reset systems and methods thereof |
WO2013066849A1 (en) | 2011-10-31 | 2013-05-10 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US20130116526A1 (en) | 2011-11-09 | 2013-05-09 | Telcare, Inc. | Handheld Blood Glucose Monitoring Device with Messaging Capability |
US8710993B2 (en) | 2011-11-23 | 2014-04-29 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
EP2890297B1 (en) | 2012-08-30 | 2018-04-11 | Abbott Diabetes Care, Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
EP2901153A4 (en) | 2012-09-26 | 2016-04-27 | Abbott Diabetes Care Inc | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US9730621B2 (en) | 2012-12-31 | 2017-08-15 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US9585563B2 (en) | 2012-12-31 | 2017-03-07 | Dexcom, Inc. | Remote monitoring of analyte measurements |
WO2014152034A1 (en) | 2013-03-15 | 2014-09-25 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
AU2015303880B2 (en) * | 2014-08-21 | 2020-06-11 | Qurasense Inc. | System and method for non-invasive analysis of bodily fluids |
JP2017534327A (en) * | 2014-09-23 | 2017-11-24 | エスアールアイ インターナショナルSRI International | Continuous electrochemical measurement of blood components |
US9841014B2 (en) * | 2014-10-20 | 2017-12-12 | Medtronic Minimed, Inc. | Insulin pump data acquisition device and system |
US20160287149A1 (en) * | 2014-10-22 | 2016-10-06 | Shenzhen Waveguider Optical Telecom Technology Inc . | Continuous glucose monitoring system and monitoring terminal |
GB2535471A (en) * | 2015-02-16 | 2016-08-24 | Camlab Ltd | A computer device for acting as a meter |
WO2016183524A1 (en) | 2015-05-14 | 2016-11-17 | Abbott Diabetes Care Inc. | Systems, devices, and methods for monitoring medical devices |
WO2017011346A1 (en) | 2015-07-10 | 2017-01-19 | Abbott Diabetes Care Inc. | System, device and method of dynamic glucose profile response to physiological parameters |
US20170124275A1 (en) | 2015-10-30 | 2017-05-04 | Dexcom, Inc. | Data backfilling for continuous glucose monitoring |
CA3200794A1 (en) | 2015-12-28 | 2017-07-06 | Dexcom, Inc. | Systems and methods for remote and host monitoring communications |
CN113081065A (en) | 2016-03-18 | 2021-07-09 | 古拉森斯股份有限公司 | Collection device for diagnosing vaginal secretions |
KR101879940B1 (en) * | 2016-08-30 | 2018-07-18 | 최규동 | Pilot Bio-Signal Monitoring System using Wearable Continuous Body Fluid checking apparatus |
US10827958B2 (en) | 2016-11-29 | 2020-11-10 | Dexcom, Inc. | Sensor holder device for invasive biosensors |
US10334515B2 (en) | 2017-01-13 | 2019-06-25 | ENK Wireless, Inc. | Conveying information via auxiliary device selection |
WO2018175489A1 (en) | 2017-03-21 | 2018-09-27 | Abbott Diabetes Care Inc. | Methods, devices and system for providing diabetic condition diagnosis and therapy |
CA3047218C (en) * | 2017-03-21 | 2023-08-29 | F. Hoffmann-La Roche Ag | Medical device and method for manufacturing a medical device useful for continuous monitoring of analytes and/or body functions |
CN111246797A (en) | 2017-10-24 | 2020-06-05 | 德克斯康公司 | Pre-attached analyte sensors |
US11331022B2 (en) * | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
KR102031340B1 (en) * | 2018-03-14 | 2019-10-11 | 주식회사 필로시스 | System, method, and device to measure blood glucose |
KR20210043306A (en) * | 2019-10-11 | 2021-04-21 | 삼성전자주식회사 | Electronic apparatus and control method thereof |
CN111122667A (en) * | 2019-12-30 | 2020-05-08 | 江西飞尚科技有限公司 | Distributed air quality monitoring device and monitoring method thereof |
KR20230043779A (en) | 2020-07-29 | 2023-03-31 | 바이오링크 인코포레이티드 | Continuous Analyte Monitoring System with Microneedle Array |
CA3184224A1 (en) | 2021-05-08 | 2022-11-17 | Joshua Ray Windmiller | Fault detection for microneedle array based continuous analyte monitoring device |
Citations (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5289497A (en) * | 1991-05-23 | 1994-02-22 | Interdigital Technology Corporation | Broadcast synchronized communication system |
US5400794A (en) * | 1993-03-19 | 1995-03-28 | Gorman; Peter G. | Biomedical response monitor and technique using error correction |
US5410326A (en) * | 1992-12-04 | 1995-04-25 | Goldstein; Steven W. | Programmable remote control device for interacting with a plurality of remotely controlled devices |
US5489414A (en) * | 1993-04-23 | 1996-02-06 | Boehringer Mannheim, Gmbh | System for analyzing compounds contained in liquid samples |
US5499243A (en) * | 1993-01-22 | 1996-03-12 | Hall; Dennis R. | Method and apparatus for coordinating transfer of information between a base station and a plurality of radios |
US5600301A (en) * | 1993-03-11 | 1997-02-04 | Schrader Automotive Inc. | Remote tire pressure monitoring system employing coded tire identification and radio frequency transmission, and enabling recalibration upon tire rotation or replacement |
US5601435A (en) * | 1994-11-04 | 1997-02-11 | Intercare | Method and apparatus for interactively monitoring a physiological condition and for interactively providing health related information |
US5623933A (en) * | 1993-08-03 | 1997-04-29 | Seiko Epson Corporation | Pulse wave analysis device |
US5707502A (en) * | 1996-07-12 | 1998-01-13 | Chiron Diagnostics Corporation | Sensors for measuring analyte concentrations and methods of making same |
US5735285A (en) * | 1996-06-04 | 1998-04-07 | Data Critical Corp. | Method and hand-held apparatus for demodulating and viewing frequency modulated biomedical signals |
US5856758A (en) * | 1996-11-20 | 1999-01-05 | Adtran, Inc. | Low distortion driver employing positive feedback for reducing power loss in output impedance that effectively matches the impedance of driven line |
US5891049A (en) * | 1994-09-28 | 1999-04-06 | Heartstream, Inc | Time and data correlated medical display system |
US6028413A (en) * | 1997-09-19 | 2000-02-22 | Perdix Oy | Charging device for batteries in a mobile electrical device |
US6203495B1 (en) * | 1999-06-03 | 2001-03-20 | Cardiac Intelligence Corporation | System and method for providing normalized voice feedback from an individual patient in an automated collection and analysis patient care system |
US20020013522A1 (en) * | 1998-05-20 | 2002-01-31 | Steffen Lav | Medical apparatus for use by a patient for medical self treatment of diabetes |
US20020013538A1 (en) * | 1997-09-30 | 2002-01-31 | David Teller | Method and apparatus for health signs monitoring |
US20020019584A1 (en) * | 2000-03-01 | 2002-02-14 | Schulze Arthur E. | Wireless internet bio-telemetry monitoring system and interface |
US6348640B1 (en) * | 1997-10-03 | 2002-02-19 | Nir Navot | Tampon detection system |
US20020023852A1 (en) * | 1999-02-25 | 2002-02-28 | Minimed Inc. | Glucose sensor package system |
US6359270B1 (en) * | 1998-09-04 | 2002-03-19 | Ncr Corporation | Communications module mounting for domestic appliance |
US6359444B1 (en) * | 1999-05-28 | 2002-03-19 | University Of Kentucky Research Foundation | Remote resonant-circuit analyte sensing apparatus with sensing structure and associated method of sensing |
US20020045808A1 (en) * | 2000-08-18 | 2002-04-18 | Russell Ford | Formulation and manipulation of databases of analyte and associated values |
US20020065454A1 (en) * | 2000-01-21 | 2002-05-30 | Lebel Ronald J. | Microprocessor controlled ambulatory medical apparatus with hand held communication device |
US20030023461A1 (en) * | 2001-03-14 | 2003-01-30 | Dan Quintanilla | Internet based therapy management system |
US6514689B2 (en) * | 1999-05-11 | 2003-02-04 | M-Biotech, Inc. | Hydrogel biosensor |
US20030032867A1 (en) * | 2001-06-21 | 2003-02-13 | Animas Corporation. | System and method for managing diabetes |
US6522927B1 (en) * | 1999-12-01 | 2003-02-18 | Vertis Neuroscience, Inc. | Electrode assembly for a percutaneous electrical therapy system |
US20030060692A1 (en) * | 2001-08-03 | 2003-03-27 | Timothy L. Ruchti | Intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes |
US20030088166A1 (en) * | 1998-03-04 | 2003-05-08 | Therasense, Inc. | Electrochemical analyte sensor |
US20030100821A1 (en) * | 2001-01-02 | 2003-05-29 | Therasense, Inc. | Analyte monitoring device and methods of use |
US20040017300A1 (en) * | 2002-07-25 | 2004-01-29 | Kotzin Michael D. | Portable communication device and corresponding method of operation |
US20040030531A1 (en) * | 2002-03-28 | 2004-02-12 | Honeywell International Inc. | System and method for automated monitoring, recognizing, supporting, and responding to the behavior of an actor |
US20040030581A1 (en) * | 2002-06-12 | 2004-02-12 | Samuel Leven | Heart monitoring device |
US20040030226A1 (en) * | 1999-12-17 | 2004-02-12 | Quy Roger J. | Method and apparatus for health and disease management combining patient data monitoring with wireless internet connectivity |
US20040039255A1 (en) * | 1998-11-30 | 2004-02-26 | Simonsen Jan Henning | Medical system and a method of controlling the system for use by a patient for medical self treatment |
US20040054263A1 (en) * | 2001-08-20 | 2004-03-18 | Piet Moerman | Wireless diabetes management devices and methods for using the same |
US20040186365A1 (en) * | 2002-12-31 | 2004-09-23 | Therasense, Inc. | Continuous glucose monitoring system and methods of use |
US20040225199A1 (en) * | 2003-05-08 | 2004-11-11 | Evanyk Shane Walter | Advanced physiological monitoring systems and methods |
US20050003470A1 (en) * | 2003-06-10 | 2005-01-06 | Therasense, Inc. | Glucose measuring device for use in personal area network |
US20050001024A1 (en) * | 2001-12-03 | 2005-01-06 | Yosuke Kusaka | Electronic apparatus, electronic camera, electronic device, image display apparatus, and image transmission system |
US6850790B2 (en) * | 1998-05-13 | 2005-02-01 | Cygnus, Inc. | Monitoring of physiological analytes |
US20050027463A1 (en) * | 2003-08-01 | 2005-02-03 | Goode Paul V. | System and methods for processing analyte sensor data |
US6983861B2 (en) * | 2002-11-05 | 2006-01-10 | Aidox Technology Corporation | Dispensing apparatus |
US20060010098A1 (en) * | 2004-06-04 | 2006-01-12 | Goodnow Timothy T | Diabetes care host-client architecture and data management system |
US20060040793A1 (en) * | 2001-08-21 | 2006-02-23 | Martens Mark H | Exercise system with graphical feedback and method of gauging fitness progress |
US20060042080A1 (en) * | 1998-03-04 | 2006-03-02 | Therasense, Inc. | Method of making an electrochemical sensor |
US20060049359A1 (en) * | 2003-04-01 | 2006-03-09 | Cabot Microelectronics Corporation | Decontamination and sterilization system using large area x-ray source |
US7020508B2 (en) * | 2002-08-22 | 2006-03-28 | Bodymedia, Inc. | Apparatus for detecting human physiological and contextual information |
US20060264785A1 (en) * | 2005-05-19 | 2006-11-23 | Barton Dring | Monitoring systems and methods |
US20080009304A1 (en) * | 2006-07-06 | 2008-01-10 | Fry Walter G | Electronic device power management system and method |
US7318816B2 (en) * | 1997-02-05 | 2008-01-15 | Medtronic Minimed, Inc. | Insertion device for an insertion set and method of using the same |
US20080055070A1 (en) * | 2006-09-01 | 2008-03-06 | Bange Joseph E | Frequency-agile system for telemetry with implantable device |
US20080060955A1 (en) * | 2003-07-15 | 2008-03-13 | Therasense, Inc. | Glucose measuring device integrated into a holster for a personal area network device |
US20080071580A1 (en) * | 2005-06-03 | 2008-03-20 | Marcus Alan O | System and method for medical evaluation and monitoring |
US20080067627A1 (en) * | 2006-09-15 | 2008-03-20 | Josef Boeck | Fuse Structure and Method for Manufacturing Same |
US20090006133A1 (en) * | 2007-06-27 | 2009-01-01 | Roche Diagnostics Operations, Inc. | Patient information input interface for a therapy system |
US20090020502A1 (en) * | 1999-10-04 | 2009-01-22 | Bhullar Raghbir S | Biosensor and method of making |
US7492254B2 (en) * | 2003-10-24 | 2009-02-17 | Symbol Technologies, Inc. | Radio frequency identification (RFID) based sensor networks |
US20090048503A1 (en) * | 2007-08-16 | 2009-02-19 | Cardiac Pacemakers, Inc. | Glycemic control monitoring using implantable medical device |
US20100025238A1 (en) * | 2008-07-31 | 2010-02-04 | Medtronic Minimed, Inc. | Analyte sensor apparatuses having improved electrode configurations and methods for making and using them |
US7659823B1 (en) * | 2007-03-20 | 2010-02-09 | At&T Intellectual Property Ii, L.P. | Tracking variable conditions using radio frequency identification |
US7668596B2 (en) * | 2002-02-07 | 2010-02-23 | Cardiac Pacemakers, Inc. | Methods and apparatuses for implantable medical device telemetry power management |
US20110004085A1 (en) * | 2009-04-30 | 2011-01-06 | Dexcom, Inc. | Performance reports associated with continuous sensor data from multiple analysis time periods |
US20110004276A1 (en) * | 2009-07-02 | 2011-01-06 | Blair William A | Method and apparatus to detect transponder tagged objects and to communicate with medical telemetry devices, for example during medical procedures |
US7882611B2 (en) * | 2005-09-23 | 2011-02-08 | Medtronic Minimed, Inc. | Method of making an analyte sensor |
US7899511B2 (en) * | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US7905833B2 (en) * | 2004-07-13 | 2011-03-15 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7912655B2 (en) * | 2005-08-05 | 2011-03-22 | Bayer Healthcare Llc | Meter having multi-level user interface |
US7912674B2 (en) * | 2006-10-31 | 2011-03-22 | Roche Diagnostics International Ag | Method for processing a chronological sequence of measurements of a time dependent parameter |
US7914450B2 (en) * | 2003-08-01 | 2011-03-29 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7916013B2 (en) * | 2005-03-21 | 2011-03-29 | Greatbatch Ltd. | RFID detection and identification system for implantable medical devices |
US20110077469A1 (en) * | 2009-09-27 | 2011-03-31 | Blocker Richard A | Systems and methods for utilizing prolonged self monitoring in the analysis of chronic ailment treatments |
US8090445B2 (en) * | 2003-06-30 | 2012-01-03 | Codman Neuro Sciences Sárl | System and method for controlling an implantable medical device subject to magnetic field or radio frequency exposure |
US8094009B2 (en) * | 2008-08-27 | 2012-01-10 | The Invention Science Fund I, Llc | Health-related signaling via wearable items |
US8093991B2 (en) * | 2009-09-16 | 2012-01-10 | Greatbatch Ltd. | RFID detection and identification system for implantable medical devices |
US8098161B2 (en) * | 2008-12-01 | 2012-01-17 | Raytheon Company | Radio frequency identification inlay with improved readability |
US8098159B2 (en) * | 2006-06-09 | 2012-01-17 | Intelleflex Corporation | RF device comparing DAC output to incoming signal for selectively performing an action |
US8098208B2 (en) * | 2006-05-30 | 2012-01-17 | Polyic Gmbh & Co. Kg | Antenna configuration and use thereof |
US8098201B2 (en) * | 2007-11-29 | 2012-01-17 | Electronics & Telecommunications Research Institute | Radio frequency identification tag and radio frequency identification tag antenna |
US8098160B2 (en) * | 2007-01-22 | 2012-01-17 | Cisco Technology, Inc. | Method and system for remotely provisioning and/or configuring a device |
US8102021B2 (en) * | 2008-05-12 | 2012-01-24 | Sychip Inc. | RF devices |
US8103241B2 (en) * | 2007-12-07 | 2012-01-24 | Roche Diagnostics Operations, Inc. | Method and system for wireless device communication |
US8102263B2 (en) * | 2006-12-08 | 2012-01-24 | Electronics And Telecommunications Research Institute | Passive tag including volatile memory |
US8102789B2 (en) * | 2005-12-29 | 2012-01-24 | Medtronic, Inc. | System and method for synchronous wireless communication with a medical device |
US8103325B2 (en) * | 1999-03-08 | 2012-01-24 | Tyco Healthcare Group Lp | Method and circuit for storing and providing historical physiological data |
US8102154B2 (en) * | 2008-09-04 | 2012-01-24 | Medtronic Minimed, Inc. | Energy source isolation and protection circuit for an electronic device |
US8111042B2 (en) * | 2008-08-05 | 2012-02-07 | Broadcom Corporation | Integrated wireless resonant power charging and communication channel |
US8116683B2 (en) * | 2003-02-04 | 2012-02-14 | Access Business Group International Llc | Adaptive inductive power supply with communication |
US8117481B2 (en) * | 2008-06-06 | 2012-02-14 | Roche Diagnostics International Ag | Apparatus and method for processing wirelessly communicated information within an electronic device |
US8115488B2 (en) * | 2006-08-21 | 2012-02-14 | Abqmr, Inc. | Tuning low-inductance coils at low frequencies |
US8120493B2 (en) * | 2006-12-20 | 2012-02-21 | Intel Corporation | Direct communication in antenna devices |
US8124452B2 (en) * | 2009-06-14 | 2012-02-28 | Terepac Corporation | Processes and structures for IC fabrication |
US8130093B2 (en) * | 2002-12-17 | 2012-03-06 | Cardiac Pacemakers, Inc. | Repeater providing data exchange with a medical device for remote patient care and method thereof |
US8131565B2 (en) * | 2006-10-24 | 2012-03-06 | Medapps, Inc. | System for medical data collection and transmission |
US8131351B2 (en) * | 2000-12-15 | 2012-03-06 | Cardiac Pacemakers, Inc. | System and method for correlation of patient health information and implant device data |
US8131365B2 (en) * | 2008-07-09 | 2012-03-06 | Cardiac Pacemakers, Inc. | Event-based battery monitor for implantable devices |
US8132037B2 (en) * | 2008-06-06 | 2012-03-06 | Roche Diagnostics International Ag | Apparatus and method for processing wirelessly communicated data and clock information within an electronic device |
US8135352B2 (en) * | 2006-05-02 | 2012-03-13 | 3M Innovative Properties Company | Telecommunication enclosure monitoring system |
US8136735B2 (en) * | 2004-01-23 | 2012-03-20 | Semiconductor Energy Laboratory Co., Ltd. | ID label, ID card, and ID tag |
US8140299B2 (en) * | 2006-05-17 | 2012-03-20 | Siemens Aktiengesellschaft | Operating method for a sensor and a control facility communicating with the sensor |
US8140160B2 (en) * | 2002-01-29 | 2012-03-20 | Neuropace, Inc. | Systems and methods for interacting with an implantable medical device |
US8140168B2 (en) * | 2003-10-02 | 2012-03-20 | Medtronic, Inc. | External power source for an implantable medical device having an adjustable carrier frequency and system and method related therefore |
US8138925B2 (en) * | 2008-01-15 | 2012-03-20 | Corning Cable Systems, Llc | RFID systems and methods for automatically detecting and/or directing the physical configuration of a complex system |
Family Cites Families (639)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1191363A (en) | 1968-02-19 | 1970-05-13 | Pavelle Ltd | Improvements in or relating to Electronic Thermostats. |
US3949388A (en) | 1972-11-13 | 1976-04-06 | Monitron Industries, Inc. | Physiological sensor and transmitter |
US3926760A (en) | 1973-09-28 | 1975-12-16 | Du Pont | Process for electrophoretic deposition of polymer |
US4245634A (en) | 1975-01-22 | 1981-01-20 | Hospital For Sick Children | Artificial beta cell |
US4036749A (en) | 1975-04-30 | 1977-07-19 | Anderson Donald R | Purification of saline water |
US4055175A (en) | 1976-05-07 | 1977-10-25 | Miles Laboratories, Inc. | Blood glucose control apparatus |
US4129128A (en) | 1977-02-23 | 1978-12-12 | Mcfarlane Richard H | Securing device for catheter placement assembly |
US4344438A (en) | 1978-08-02 | 1982-08-17 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Optical sensor of plasma constituents |
AU530979B2 (en) | 1978-12-07 | 1983-08-04 | Aus. Training Aids Pty. Ltd., | Detecting position of bullet fired at target |
US4373527B1 (en) | 1979-04-27 | 1995-06-27 | Univ Johns Hopkins | Implantable programmable medication infusion system |
US4425920A (en) | 1980-10-24 | 1984-01-17 | Purdue Research Foundation | Apparatus and method for measurement and control of blood pressure |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4392849A (en) | 1981-07-27 | 1983-07-12 | The Cleveland Clinic Foundation | Infusion pump controller |
DE3138194A1 (en) | 1981-09-25 | 1983-04-14 | Basf Ag, 6700 Ludwigshafen | WATER-INSOLUBLE POROESES PROTEIN MATERIAL, THEIR PRODUCTION AND USE |
EP0078636B2 (en) | 1981-10-23 | 1997-04-02 | MediSense, Inc. | Sensor for components of a liquid mixture |
US4431004A (en) | 1981-10-27 | 1984-02-14 | Bessman Samuel P | Implantable glucose sensor |
US4494950A (en) | 1982-01-19 | 1985-01-22 | The Johns Hopkins University | Plural module medication delivery system |
FI831399L (en) | 1982-04-29 | 1983-10-30 | Agripat Sa | KONTAKTLINS AV HAERDAD POLYVINYL ALCOHOL |
EP0098592A3 (en) | 1982-07-06 | 1985-08-21 | Fujisawa Pharmaceutical Co., Ltd. | Portable artificial pancreas |
US4509531A (en) | 1982-07-28 | 1985-04-09 | Teledyne Industries, Inc. | Personal physiological monitor |
GB2128453A (en) | 1982-10-08 | 1984-04-26 | Philips Electronic Associated | System identification in communications systems |
US4527240A (en) | 1982-12-29 | 1985-07-02 | Kvitash Vadim I | Balascopy method for detecting and rapidly evaluating multiple imbalances within multi-parametric systems |
US5509410A (en) | 1983-06-06 | 1996-04-23 | Medisense, Inc. | Strip electrode including screen printing of a single layer |
US5682884A (en) | 1983-05-05 | 1997-11-04 | Medisense, Inc. | Strip electrode with screen printing |
CA1219040A (en) | 1983-05-05 | 1987-03-10 | Elliot V. Plotkin | Measurement of enzyme-catalysed reactions |
CA1226036A (en) | 1983-05-05 | 1987-08-25 | Irving J. Higgins | Analytical equipment and sensor electrodes therefor |
US4538616A (en) | 1983-07-25 | 1985-09-03 | Robert Rogoff | Blood sugar level sensing and monitoring transducer |
DE3429596A1 (en) | 1984-08-10 | 1986-02-20 | Siemens AG, 1000 Berlin und 8000 München | DEVICE FOR THE PHYSIOLOGICAL FREQUENCY CONTROL OF A PACEMAKER PROVIDED WITH A PICTURE ELECTRODE |
CA1254091A (en) | 1984-09-28 | 1989-05-16 | Vladimir Feingold | Implantable medication infusion system |
US5279294A (en) | 1985-04-08 | 1994-01-18 | Cascade Medical, Inc. | Medical diagnostic system |
US4671288A (en) | 1985-06-13 | 1987-06-09 | The Regents Of The University Of California | Electrochemical cell sensor for continuous short-term use in tissues and blood |
US5245314A (en) | 1985-09-18 | 1993-09-14 | Kah Jr Carl L C | Location monitoring system |
US4890620A (en) | 1985-09-20 | 1990-01-02 | The Regents Of The University Of California | Two-dimensional diffusion glucose substrate sensing electrode |
US4757022A (en) | 1986-04-15 | 1988-07-12 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US4703756A (en) | 1986-05-06 | 1987-11-03 | The Regents Of The University Of California | Complete glucose monitoring system with an implantable, telemetered sensor module |
US4731726A (en) | 1986-05-19 | 1988-03-15 | Healthware Corporation | Patient-operated glucose monitor and diabetes management system |
US5055171A (en) | 1986-10-06 | 1991-10-08 | T And G Corporation | Ionic semiconductor materials and applications thereof |
US5002054A (en) | 1987-02-25 | 1991-03-26 | Ash Medical Systems, Inc. | Interstitial filtration and collection device and method for long-term monitoring of physiological constituents of the body |
US4854322A (en) | 1987-02-25 | 1989-08-08 | Ash Medical Systems, Inc. | Capillary filtration and collection device for long-term monitoring of blood constituents |
US4777953A (en) | 1987-02-25 | 1988-10-18 | Ash Medical Systems, Inc. | Capillary filtration and collection method for long-term monitoring of blood constituents |
US4759828A (en) | 1987-04-09 | 1988-07-26 | Nova Biomedical Corporation | Glucose electrode and method of determining glucose |
US4749985A (en) | 1987-04-13 | 1988-06-07 | United States Of America As Represented By The United States Department Of Energy | Functional relationship-based alarm processing |
EP0290683A3 (en) | 1987-05-01 | 1988-12-14 | Diva Medical Systems B.V. | Diabetes management system and apparatus |
GB8725936D0 (en) | 1987-11-05 | 1987-12-09 | Genetics Int Inc | Sensing system |
US4925268A (en) | 1988-07-25 | 1990-05-15 | Abbott Laboratories | Fiber-optic physiological probes |
EP0353328A1 (en) | 1988-08-03 | 1990-02-07 | Dräger Nederland B.V. | A polarographic-amperometric three-electrode sensor |
US5340722A (en) | 1988-08-24 | 1994-08-23 | Avl Medical Instruments Ag | Method for the determination of the concentration of an enzyme substrate and a sensor for carrying out the method |
US4995402A (en) | 1988-10-12 | 1991-02-26 | Thorne, Smith, Astill Technologies, Inc. | Medical droplet whole blood and like monitoring |
US5360404A (en) | 1988-12-14 | 1994-11-01 | Inviro Medical Devices Ltd. | Needle guard and needle assembly for syringe |
US5068536A (en) | 1989-01-19 | 1991-11-26 | Futrex, Inc. | Method for providing custom calibration for near infrared instruments for measurement of blood glucose |
DE69027233T2 (en) | 1989-03-03 | 1996-10-10 | Edward W Stark | Signal processing method and apparatus |
JPH02298855A (en) | 1989-03-20 | 1990-12-11 | Assoc Univ Inc | Electrochemical biosensor using immobilized enzyme and redox polymer |
US4953552A (en) | 1989-04-21 | 1990-09-04 | Demarzo Arthur P | Blood glucose monitoring system |
EP0396788A1 (en) | 1989-05-08 | 1990-11-14 | Dräger Nederland B.V. | Process and sensor for measuring the glucose content of glucosecontaining fluids |
FR2648353B1 (en) | 1989-06-16 | 1992-03-27 | Europhor Sa | MICRODIALYSIS PROBE |
US5431160A (en) | 1989-07-19 | 1995-07-11 | University Of New Mexico | Miniature implantable refillable glucose sensor and material therefor |
US4986271A (en) | 1989-07-19 | 1991-01-22 | The University Of New Mexico | Vivo refillable glucose sensor |
US5264104A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
US5320725A (en) | 1989-08-02 | 1994-06-14 | E. Heller & Company | Electrode and method for the detection of hydrogen peroxide |
US5264105A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
US5262035A (en) | 1989-08-02 | 1993-11-16 | E. Heller And Company | Enzyme electrodes |
US5050612A (en) | 1989-09-12 | 1991-09-24 | Matsumura Kenneth N | Device for computer-assisted monitoring of the body |
US5082550A (en) | 1989-12-11 | 1992-01-21 | The United States Of America As Represented By The Department Of Energy | Enzyme electrochemical sensor electrode and method of making it |
US5342789A (en) | 1989-12-14 | 1994-08-30 | Sensor Technologies, Inc. | Method and device for detecting and quantifying glucose in body fluids |
US5051688A (en) | 1989-12-20 | 1991-09-24 | Rohm Co., Ltd. | Crossed coil meter driving device having a plurality of input parameters |
US5165407A (en) | 1990-04-19 | 1992-11-24 | The University Of Kansas | Implantable glucose sensor |
US5124661A (en) | 1990-07-23 | 1992-06-23 | I-Stat Corporation | Reusable test unit for simulating electrochemical sensor signals for quality assurance of portable blood analyzer instruments |
ATE106015T1 (en) | 1990-09-28 | 1994-06-15 | Pfizer | METER DELIVERY DEVICE CONTAINING A HYDROPHOBIC AGENT. |
EP0562039B2 (en) | 1990-12-12 | 2001-04-18 | Sherwood Medical Company | Infrared thermometer utilizing calibration mapping |
JPH04278450A (en) | 1991-03-04 | 1992-10-05 | Adam Heller | Biosensor and method for analyzing subject |
US5593852A (en) | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
US5262305A (en) | 1991-03-04 | 1993-11-16 | E. Heller & Company | Interferant eliminating biosensors |
US5469855A (en) | 1991-03-08 | 1995-11-28 | Exergen Corporation | Continuous temperature monitor |
US5135004A (en) * | 1991-03-12 | 1992-08-04 | Incontrol, Inc. | Implantable myocardial ischemia monitor and related method |
US5122925A (en) | 1991-04-22 | 1992-06-16 | Control Products, Inc. | Package for electronic components |
CA2074702C (en) | 1991-07-29 | 1996-11-19 | Donald J. Urbas | Programmable transponder |
GB9120144D0 (en) | 1991-09-20 | 1991-11-06 | Imperial College | A dialysis electrode device |
US5322063A (en) | 1991-10-04 | 1994-06-21 | Eli Lilly And Company | Hydrophilic polyurethane membranes for electrochemical glucose sensors |
US5372427A (en) | 1991-12-19 | 1994-12-13 | Texas Instruments Incorporated | Temperature sensor |
US5285792A (en) | 1992-01-10 | 1994-02-15 | Physio-Control Corporation | System for producing prioritized alarm messages in a medical instrument |
US5246867A (en) | 1992-01-17 | 1993-09-21 | University Of Maryland At Baltimore | Determination and quantification of saccharides by luminescence lifetimes and energy transfer |
IL104365A0 (en) | 1992-01-31 | 1993-05-13 | Gensia Pharma | Method and apparatus for closed loop drug delivery |
US5328927A (en) | 1992-03-03 | 1994-07-12 | Merck Sharpe & Dohme, Ltd. | Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
ZA931077B (en) | 1992-03-05 | 1994-01-04 | Qualcomm Inc | Apparatus and method for reducing message collision between mobile stations simultaneously accessing a base station in a cdma cellular communications system |
EP0563795B1 (en) | 1992-03-31 | 1998-07-22 | Dai Nippon Printing Co., Ltd. | Enzyme-immobilized electrode, composition for preparation of the same and electrically conductive enzyme |
CA2133424A1 (en) | 1992-04-03 | 1993-10-14 | Harry Louis Platt | Sensor and system for physiological monitoring |
US5711001A (en) | 1992-05-08 | 1998-01-20 | Motorola, Inc. | Method and circuit for acquisition by a radio receiver |
GB9211402D0 (en) | 1992-05-29 | 1992-07-15 | Univ Manchester | Sensor devices |
US5333615A (en) | 1992-06-22 | 1994-08-02 | William Craelius | Apparatus for digitally recording and analyzing electrocardial and other bioelectric signals |
DK95792A (en) | 1992-07-24 | 1994-01-25 | Radiometer As | Sensor for non-invasive, in vivo determination of an analyte and blood flow |
US6283761B1 (en) | 1992-09-08 | 2001-09-04 | Raymond Anthony Joao | Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information |
WO1994010553A1 (en) | 1992-10-23 | 1994-05-11 | Optex Biomedical, Inc. | Fibre-optic probe for the measurement of fluid parameters |
US20030212579A1 (en) | 2002-05-08 | 2003-11-13 | Brown Stephen J. | Remote health management system |
US5956501A (en) | 1997-01-10 | 1999-09-21 | Health Hero Network, Inc. | Disease simulation system and method |
US5899855A (en) | 1992-11-17 | 1999-05-04 | Health Hero Network, Inc. | Modular microprocessor-based health monitoring system |
US5918603A (en) | 1994-05-23 | 1999-07-06 | Health Hero Network, Inc. | Method for treating medical conditions using a microprocessor-based video game |
ZA938555B (en) | 1992-11-23 | 1994-08-02 | Lilly Co Eli | Technique to improve the performance of electrochemical sensors |
US5342408A (en) | 1993-01-07 | 1994-08-30 | Incontrol, Inc. | Telemetry system for an implantable cardiac device |
US5299571A (en) | 1993-01-22 | 1994-04-05 | Eli Lilly And Company | Apparatus and method for implantation of sensors |
DE4329898A1 (en) | 1993-09-04 | 1995-04-06 | Marcus Dr Besson | Wireless medical diagnostic and monitoring device |
US5582184A (en) | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
US5791344A (en) | 1993-11-19 | 1998-08-11 | Alfred E. Mann Foundation For Scientific Research | Patient monitoring system |
US5497772A (en) | 1993-11-19 | 1996-03-12 | Alfred E. Mann Foundation For Scientific Research | Glucose monitoring system |
FR2713372B1 (en) | 1993-12-01 | 1996-03-01 | Neopost Ind | Thermal protection device for secure electronic device, in particular postage meter. |
DE4401400A1 (en) | 1994-01-19 | 1995-07-20 | Ernst Prof Dr Pfeiffer | Method and arrangement for continuously monitoring the concentration of a metabolite |
US5536249A (en) | 1994-03-09 | 1996-07-16 | Visionary Medical Products, Inc. | Pen-type injector with a microprocessor and blood characteristic monitor |
US5391250A (en) | 1994-03-15 | 1995-02-21 | Minimed Inc. | Method of fabricating thin film sensors |
US5390671A (en) | 1994-03-15 | 1995-02-21 | Minimed Inc. | Transcutaneous sensor insertion set |
US5609575A (en) | 1994-04-11 | 1997-03-11 | Graseby Medical Limited | Infusion pump and method with dose-rate calculation |
US5569186A (en) | 1994-04-25 | 1996-10-29 | Minimed Inc. | Closed loop infusion pump system with removable glucose sensor |
DE4415896A1 (en) * | 1994-05-05 | 1995-11-09 | Boehringer Mannheim Gmbh | Analysis system for monitoring the concentration of an analyte in the blood of a patient |
US5472317A (en) | 1994-06-03 | 1995-12-05 | Minimed Inc. | Mounting clip for a medication infusion pump |
US5809417A (en) | 1994-07-05 | 1998-09-15 | Lucent Technologies Inc. | Cordless telephone arranged for operating with multiple portable units in a frequency hopping system |
US5798961A (en) | 1994-08-23 | 1998-08-25 | Emc Corporation | Non-volatile memory module |
US5462051A (en) | 1994-08-31 | 1995-10-31 | Colin Corporation | Medical communication system |
US5724030A (en) | 1994-10-13 | 1998-03-03 | Bio Medic Data Systems, Inc. | System monitoring reprogrammable implantable transponder |
ATE160079T1 (en) | 1995-02-04 | 1997-11-15 | Baumann & Haldi Sa | SINGLE ARRANGEMENT FOR THE MEASURING, PROCESSING AND TRANSMISSION OF ESSENTIALLY PHYSIOLOGICAL PARAMETERS |
US5586553A (en) | 1995-02-16 | 1996-12-24 | Minimed Inc. | Transcutaneous sensor insertion set |
US5568806A (en) | 1995-02-16 | 1996-10-29 | Minimed Inc. | Transcutaneous sensor insertion set |
US5628310A (en) | 1995-05-19 | 1997-05-13 | Joseph R. Lakowicz | Method and apparatus to perform trans-cutaneous analyte monitoring |
US5995860A (en) | 1995-07-06 | 1999-11-30 | Thomas Jefferson University | Implantable sensor and system for measurement and control of blood constituent levels |
US5581206A (en) | 1995-07-28 | 1996-12-03 | Micron Quantum Devices, Inc. | Power level detection circuit |
US5628890A (en) | 1995-09-27 | 1997-05-13 | Medisense, Inc. | Electrochemical sensor |
US5665222A (en) | 1995-10-11 | 1997-09-09 | E. Heller & Company | Soybean peroxidase electrochemical sensor |
US5748103A (en) | 1995-11-13 | 1998-05-05 | Vitalcom, Inc. | Two-way TDMA telemetry system with power conservation features |
US5711861A (en) | 1995-11-22 | 1998-01-27 | Ward; W. Kenneth | Device for monitoring changes in analyte concentration |
FI960636A (en) | 1996-02-12 | 1997-08-13 | Nokia Mobile Phones Ltd | A procedure for monitoring the health of a patient |
US5833603A (en) | 1996-03-13 | 1998-11-10 | Lipomatrix, Inc. | Implantable biosensing transponder |
FR2748171B1 (en) | 1996-04-30 | 1998-07-17 | Motorola Inc | METHOD FOR GENERATING A CLOCK SIGNAL FOR USE IN A DATA RECEIVER, CLOCK GENERATOR, DATA RECEIVER AND REMOTE CONTROL ACCESS SYSTEM FOR VEHICLES |
DE19618597B4 (en) | 1996-05-09 | 2005-07-21 | Institut für Diabetestechnologie Gemeinnützige Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm | Method for determining the concentration of tissue glucose |
US6130602A (en) | 1996-05-13 | 2000-10-10 | Micron Technology, Inc. | Radio frequency data communications device |
US6230051B1 (en) | 1996-06-18 | 2001-05-08 | Alza Corporation | Device for enhancing transdermal agent delivery or sampling |
US5830064A (en) | 1996-06-21 | 1998-11-03 | Pear, Inc. | Apparatus and method for distinguishing events which collectively exceed chance expectations and thereby controlling an output |
JP3581218B2 (en) | 1996-07-03 | 2004-10-27 | 株式会社東芝 | Mobile communication terminal device and its mobile phone and data terminal device |
IL127213A (en) | 1996-07-08 | 2003-09-17 | Animas Corp | Implantable sensor and system for in vivo measurement and control of fluid constituent levels |
US6544193B2 (en) | 1996-09-04 | 2003-04-08 | Marcio Marc Abreu | Noninvasive measurement of chemical substances |
US6071251A (en) | 1996-12-06 | 2000-06-06 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
US5964993A (en) | 1996-12-19 | 1999-10-12 | Implanted Biosystems Inc. | Glucose sensor |
US6130623A (en) | 1996-12-31 | 2000-10-10 | Lucent Technologies Inc. | Encryption for modulated backscatter systems |
US6122351A (en) | 1997-01-21 | 2000-09-19 | Med Graph, Inc. | Method and system aiding medical diagnosis and treatment |
US6093172A (en) | 1997-02-05 | 2000-07-25 | Minimed Inc. | Injector for a subcutaneous insertion set |
US6293925B1 (en) | 1997-12-31 | 2001-09-25 | Minimed Inc. | Insertion device for an insertion set and method of using the same |
ATE227844T1 (en) | 1997-02-06 | 2002-11-15 | Therasense Inc | SMALL VOLUME SENSOR FOR IN-VITRO DETERMINATION |
US5749907A (en) | 1997-02-18 | 1998-05-12 | Pacesetter, Inc. | System and method for identifying and displaying medical data which violate programmable alarm conditions |
US6309884B1 (en) | 1997-02-26 | 2001-10-30 | Diasense, Inc. | Individual calibration of blood glucose for supporting noninvasive self-monitoring blood glucose |
US6159147A (en) | 1997-02-28 | 2000-12-12 | Qrs Diagnostics, Llc | Personal computer card for collection of real-time biological data |
US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
US7657297B2 (en) | 2004-05-03 | 2010-02-02 | Dexcom, Inc. | Implantable analyte sensor |
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US6862465B2 (en) | 1997-03-04 | 2005-03-01 | Dexcom, Inc. | Device and method for determining analyte levels |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US6558321B1 (en) * | 1997-03-04 | 2003-05-06 | Dexcom, Inc. | Systems and methods for remote monitoring and modulation of medical devices |
US6741877B1 (en) | 1997-03-04 | 2004-05-25 | Dexcom, Inc. | Device and method for determining analyte levels |
US5959529A (en) | 1997-03-07 | 1999-09-28 | Kail, Iv; Karl A. | Reprogrammable remote sensor monitoring system |
US6309975B1 (en) * | 1997-03-14 | 2001-10-30 | Micron Technology, Inc. | Methods of making implanted structures |
US6699187B2 (en) | 1997-03-27 | 2004-03-02 | Medtronic, Inc. | System and method for providing remote expert communications and video capabilities for use during a medical procedure |
US6270455B1 (en) | 1997-03-28 | 2001-08-07 | Health Hero Network, Inc. | Networked system for interactive communications and remote monitoring of drug delivery |
US5942979A (en) | 1997-04-07 | 1999-08-24 | Luppino; Richard | On guard vehicle safety warning system |
US5961451A (en) | 1997-04-07 | 1999-10-05 | Motorola, Inc. | Noninvasive apparatus having a retaining member to retain a removable biosensor |
US5935224A (en) | 1997-04-24 | 1999-08-10 | Microsoft Corporation | Method and apparatus for adaptively coupling an external peripheral device to either a universal serial bus port on a computer or hub or a game port on a computer |
US6085342A (en) | 1997-05-06 | 2000-07-04 | Telefonaktiebolaget L M Ericsson (Publ) | Electronic system having a chip integrated power-on reset circuit with glitch sensor |
US6558351B1 (en) | 1999-06-03 | 2003-05-06 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
US5954643A (en) | 1997-06-09 | 1999-09-21 | Minimid Inc. | Insertion set for a transcutaneous sensor |
US7267665B2 (en) | 1999-06-03 | 2007-09-11 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
JP2002505008A (en) | 1997-06-16 | 2002-02-12 | エラン コーポレーション ピーエルシー | Methods for calibrating and testing sensors for in vivo measurement of analytes and devices for use in such methods |
US6056435A (en) | 1997-06-24 | 2000-05-02 | Exergen Corporation | Ambient and perfusion normalized temperature detector |
US6731976B2 (en) | 1997-09-03 | 2004-05-04 | Medtronic, Inc. | Device and method to measure and communicate body parameters |
US6764581B1 (en) | 1997-09-05 | 2004-07-20 | Abbott Laboratories | Electrode with thin working layer |
US6071391A (en) | 1997-09-12 | 2000-06-06 | Nok Corporation | Enzyme electrode structure |
US6117290A (en) | 1997-09-26 | 2000-09-12 | Pepex Biomedical, Llc | System and method for measuring a bioanalyte such as lactate |
EP1445910A3 (en) | 1997-10-15 | 2005-03-02 | Nokia Corporation | Method of providing information in a communication system using a mobile telephone |
US6736957B1 (en) | 1997-10-16 | 2004-05-18 | Abbott Laboratories | Biosensor electrode mediators for regeneration of cofactors and process for using |
US6119028A (en) | 1997-10-20 | 2000-09-12 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces |
US6088608A (en) | 1997-10-20 | 2000-07-11 | Alfred E. Mann Foundation | Electrochemical sensor and integrity tests therefor |
FI107080B (en) | 1997-10-27 | 2001-05-31 | Nokia Mobile Phones Ltd | measuring device |
ATE352252T1 (en) | 1997-11-12 | 2007-02-15 | Lightouch Medical Inc | METHOD FOR NON-INVASIVE ANALYTE MEASUREMENT |
CA2547296C (en) | 1997-12-04 | 2010-08-24 | Roche Diagnostics Corporation | Apparatus for determining concentration of medical component |
AU728964B2 (en) | 1997-12-04 | 2001-01-25 | Roche Diagnostics Operations Inc. | Instrument setup utility program |
US6579690B1 (en) | 1997-12-05 | 2003-06-17 | Therasense, Inc. | Blood analyte monitoring through subcutaneous measurement |
EP1044028B2 (en) | 1997-12-31 | 2010-01-20 | Medtronic MiniMed, Inc. | Insertion device for an insertion set |
US6097480A (en) | 1998-01-27 | 2000-08-01 | Kaplan; Milton | Vehicle interlock system |
US6024699A (en) | 1998-03-13 | 2000-02-15 | Healthware Corporation | Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients |
US6579231B1 (en) | 1998-03-27 | 2003-06-17 | Mci Communications Corporation | Personal medical monitoring unit and system |
SE9801121D0 (en) | 1998-03-30 | 1998-03-30 | Astra Ab | Electrical device |
JP3104672B2 (en) | 1998-03-31 | 2000-10-30 | 日本電気株式会社 | Current detection type sensor element and method of manufacturing the same |
JPH11296598A (en) | 1998-04-07 | 1999-10-29 | Seizaburo Arita | System and method for predicting blood-sugar level and record medium where same method is recorded |
CA2325886C (en) | 1998-04-09 | 2009-07-21 | California Institute Of Technology | Electronic techniques for analyte detection |
US6091987A (en) | 1998-04-29 | 2000-07-18 | Medtronic, Inc. | Power consumption reduction in medical devices by employing different supply voltages |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
GB2337122B (en) | 1998-05-08 | 2002-11-13 | Medisense Inc | Test strip |
DK1077636T3 (en) | 1998-05-13 | 2004-05-24 | Cygnus Therapeutic Systems | Signal processing for measurement of physiological analytes |
US6121611A (en) | 1998-05-20 | 2000-09-19 | Molecular Imaging Corporation | Force sensing probe for scanning probe microscopy |
JP2000031951A (en) | 1998-07-15 | 2000-01-28 | Fujitsu Ltd | Burst synchronization circuit |
US6493069B1 (en) | 1998-07-24 | 2002-12-10 | Terumo Kabushiki Kaisha | Method and instrument for measuring blood sugar level |
US6558320B1 (en) * | 2000-01-20 | 2003-05-06 | Medtronic Minimed, Inc. | Handheld personal data assistant (PDA) with a medical device and method of using the same |
US6248067B1 (en) | 1999-02-05 | 2001-06-19 | Minimed Inc. | Analyte sensor and holter-type monitor system and method of using the same |
KR20000019716A (en) | 1998-09-15 | 2000-04-15 | 박호군 | Composition comprising bioflavonoid compounds for descending blood sugar |
US6740518B1 (en) | 1998-09-17 | 2004-05-25 | Clinical Micro Sensors, Inc. | Signal detection techniques for the detection of analytes |
PT1102559E (en) | 1998-09-30 | 2003-10-31 | Cygnus Therapeutic Systems | METHOD AND DEVICE FOR PREPARING PHYSIOLOGICAL VALUES |
US6402689B1 (en) | 1998-09-30 | 2002-06-11 | Sicel Technologies, Inc. | Methods, systems, and associated implantable devices for dynamic monitoring of physiological and biological properties of tumors |
US6591125B1 (en) | 2000-06-27 | 2003-07-08 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US20060202859A1 (en) | 1998-10-08 | 2006-09-14 | Mastrototaro John J | Telemetered characteristic monitor system and method of using the same |
US6338790B1 (en) | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
EP1119285A1 (en) | 1998-10-08 | 2001-08-01 | Minimed Inc. | Telemetered characteristic monitor system |
US6496729B2 (en) | 1998-10-28 | 2002-12-17 | Medtronic, Inc. | Power consumption reduction in medical devices employing multiple supply voltages and clock frequency control |
US6366794B1 (en) | 1998-11-20 | 2002-04-02 | The University Of Connecticut | Generic integrated implantable potentiostat telemetry unit for electrochemical sensors |
AU768312B2 (en) | 1998-11-30 | 2003-12-11 | Abbott Laboratories | Analyte test instrument having improved calibration and communication processes |
DK1144028T3 (en) | 1998-11-30 | 2004-10-18 | Novo Nordisk As | A system for assisting a user during medical self-treatment, wherein said self-treatment comprises a plurality of actions |
US6773671B1 (en) | 1998-11-30 | 2004-08-10 | Abbott Laboratories | Multichemistry measuring device and test strips |
US6161095A (en) | 1998-12-16 | 2000-12-12 | Health Hero Network, Inc. | Treatment regimen compliance and efficacy with feedback |
JP2002536103A (en) | 1999-02-12 | 2002-10-29 | シグナス, インコーポレイテッド | Devices and methods for frequent measurement of analytes present in biological systems |
US6424847B1 (en) | 1999-02-25 | 2002-07-23 | Medtronic Minimed, Inc. | Glucose monitor calibration methods |
US6285897B1 (en) | 1999-04-07 | 2001-09-04 | Endonetics, Inc. | Remote physiological monitoring system |
US6494829B1 (en) | 1999-04-15 | 2002-12-17 | Nexan Limited | Physiological sensor array |
US6416471B1 (en) | 1999-04-15 | 2002-07-09 | Nexan Limited | Portable remote patient telemonitoring system |
US6200265B1 (en) | 1999-04-16 | 2001-03-13 | Medtronic, Inc. | Peripheral memory patch and access method for use with an implantable medical device |
US6669663B1 (en) | 1999-04-30 | 2003-12-30 | Medtronic, Inc. | Closed loop medicament pump |
US6546268B1 (en) | 1999-06-02 | 2003-04-08 | Ball Semiconductor, Inc. | Glucose sensor |
US7806886B2 (en) | 1999-06-03 | 2010-10-05 | Medtronic Minimed, Inc. | Apparatus and method for controlling insulin infusion with state variable feedback |
GB2351153B (en) | 1999-06-18 | 2003-03-26 | Abbott Lab | Electrochemical sensor for analysis of liquid samples |
EP1192269A2 (en) | 1999-06-18 | 2002-04-03 | Therasense, Inc. | MASS TRANSPORT LIMITED i IN VIVO /i ANALYTE SENSOR |
US6423035B1 (en) | 1999-06-18 | 2002-07-23 | Animas Corporation | Infusion pump with a sealed drive mechanism and improved method of occlusion detection |
US6804558B2 (en) | 1999-07-07 | 2004-10-12 | Medtronic, Inc. | System and method of communicating between an implantable medical device and a remote computer system or health care provider |
US6413393B1 (en) | 1999-07-07 | 2002-07-02 | Minimed, Inc. | Sensor including UV-absorbing polymer and method of manufacture |
US6514460B1 (en) | 1999-07-28 | 2003-02-04 | Abbott Laboratories | Luminous glucose monitoring device |
US7113821B1 (en) | 1999-08-25 | 2006-09-26 | Johnson & Johnson Consumer Companies, Inc. | Tissue electroperforation for enhanced drug delivery |
US6608562B1 (en) | 1999-08-31 | 2003-08-19 | Denso Corporation | Vital signal detecting apparatus |
AT408182B (en) | 1999-09-17 | 2001-09-25 | Schaupp Lukas Dipl Ing Dr Tech | DEVICE FOR VIVO MEASURING SIZES IN LIVING ORGANISMS |
EP1217942A1 (en) | 1999-09-24 | 2002-07-03 | Healthetech, Inc. | Physiological monitor and associated computation, display and communication unit |
US6662439B1 (en) | 1999-10-04 | 2003-12-16 | Roche Diagnostics Corporation | Laser defined features for patterned laminates and electrodes |
US7276146B2 (en) | 2001-11-16 | 2007-10-02 | Roche Diagnostics Operations, Inc. | Electrodes, methods, apparatuses comprising micro-electrode arrays |
US6294997B1 (en) | 1999-10-04 | 2001-09-25 | Intermec Ip Corp. | RFID tag having timing and environment modules |
US7073246B2 (en) | 1999-10-04 | 2006-07-11 | Roche Diagnostics Operations, Inc. | Method of making a biosensor |
US6767440B1 (en) | 2001-04-24 | 2004-07-27 | Roche Diagnostics Corporation | Biosensor |
US6645359B1 (en) | 2000-10-06 | 2003-11-11 | Roche Diagnostics Corporation | Biosensor |
JP2004513669A (en) | 1999-10-08 | 2004-05-13 | ヘルセテック インコーポレイテッド | Integrated calorie management system |
US6616819B1 (en) | 1999-11-04 | 2003-09-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
EP1230249B1 (en) | 1999-11-15 | 2004-06-02 | Therasense, Inc. | Transition metal complexes with bidentate ligand having an imidazole ring |
US6291200B1 (en) | 1999-11-17 | 2001-09-18 | Agentase, Llc | Enzyme-containing polymeric sensors |
US6658396B1 (en) | 1999-11-29 | 2003-12-02 | Tang Sharon S | Neural network drug dosage estimation |
US6418346B1 (en) | 1999-12-14 | 2002-07-09 | Medtronic, Inc. | Apparatus and method for remote therapy and diagnosis in medical devices via interface systems |
US6497655B1 (en) | 1999-12-17 | 2002-12-24 | Medtronic, Inc. | Virtual remote monitor, alert, diagnostics and programming for implantable medical device systems |
US7060031B2 (en) | 1999-12-17 | 2006-06-13 | Medtronic, Inc. | Method and apparatus for remotely programming implantable medical devices |
US20020091796A1 (en) | 2000-01-03 | 2002-07-11 | John Higginson | Method and apparatus for transmitting data over a network using a docking device |
US7286894B1 (en) | 2000-01-07 | 2007-10-23 | Pasco Scientific | Hand-held computer device and method for interactive data acquisition, analysis, annotation, and calibration |
EP1248660B1 (en) | 2000-01-21 | 2012-04-11 | Medtronic MiniMed, Inc. | Microprocessor controlled ambulatory medical apparatus with hand held communication device |
US7369635B2 (en) | 2000-01-21 | 2008-05-06 | Medtronic Minimed, Inc. | Rapid discrimination preambles and methods for using the same |
US6748445B1 (en) | 2000-02-01 | 2004-06-08 | Microsoft Corporation | System and method for exchanging data |
US20010037060A1 (en) | 2000-02-08 | 2001-11-01 | Thompson Richard P. | Web site for glucose monitoring |
US7003336B2 (en) | 2000-02-10 | 2006-02-21 | Medtronic Minimed, Inc. | Analyte sensor method of making the same |
US6484045B1 (en) | 2000-02-10 | 2002-11-19 | Medtronic Minimed, Inc. | Analyte sensor and method of making the same |
US20030060765A1 (en) | 2000-02-16 | 2003-03-27 | Arthur Campbell | Infusion device menu structure and method of using the same |
US6689191B2 (en) * | 2000-02-22 | 2004-02-10 | Omg Americas, Inc. | Rapid conversion of metal-containing compounds to form metals or metal alloys |
US7890295B2 (en) | 2000-02-23 | 2011-02-15 | Medtronic Minimed, Inc. | Real time self-adjusting calibration algorithm |
US6895263B2 (en) | 2000-02-23 | 2005-05-17 | Medtronic Minimed, Inc. | Real time self-adjusting calibration algorithm |
US7027931B1 (en) | 2000-02-24 | 2006-04-11 | Bionostics, Inc. | System for statistical analysis of quality control data |
US6405066B1 (en) | 2000-03-17 | 2002-06-11 | The Regents Of The University Of California | Implantable analyte sensor |
IL151720A0 (en) | 2000-03-29 | 2003-04-10 | Univ Virginia | Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data |
WO2001075775A2 (en) | 2000-04-04 | 2001-10-11 | Contact Technology Systems, Inc. | Arc fault current interrupter testing device |
US6610012B2 (en) | 2000-04-10 | 2003-08-26 | Healthetech, Inc. | System and method for remote pregnancy monitoring |
US6561975B1 (en) | 2000-04-19 | 2003-05-13 | Medtronic, Inc. | Method and apparatus for communicating with medical device systems |
US6440068B1 (en) | 2000-04-28 | 2002-08-27 | International Business Machines Corporation | Measuring user health as measured by multiple diverse health measurement devices utilizing a personal storage device |
AU2001263022A1 (en) | 2000-05-12 | 2001-11-26 | Therasense, Inc. | Electrodes with multilayer membranes and methods of using and making the electrodes |
US6442413B1 (en) | 2000-05-15 | 2002-08-27 | James H. Silver | Implantable sensor |
US7181261B2 (en) | 2000-05-15 | 2007-02-20 | Silver James H | Implantable, retrievable, thrombus minimizing sensors |
US6459917B1 (en) | 2000-05-22 | 2002-10-01 | Ashok Gowda | Apparatus for access to interstitial fluid, blood, or blood plasma components |
US6735479B2 (en) | 2000-06-14 | 2004-05-11 | Medtronic, Inc. | Lifestyle management system |
US6494830B1 (en) | 2000-06-22 | 2002-12-17 | Guidance Interactive Technologies, Inc. | Handheld controller for monitoring/using medical parameters |
BR0111918B1 (en) | 2000-06-23 | 2010-11-30 | apparatus for monitoring and reporting human physiological information. | |
US6540675B2 (en) | 2000-06-27 | 2003-04-01 | Rosedale Medical, Inc. | Analyte monitor |
US6400974B1 (en) | 2000-06-29 | 2002-06-04 | Sensors For Medicine And Science, Inc. | Implanted sensor processing system and method for processing implanted sensor output |
DE60133653T2 (en) | 2000-08-18 | 2009-06-04 | Animas Technologies Llc | APPARATUS FOR PREDICTING HYPOGLYECURE DROPS |
US20020026111A1 (en) | 2000-08-28 | 2002-02-28 | Neil Ackerman | Methods of monitoring glucose levels in a subject and uses thereof |
DE60116520T2 (en) | 2000-10-10 | 2006-08-31 | Microchips, Inc., Bedford | MICROCHIP RESERVOIR DEVICES WITH WIRELESS TRANSMISSION OF ENERGY AND DATA |
US6712025B2 (en) | 2000-10-13 | 2004-03-30 | Dogwatch, Inc. | Receiver/stimulus unit for an animal control system |
US6695860B1 (en) | 2000-11-13 | 2004-02-24 | Isense Corp. | Transcutaneous sensor insertion device |
US6574510B2 (en) | 2000-11-30 | 2003-06-03 | Cardiac Pacemakers, Inc. | Telemetry apparatus and method for an implantable medical device |
US7018341B2 (en) | 2000-12-11 | 2006-03-28 | Resmed Limited | Methods and apparatus for stroke patient treatment |
TW492117B (en) | 2000-12-15 | 2002-06-21 | Acer Labs Inc | Substrate layout method and structure thereof for decreasing crosstalk between adjacent signals |
US20020074162A1 (en) | 2000-12-15 | 2002-06-20 | Bor-Ray Su | Substrate layout method and structure for reducing cross talk of adjacent signals |
US7052483B2 (en) | 2000-12-19 | 2006-05-30 | Animas Corporation | Transcutaneous inserter for low-profile infusion sets |
US6970529B2 (en) | 2001-01-16 | 2005-11-29 | International Business Machines Corporation | Unified digital architecture |
US6603770B2 (en) | 2001-01-16 | 2003-08-05 | Physical Optics Corporation | Apparatus and method for accessing a network |
US20040197846A1 (en) | 2001-01-18 | 2004-10-07 | Linda Hockersmith | Determination of glucose sensitivity and a method to manipulate blood glucose concentration |
TW536689B (en) | 2001-01-18 | 2003-06-11 | Sharp Kk | Display, portable device, and substrate |
CN1525834A (en) | 2001-01-22 | 2004-09-01 | - | Lancet device having capillary action |
US6968294B2 (en) | 2001-03-15 | 2005-11-22 | Koninklijke Philips Electronics N.V. | Automatic system for monitoring person requiring care and his/her caretaker |
US6611206B2 (en) | 2001-03-15 | 2003-08-26 | Koninklijke Philips Electronics N.V. | Automatic system for monitoring independent person requiring occasional assistance |
WO2002078512A2 (en) | 2001-04-02 | 2002-10-10 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
US6698269B2 (en) | 2001-04-27 | 2004-03-02 | Oceana Sensor Technologies, Inc. | Transducer in-situ testing apparatus and method |
US20020164836A1 (en) | 2001-05-07 | 2002-11-07 | Advanced Semiconductor Engineering Inc. | Method of manufacturing printed circuit board |
US7395214B2 (en) | 2001-05-11 | 2008-07-01 | Craig P Shillingburg | Apparatus, device and method for prescribing, administering and monitoring a treatment regimen for a patient |
US6676816B2 (en) | 2001-05-11 | 2004-01-13 | Therasense, Inc. | Transition metal complexes with (pyridyl)imidazole ligands and sensors using said complexes |
US6932894B2 (en) | 2001-05-15 | 2005-08-23 | Therasense, Inc. | Biosensor membranes composed of polymers containing heterocyclic nitrogens |
US6549796B2 (en) | 2001-05-25 | 2003-04-15 | Lifescan, Inc. | Monitoring analyte concentration using minimally invasive devices |
EP1393400B1 (en) | 2001-06-01 | 2008-07-09 | Polyfuel, Inc. | Removable fuel cartridge, fuel cell assembly comprising said fuel cartridge for portable electronic devices and corresponding device |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
US7011630B2 (en) | 2001-06-22 | 2006-03-14 | Animas Technologies, Llc | Methods for computing rolling analyte measurement values, microprocessors comprising programming to control performance of the methods, and analyte monitoring devices employing the methods |
US7044911B2 (en) | 2001-06-29 | 2006-05-16 | Philometron, Inc. | Gateway platform for biological monitoring and delivery of therapeutic compounds |
US20030208113A1 (en) | 2001-07-18 | 2003-11-06 | Mault James R | Closed loop glycemic index system |
JP2003035229A (en) * | 2001-07-25 | 2003-02-07 | Suzuki Motor Corp | Intake device of v-type engine |
US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US6544212B2 (en) | 2001-07-31 | 2003-04-08 | Roche Diagnostics Corporation | Diabetes management system |
US6781522B2 (en) * | 2001-08-22 | 2004-08-24 | Kivalo, Inc. | Portable storage case for housing a medical monitoring device and an associated method for communicating therewith |
JP3962250B2 (en) * | 2001-08-29 | 2007-08-22 | 株式会社レアメタル | In vivo information detection system and tag device and relay device used therefor |
US6827702B2 (en) | 2001-09-07 | 2004-12-07 | Medtronic Minimed, Inc. | Safety limits for closed-loop infusion pump control |
CN1555244A (en) | 2001-09-13 | 2004-12-15 | Method for transmitting vital health statistics to a remote location form an aircraft | |
US7052591B2 (en) | 2001-09-21 | 2006-05-30 | Therasense, Inc. | Electrodeposition of redox polymers and co-electrodeposition of enzymes by coordinative crosslinking |
US6830562B2 (en) | 2001-09-27 | 2004-12-14 | Unomedical A/S | Injector device for placing a subcutaneous infusion set |
JP2003108677A (en) * | 2001-09-28 | 2003-04-11 | Matsushita Electric Ind Co Ltd | Medical information communication system |
US20050137480A1 (en) | 2001-10-01 | 2005-06-23 | Eckhard Alt | Remote control of implantable device through medical implant communication service band |
DE60237463D1 (en) | 2001-11-16 | 2010-10-07 | Roche Diagnostics Gmbh | FLEXIBLE SENSOR AND MANUFACTURING PROCESS |
US20030116447A1 (en) | 2001-11-16 | 2003-06-26 | Surridge Nigel A. | Electrodes, methods, apparatuses comprising micro-electrode arrays |
US20050043965A1 (en) | 2001-11-28 | 2005-02-24 | Gabriel Heller | Methods and apparatus for automated interactive medical management |
US20030119457A1 (en) | 2001-12-19 | 2003-06-26 | Standke Randolph E. | Filter technique for increasing antenna isolation in portable communication devices |
US7204823B2 (en) | 2001-12-19 | 2007-04-17 | Medtronic Minimed, Inc. | Medication delivery system and monitor |
US7729776B2 (en) | 2001-12-19 | 2010-06-01 | Cardiac Pacemakers, Inc. | Implantable medical device with two or more telemetry systems |
US7082334B2 (en) | 2001-12-19 | 2006-07-25 | Medtronic, Inc. | System and method for transmission of medical and like data from a patient to a dedicated internet website |
US7022072B2 (en) | 2001-12-27 | 2006-04-04 | Medtronic Minimed, Inc. | System for monitoring physiological characteristics |
US20080255438A1 (en) | 2001-12-27 | 2008-10-16 | Medtronic Minimed, Inc. | System for monitoring physiological characteristics |
US7399277B2 (en) | 2001-12-27 | 2008-07-15 | Medtronic Minimed, Inc. | System for monitoring physiological characteristics |
US20050027182A1 (en) | 2001-12-27 | 2005-02-03 | Uzair Siddiqui | System for monitoring physiological characteristics |
US7169107B2 (en) | 2002-01-25 | 2007-01-30 | Karen Jersey-Willuhn | Conductivity reconstruction based on inverse finite element measurements in a tissue monitoring system |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US7613491B2 (en) | 2002-05-22 | 2009-11-03 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US20030212379A1 (en) * | 2002-02-26 | 2003-11-13 | Bylund Adam David | Systems and methods for remotely controlling medication infusion and analyte monitoring |
US7056302B2 (en) | 2002-02-26 | 2006-06-06 | Sterling Medivations, Inc. | Insertion device for an insertion set and method of using the same |
US7468032B2 (en) | 2002-12-18 | 2008-12-23 | Cardiac Pacemakers, Inc. | Advanced patient management for identifying, displaying and assisting with correlating health-related data |
US7043305B2 (en) | 2002-03-06 | 2006-05-09 | Cardiac Pacemakers, Inc. | Method and apparatus for establishing context among events and optimizing implanted medical device performance |
US6998247B2 (en) | 2002-03-08 | 2006-02-14 | Sensys Medical, Inc. | Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers |
US6936006B2 (en) | 2002-03-22 | 2005-08-30 | Novo Nordisk, A/S | Atraumatic insertion of a subcutaneous device |
US7410468B2 (en) | 2002-04-19 | 2008-08-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7708701B2 (en) | 2002-04-19 | 2010-05-04 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device |
WO2003090614A1 (en) | 2002-04-25 | 2003-11-06 | Matsushita Electric Industrial Co., Ltd. | Dosage determination supporting device, injector, and health management supporting system |
US6810309B2 (en) | 2002-04-25 | 2004-10-26 | Visteon Global Technologies, Inc. | Vehicle personalization via biometric identification |
US6983867B1 (en) | 2002-04-29 | 2006-01-10 | Dl Technology Llc | Fluid dispense pump with drip prevention mechanism and method for controlling same |
GB2388716B (en) | 2002-05-13 | 2004-10-20 | Splashpower Ltd | Improvements relating to contact-less power transfer |
US7226978B2 (en) | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US7124027B1 (en) | 2002-07-11 | 2006-10-17 | Yazaki North America, Inc. | Vehicular collision avoidance system |
US20040010207A1 (en) | 2002-07-15 | 2004-01-15 | Flaherty J. Christopher | Self-contained, automatic transcutaneous physiologic sensing system |
JP2004054394A (en) | 2002-07-17 | 2004-02-19 | Toshiba Corp | Radio information processing system, radio information recording medium, radio information processor and communication method for radio information processing system |
US7034677B2 (en) | 2002-07-19 | 2006-04-25 | Smiths Detection Inc. | Non-specific sensor array detectors |
US7470533B2 (en) | 2002-12-20 | 2008-12-30 | Acea Biosciences | Impedance based devices and methods for use in assays |
US7278983B2 (en) | 2002-07-24 | 2007-10-09 | Medtronic Minimed, Inc. | Physiological monitoring device for controlling a medication infusion device |
EP2327359B1 (en) | 2002-08-13 | 2015-01-21 | University Of Virginia Patent Foundation | Method, system, and computer program product for processing of self-monitoring blood glucose (smbg) data to enhance diabetic self-management |
US7404796B2 (en) | 2004-03-01 | 2008-07-29 | Becton Dickinson And Company | System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor |
US7192405B2 (en) | 2002-09-30 | 2007-03-20 | Becton, Dickinson And Company | Integrated lancet and bodily fluid sensor |
KR101226540B1 (en) | 2002-10-11 | 2013-01-25 | 벡톤 디킨슨 앤드 컴퍼니 | System and method for initiating and maintaining continuous, long-term control of a concentration of a substance in a patient using a feedback or model-based controller coupled to a single-needle or multi-needle intradermal (ID) delivery device |
US7381184B2 (en) | 2002-11-05 | 2008-06-03 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US7572237B2 (en) | 2002-11-06 | 2009-08-11 | Abbott Diabetes Care Inc. | Automatic biological analyte testing meter with integrated lancing device and methods of use |
GB0226648D0 (en) | 2002-11-15 | 2002-12-24 | Koninkl Philips Electronics Nv | Usage data harvesting |
US20040100376A1 (en) | 2002-11-26 | 2004-05-27 | Kimberly-Clark Worldwide, Inc. | Healthcare monitoring system |
US7580395B2 (en) | 2002-11-29 | 2009-08-25 | Intermec Ip Corp. | Information gathering apparatus and method having multiple wireless communication options |
US20040122353A1 (en) | 2002-12-19 | 2004-06-24 | Medtronic Minimed, Inc. | Relay device for transferring information between a sensor system and a fluid delivery system |
US7154398B2 (en) | 2003-01-06 | 2006-12-26 | Chen Thomas C H | Wireless communication and global location enabled intelligent health monitoring system |
US7228162B2 (en) | 2003-01-13 | 2007-06-05 | Isense Corporation | Analyte sensor |
US7587287B2 (en) * | 2003-04-04 | 2009-09-08 | Abbott Diabetes Care Inc. | Method and system for transferring analyte test data |
US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US20040204868A1 (en) | 2003-04-09 | 2004-10-14 | Maynard John D. | Reduction of errors in non-invasive tissue sampling |
AU2003902187A0 (en) | 2003-05-08 | 2003-05-22 | Aimedics Pty Ltd | Patient monitor |
US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
US8460243B2 (en) | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
WO2005010483A2 (en) | 2003-06-10 | 2005-02-03 | Smiths Detection Inc. | Sensor arrangement |
US20040254433A1 (en) | 2003-06-12 | 2004-12-16 | Bandis Steven D. | Sensor introducer system, apparatus and method |
US7155290B2 (en) | 2003-06-23 | 2006-12-26 | Cardiac Pacemakers, Inc. | Secure long-range telemetry for implantable medical device |
US7510564B2 (en) | 2003-06-27 | 2009-03-31 | Abbott Diabetes Care Inc. | Lancing device |
US7366556B2 (en) | 2003-12-05 | 2008-04-29 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7074307B2 (en) | 2003-07-25 | 2006-07-11 | Dexcom, Inc. | Electrode systems for electrochemical sensors |
US7467003B2 (en) | 2003-12-05 | 2008-12-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
JP4708342B2 (en) | 2003-07-25 | 2011-06-22 | デックスコム・インコーポレーテッド | Oxygen augmentation membrane system for use in implantable devices |
US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7424318B2 (en) | 2003-12-05 | 2008-09-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7108778B2 (en) | 2003-07-25 | 2006-09-19 | Dexcom, Inc. | Electrochemical sensors including electrode systems with increased oxygen generation |
US7651596B2 (en) | 2005-04-08 | 2010-01-26 | Dexcom, Inc. | Cellulosic-based interference domain for an analyte sensor |
US7460898B2 (en) | 2003-12-05 | 2008-12-02 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US20050176136A1 (en) | 2003-11-19 | 2005-08-11 | Dexcom, Inc. | Afinity domain for analyte sensor |
WO2007120442A2 (en) | 2003-07-25 | 2007-10-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7519408B2 (en) | 2003-11-19 | 2009-04-14 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8626257B2 (en) | 2003-08-01 | 2014-01-07 | Dexcom, Inc. | Analyte sensor |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
US20080119703A1 (en) | 2006-10-04 | 2008-05-22 | Mark Brister | Analyte sensor |
US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8233959B2 (en) | 2003-08-22 | 2012-07-31 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
KR101330431B1 (en) | 2003-09-11 | 2013-11-20 | 테라노스, 인코포레이티드 | Medical device for analyte monitoring and drug delivery |
ES2341963T3 (en) | 2003-09-30 | 2010-06-30 | F. Hoffmann-La Roche Ag | DETECTOR WITH IMPROVED BIOCOMPATIBILITY. |
US7203549B2 (en) | 2003-10-02 | 2007-04-10 | Medtronic, Inc. | Medical device programmer with internal antenna and display |
US20050090607A1 (en) | 2003-10-28 | 2005-04-28 | Dexcom, Inc. | Silicone composition for biocompatible membrane |
EP1761880B1 (en) | 2003-10-29 | 2013-02-27 | Innovision Research & Technology PLC | Rfid apparatus |
US6928380B2 (en) | 2003-10-30 | 2005-08-09 | International Business Machines Corporation | Thermal measurements of electronic devices during operation |
US7299082B2 (en) | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
EP1680175B1 (en) | 2003-11-06 | 2019-06-05 | LifeScan, Inc. | Drug delivery pen with event notification means |
US7419573B2 (en) | 2003-11-06 | 2008-09-02 | 3M Innovative Properties Company | Circuit for electrochemical sensor strip |
US8615282B2 (en) | 2004-07-13 | 2013-12-24 | Dexcom, Inc. | Analyte sensor |
CA2536188A1 (en) | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Electrical devices and anti-scarring agents |
US20050113886A1 (en) | 2003-11-24 | 2005-05-26 | Fischell David R. | Implantable medical system with long range telemetry |
US8364230B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
US8425417B2 (en) | 2003-12-05 | 2013-04-23 | Dexcom, Inc. | Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device |
US8425416B2 (en) | 2006-10-04 | 2013-04-23 | Dexcom, Inc. | Analyte sensor |
US20080200788A1 (en) | 2006-10-04 | 2008-08-21 | Dexcorn, Inc. | Analyte sensor |
EP1711790B1 (en) | 2003-12-05 | 2010-09-08 | DexCom, Inc. | Calibration techniques for a continuous analyte sensor |
US20080197024A1 (en) | 2003-12-05 | 2008-08-21 | Dexcom, Inc. | Analyte sensor |
US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
EP2228642B1 (en) | 2003-12-08 | 2017-07-19 | DexCom, Inc. | Systems and methods for improving electrochemical analyte sensors |
EP2316331B1 (en) | 2003-12-09 | 2016-06-29 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US7384397B2 (en) | 2003-12-30 | 2008-06-10 | Medtronic Minimed, Inc. | System and method for sensor recalibration |
US7637868B2 (en) | 2004-01-12 | 2009-12-29 | Dexcom, Inc. | Composite material for implantable device |
CA2554007C (en) | 2004-01-27 | 2013-03-26 | Altivera L.L.C. | Diagnostic radio frequency identification sensors and applications thereof |
US8165651B2 (en) | 2004-02-09 | 2012-04-24 | Abbott Diabetes Care Inc. | Analyte sensor, and associated system and method employing a catalytic agent |
WO2005079257A2 (en) | 2004-02-12 | 2005-09-01 | Dexcom, Inc. | Biointerface with macro- and micro- architecture |
EP1718198A4 (en) | 2004-02-17 | 2008-06-04 | Therasense Inc | Method and system for providing data communication in continuous glucose monitoring and management system |
US20060154642A1 (en) | 2004-02-20 | 2006-07-13 | Scannell Robert F Jr | Medication & health, environmental, and security monitoring, alert, intervention, information and network system with associated and supporting apparatuses |
JP3590053B1 (en) | 2004-02-24 | 2004-11-17 | 株式会社日立製作所 | Blood glucose measurement device |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
DE102004011135A1 (en) | 2004-03-08 | 2005-09-29 | Disetronic Licensing Ag | Method and apparatus for calculating a bolus amount |
US7228182B2 (en) | 2004-03-15 | 2007-06-05 | Cardiac Pacemakers, Inc. | Cryptographic authentication for telemetry with an implantable medical device |
GB0405798D0 (en) | 2004-03-15 | 2004-04-21 | E San Ltd | Medical data display |
US7831828B2 (en) | 2004-03-15 | 2010-11-09 | Cardiac Pacemakers, Inc. | System and method for securely authenticating a data exchange session with an implantable medical device |
DK1734858T3 (en) | 2004-03-22 | 2014-10-20 | Bodymedia Inc | NON-INVASIVE TEMPERATURE MONITORING DEVICE |
US20080000969A1 (en) * | 2004-03-25 | 2008-01-03 | Cryptomathic A/S | Electronic Voting Systems |
EP1735729A2 (en) | 2004-03-26 | 2006-12-27 | Novo Nordisk A/S | Device for displaying data relevant for a diabetic patient |
US20050221504A1 (en) | 2004-04-01 | 2005-10-06 | Petruno Patrick T | Optoelectronic rapid diagnostic test system |
US6971274B2 (en) | 2004-04-02 | 2005-12-06 | Sierra Instruments, Inc. | Immersible thermal mass flow meter |
US7204540B2 (en) * | 2004-04-16 | 2007-04-17 | Wheatley Donald G | Method for covering structure having automatic coupling system |
US7324850B2 (en) | 2004-04-29 | 2008-01-29 | Cardiac Pacemakers, Inc. | Method and apparatus for communication between a handheld programmer and an implantable medical device |
US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
US20050245799A1 (en) | 2004-05-03 | 2005-11-03 | Dexcom, Inc. | Implantable analyte sensor |
US7125382B2 (en) | 2004-05-20 | 2006-10-24 | Digital Angel Corporation | Embedded bio-sensor system |
US7118667B2 (en) | 2004-06-02 | 2006-10-10 | Jin Po Lee | Biosensors having improved sample application and uses thereof |
US7289855B2 (en) | 2004-06-09 | 2007-10-30 | Medtronic, Inc. | Implantable medical device package antenna |
WO2005123181A2 (en) | 2004-06-10 | 2005-12-29 | Ndi Medical, Llc | Implantable pulse generator for providing functional and/or therapeutic stimulation of muscles and/or nerves and/or central nervous system tissue |
US20070100222A1 (en) | 2004-06-14 | 2007-05-03 | Metronic Minimed, Inc. | Analyte sensing apparatus for hospital use |
US7556723B2 (en) | 2004-06-18 | 2009-07-07 | Roche Diagnostics Operations, Inc. | Electrode design for biosensor |
US7565197B2 (en) | 2004-06-18 | 2009-07-21 | Medtronic, Inc. | Conditional requirements for remote medical device programming |
US7623988B2 (en) | 2004-06-23 | 2009-11-24 | Cybiocare Inc. | Method and apparatus for the monitoring of clinical states |
DE102004031092A1 (en) | 2004-06-28 | 2006-01-12 | Giesecke & Devrient Gmbh | transponder unit |
US20060001538A1 (en) | 2004-06-30 | 2006-01-05 | Ulrich Kraft | Methods of monitoring the concentration of an analyte |
US20060015020A1 (en) | 2004-07-06 | 2006-01-19 | Dexcom, Inc. | Systems and methods for manufacture of an analyte-measuring device including a membrane system |
US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
WO2006127694A2 (en) | 2004-07-13 | 2006-11-30 | Dexcom, Inc. | Analyte sensor |
US7654956B2 (en) | 2004-07-13 | 2010-02-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20080242961A1 (en) | 2004-07-13 | 2008-10-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US7344500B2 (en) | 2004-07-27 | 2008-03-18 | Medtronic Minimed, Inc. | Sensing system with auxiliary display |
US8313433B2 (en) | 2004-08-06 | 2012-11-20 | Medtronic Minimed, Inc. | Medical data management system and process |
WO2006026741A1 (en) * | 2004-08-31 | 2006-03-09 | Lifescan Scotland Limited | Wearable sensor device and system |
EP1788930A1 (en) | 2004-09-03 | 2007-05-30 | Novo Nordisk A/S | A method of calibrating a system for measuring the concentration of substances in body and an apparatus for exercising the method |
US8211038B2 (en) * | 2004-09-17 | 2012-07-03 | Abbott Diabetes Care Inc. | Multiple-biosensor article |
US20090247931A1 (en) | 2004-09-23 | 2009-10-01 | Novo Nordisk A/S | Device for self-care support |
WO2006050468A2 (en) | 2004-11-02 | 2006-05-11 | Medtronic, Inc. | Techniques for data reporting in an implantable medical device |
US7408132B2 (en) | 2004-11-08 | 2008-08-05 | Rrc Power Solutions Gmbh | Temperature sensor for power supply |
US7237712B2 (en) | 2004-12-01 | 2007-07-03 | Alfred E. Mann Foundation For Scientific Research | Implantable device and communication integrated circuit implementable therein |
EP1827214B1 (en) | 2004-12-13 | 2012-02-15 | Koninklijke Philips Electronics N.V. | Mobile monitoring |
US7461192B2 (en) | 2004-12-15 | 2008-12-02 | Rambus Inc. | Interface for bridging out-of-band information and preventing false presence detection of terminating devices |
WO2006072035A1 (en) | 2004-12-29 | 2006-07-06 | Lifescan Scotland Limited | Method of inputting data into an analyte testing device |
US7731657B2 (en) | 2005-08-30 | 2010-06-08 | Abbott Diabetes Care Inc. | Analyte sensor introducer and methods of use |
US7883464B2 (en) | 2005-09-30 | 2011-02-08 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
US20070027381A1 (en) | 2005-07-29 | 2007-02-01 | Therasense, Inc. | Inserter and methods of use |
US9398882B2 (en) | 2005-09-30 | 2016-07-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor and data processing device |
US8512243B2 (en) | 2005-09-30 | 2013-08-20 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US20060166629A1 (en) | 2005-01-24 | 2006-07-27 | Therasense, Inc. | Method and apparatus for providing EMC Class-B compliant RF transmitter for data monitoring an detection systems |
US20060173260A1 (en) * | 2005-01-31 | 2006-08-03 | Gmms Ltd | System, device and method for diabetes treatment and monitoring |
US7547281B2 (en) | 2005-02-01 | 2009-06-16 | Medtronic Minimed, Inc. | Algorithm sensor augmented bolus estimator for semi-closed loop infusion system |
US7545272B2 (en) | 2005-02-08 | 2009-06-09 | Therasense, Inc. | RF tag on test strips, test strip vials and boxes |
US8133178B2 (en) | 2006-02-22 | 2012-03-13 | Dexcom, Inc. | Analyte sensor |
US20090076360A1 (en) | 2007-09-13 | 2009-03-19 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20060202805A1 (en) | 2005-03-14 | 2006-09-14 | Alfred E. Mann Foundation For Scientific Research | Wireless acquisition and monitoring system |
US20070071681A1 (en) | 2005-03-15 | 2007-03-29 | Entelos, Inc. | Apparatus and method for computer modeling type 1 diabetes |
EP1863559A4 (en) | 2005-03-21 | 2008-07-30 | Abbott Diabetes Care Inc | Method and system for providing integrated medication infusion and analyte monitoring system |
JP2006280464A (en) * | 2005-03-31 | 2006-10-19 | Semiconductor Energy Lab Co Ltd | Biological information detecting apparatus, health care apparatus, health care assisting system using them, and health care assisting method |
US7889069B2 (en) | 2005-04-01 | 2011-02-15 | Codman & Shurtleff, Inc. | Wireless patient monitoring system |
US7270633B1 (en) | 2005-04-22 | 2007-09-18 | Cardiac Pacemakers, Inc. | Ambulatory repeater for use in automated patient care and method thereof |
GB2425601B (en) * | 2005-04-26 | 2008-01-30 | Bio Nano Sensium Technologies | Sensor configuration |
DE102005019306B4 (en) | 2005-04-26 | 2011-09-01 | Disetronic Licensing Ag | Energy-optimized data transmission of a medical device |
US8700157B2 (en) | 2005-04-29 | 2014-04-15 | Medtronic, Inc. | Telemetry head programmer for implantable medical device and system and method |
US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
US7467065B2 (en) | 2005-05-02 | 2008-12-16 | Home Diagnostics, Inc. | Computer interface for diagnostic meter |
US20060253085A1 (en) | 2005-05-06 | 2006-11-09 | Medtronic Minimed, Inc. | Dual insertion set |
US7641649B2 (en) | 2005-05-06 | 2010-01-05 | Medtronic Minimed, Inc. | Reservoir support and method for infusion device |
US7604178B2 (en) | 2005-05-11 | 2009-10-20 | Intelleflex Corporation | Smart tag activation |
JP5037496B2 (en) | 2005-05-13 | 2012-09-26 | トラスティーズ オブ ボストン ユニバーシティ | Fully automatic control system for type 1 diabetes |
BRPI0502015A (en) * | 2005-06-01 | 2007-01-23 | Petroleo Brasileiro Sa | catalytically selective cracking process of the natural gas liquid fraction to light olefins and other products |
US20060272652A1 (en) | 2005-06-03 | 2006-12-07 | Medtronic Minimed, Inc. | Virtual patient software system for educating and treating individuals with diabetes |
US20070033074A1 (en) | 2005-06-03 | 2007-02-08 | Medtronic Minimed, Inc. | Therapy management system |
US7848736B2 (en) * | 2006-01-18 | 2010-12-07 | Sms.Ac, Inc. | Package billing for micro-transactions |
JP4240007B2 (en) * | 2005-06-06 | 2009-03-18 | ニプロ株式会社 | Telemedicine system |
US20070016449A1 (en) | 2005-06-29 | 2007-01-18 | Gary Cohen | Flexible glucose analysis using varying time report deltas and configurable glucose target ranges |
WO2007007459A1 (en) | 2005-07-12 | 2007-01-18 | Omron Healthcare Co., Ltd. | Biochemical measuring instrument for measuring information about component of living body accurately |
CN102983639B (en) | 2005-07-12 | 2016-01-27 | 麻省理工学院 | Wireless non-radiative energy transmits |
US20070111196A1 (en) | 2005-08-19 | 2007-05-17 | Javier Alarcon | Sterilization of Biosensors |
US7625982B2 (en) * | 2005-08-22 | 2009-12-01 | Chevron Phillips Chemical Company Lp | Multimodal polyethylene compositions and pipe made from same |
EP1758039A1 (en) | 2005-08-27 | 2007-02-28 | Roche Diagnostics GmbH | Communication adaptor for portable medical or therapeutical devices |
WO2007028271A2 (en) | 2005-09-09 | 2007-03-15 | F. Hoffmann-La Roche Ag | A system, tools, devices and a program for diabetes care |
US9072476B2 (en) | 2005-09-23 | 2015-07-07 | Medtronic Minimed, Inc. | Flexible sensor apparatus |
US7756561B2 (en) | 2005-09-30 | 2010-07-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing rechargeable power in data monitoring and management systems |
US9521968B2 (en) | 2005-09-30 | 2016-12-20 | Abbott Diabetes Care Inc. | Analyte sensor retention mechanism and methods of use |
US7701052B2 (en) | 2005-10-21 | 2010-04-20 | E. I. Du Pont De Nemours And Company | Power core devices |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
WO2007056592A2 (en) | 2005-11-08 | 2007-05-18 | M2 Medical A/S | Method and system for manual and autonomous control of an infusion pump |
US20070173706A1 (en) | 2005-11-11 | 2007-07-26 | Isense Corporation | Method and apparatus for insertion of a sensor |
WO2007062173A1 (en) | 2005-11-22 | 2007-05-31 | Vocollect Healthcare Systems, Inc. | Advanced diabetes management system (adms) |
US7941200B2 (en) | 2005-12-08 | 2011-05-10 | Roche Diagnostics Operations, Inc. | System and method for determining drug administration information |
US8515518B2 (en) | 2005-12-28 | 2013-08-20 | Abbott Diabetes Care Inc. | Analyte monitoring |
US8160670B2 (en) | 2005-12-28 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent |
WO2007120363A2 (en) | 2005-12-28 | 2007-10-25 | Abbott Diabetes Care, Inc. | Medical device insertion |
US20070179349A1 (en) | 2006-01-19 | 2007-08-02 | Hoyme Kenneth P | System and method for providing goal-oriented patient management based upon comparative population data analysis |
US7574266B2 (en) | 2006-01-19 | 2009-08-11 | Medtronic, Inc. | System and method for telemetry with an implantable medical device |
US7872574B2 (en) | 2006-02-01 | 2011-01-18 | Innovation Specialists, Llc | Sensory enhancement systems and methods in personal electronic devices |
EP2335754B1 (en) | 2006-02-09 | 2013-12-18 | DEKA Products Limited Partnership | Patch-sized fluid delivery systems |
US7826879B2 (en) | 2006-02-28 | 2010-11-02 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
US7576657B2 (en) | 2006-03-22 | 2009-08-18 | Symbol Technologies, Inc. | Single frequency low power RFID device |
US8473022B2 (en) | 2008-01-31 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte sensor with time lag compensation |
US7653425B2 (en) | 2006-08-09 | 2010-01-26 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US7618369B2 (en) | 2006-10-02 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
US9392969B2 (en) | 2008-08-31 | 2016-07-19 | Abbott Diabetes Care Inc. | Closed loop control and signal attenuation detection |
US8140312B2 (en) | 2007-05-14 | 2012-03-20 | Abbott Diabetes Care Inc. | Method and system for determining analyte levels |
WO2007121763A1 (en) | 2006-04-20 | 2007-11-01 | Lifescan Scotland Limited | Method for transmitting data in a blood glucose system and corresponding blood glucose system |
US7359837B2 (en) | 2006-04-27 | 2008-04-15 | Medtronic, Inc. | Peak data retention of signal data in an implantable medical device |
US20070258395A1 (en) | 2006-04-28 | 2007-11-08 | Medtronic Minimed, Inc. | Wireless data communication protocols for a medical device network |
US20070255126A1 (en) * | 2006-04-28 | 2007-11-01 | Moberg Sheldon B | Data communication in networked fluid infusion systems |
US7942844B2 (en) | 2006-04-28 | 2011-05-17 | Medtronic Minimed, Inc. | Remote monitoring for networked fluid infusion systems |
US20070253021A1 (en) | 2006-04-28 | 2007-11-01 | Medtronic Minimed, Inc. | Identification of devices in a medical device network and wireless data communication techniques utilizing device identifiers |
GB0608829D0 (en) | 2006-05-04 | 2006-06-14 | Husheer Shamus L G | In-situ measurement of physical parameters |
US7920907B2 (en) | 2006-06-07 | 2011-04-05 | Abbott Diabetes Care Inc. | Analyte monitoring system and method |
US7796038B2 (en) | 2006-06-12 | 2010-09-14 | Intelleflex Corporation | RFID sensor tag with manual modes and functions |
US20090105560A1 (en) | 2006-06-28 | 2009-04-23 | David Solomon | Lifestyle and eating advisor based on physiological and biological rhythm monitoring |
GB0616331D0 (en) | 2006-08-16 | 2006-09-27 | Innovision Res & Tech Plc | Near Field RF Communicators And Near Field Communications Enabled Devices |
US20080058678A1 (en) | 2006-09-05 | 2008-03-06 | Shinichi Miyata | Kit for the determination of an analyte in a bodily fluid sample that includes a meter with a display-based tutorial module |
US20080057484A1 (en) | 2006-09-05 | 2008-03-06 | Shinichi Miyata | Event-driven method for tutoring a user in the determination of an analyte in a bodily fluid sample |
US9056165B2 (en) | 2006-09-06 | 2015-06-16 | Medtronic Minimed, Inc. | Intelligent therapy recommendation algorithm and method of using the same |
US20080071328A1 (en) | 2006-09-06 | 2008-03-20 | Medtronic, Inc. | Initiating medical system communications |
US7779332B2 (en) | 2006-09-25 | 2010-08-17 | Alfred E. Mann Foundation For Scientific Research | Rotationally invariant non-coherent burst coding |
US8275438B2 (en) | 2006-10-04 | 2012-09-25 | Dexcom, Inc. | Analyte sensor |
US8449464B2 (en) | 2006-10-04 | 2013-05-28 | Dexcom, Inc. | Analyte sensor |
US7831287B2 (en) | 2006-10-04 | 2010-11-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8298142B2 (en) | 2006-10-04 | 2012-10-30 | Dexcom, Inc. | Analyte sensor |
US8447376B2 (en) | 2006-10-04 | 2013-05-21 | Dexcom, Inc. | Analyte sensor |
US8562528B2 (en) | 2006-10-04 | 2013-10-22 | Dexcom, Inc. | Analyte sensor |
US8478377B2 (en) | 2006-10-04 | 2013-07-02 | Dexcom, Inc. | Analyte sensor |
US20080092638A1 (en) * | 2006-10-19 | 2008-04-24 | Bayer Healthcare Llc | Wireless analyte monitoring system |
WO2008052199A2 (en) | 2006-10-26 | 2008-05-02 | Abbott Diabetes Care, Inc. | Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors |
US20080119705A1 (en) | 2006-11-17 | 2008-05-22 | Medtronic Minimed, Inc. | Systems and Methods for Diabetes Management Using Consumer Electronic Devices |
FI20065735A0 (en) | 2006-11-20 | 2006-11-20 | Salla Koski | Measurement, monitoring and management system and its constituent equipment |
US20100228111A1 (en) * | 2006-11-23 | 2010-09-09 | Alf Friman | Blood glucose meter capable of wireless communication |
US20080139910A1 (en) | 2006-12-06 | 2008-06-12 | Metronic Minimed, Inc. | Analyte sensor and method of using the same |
WO2008071218A1 (en) | 2006-12-14 | 2008-06-19 | Egomedical Swiss Ag | Monitoring device |
US20080154513A1 (en) | 2006-12-21 | 2008-06-26 | University Of Virginia Patent Foundation | Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes |
US20080161666A1 (en) | 2006-12-29 | 2008-07-03 | Abbott Diabetes Care, Inc. | Analyte devices and methods |
MX2009007613A (en) | 2007-01-15 | 2009-09-22 | Deka Products Lp | Device and method for food management. |
US7742747B2 (en) | 2007-01-25 | 2010-06-22 | Icera Canada ULC | Automatic IIP2 calibration architecture |
US10154804B2 (en) | 2007-01-31 | 2018-12-18 | Medtronic Minimed, Inc. | Model predictive method and system for controlling and supervising insulin infusion |
US8808515B2 (en) * | 2007-01-31 | 2014-08-19 | Abbott Diabetes Care Inc. | Heterocyclic nitrogen containing polymers coated analyte monitoring device and methods of use |
US9597019B2 (en) | 2007-02-09 | 2017-03-21 | Lifescan, Inc. | Method of ensuring date and time on a test meter is accurate |
US8758245B2 (en) | 2007-03-20 | 2014-06-24 | Lifescan, Inc. | Systems and methods for pattern recognition in diabetes management |
WO2008130897A2 (en) | 2007-04-14 | 2008-10-30 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in medical communication system |
CA2683721C (en) | 2007-04-14 | 2017-05-23 | Abbott Diabetes Care Inc. | Method and apparatus for providing dynamic multi-stage signal amplification in a medical device |
WO2009096992A1 (en) | 2007-04-14 | 2009-08-06 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in medical communication system |
WO2008130896A1 (en) | 2007-04-14 | 2008-10-30 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in medical communication system |
WO2008130898A1 (en) | 2007-04-14 | 2008-10-30 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in medical communication system |
CA2683930A1 (en) | 2007-04-14 | 2008-10-23 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
CA2685374A1 (en) | 2007-04-27 | 2008-11-06 | Abbott Diabetes Care Inc. | Test strip identification using conductive patterns |
US8692655B2 (en) | 2007-05-07 | 2014-04-08 | Bloomberg Finance L.P. | Dynamically programmable RFID transponder |
US8560038B2 (en) | 2007-05-14 | 2013-10-15 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8103471B2 (en) | 2007-05-14 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8260558B2 (en) | 2007-05-14 | 2012-09-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10002233B2 (en) | 2007-05-14 | 2018-06-19 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8444560B2 (en) | 2007-05-14 | 2013-05-21 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US20080312845A1 (en) | 2007-05-14 | 2008-12-18 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9125548B2 (en) | 2007-05-14 | 2015-09-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
CA2685167A1 (en) | 2007-05-14 | 2008-11-27 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US7996158B2 (en) | 2007-05-14 | 2011-08-09 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US20080287755A1 (en) | 2007-05-17 | 2008-11-20 | Isense Corporation | Method and apparatus for trend alert calculation and display |
US8072310B1 (en) | 2007-06-05 | 2011-12-06 | Pulsed Indigo Inc. | System for detecting and measuring parameters of passive transponders |
US20080306434A1 (en) | 2007-06-08 | 2008-12-11 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US20080312518A1 (en) | 2007-06-14 | 2008-12-18 | Arkal Medical, Inc | On-demand analyte monitor and method of use |
AU2008265542B2 (en) * | 2007-06-21 | 2014-07-24 | Abbott Diabetes Care Inc. | Health monitor |
WO2009005957A1 (en) | 2007-06-29 | 2009-01-08 | Roche Diagnostics Gmbh | Apparatus and method for remotely controlling an ambulatory medical device |
US7768386B2 (en) | 2007-07-31 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US20090036760A1 (en) | 2007-07-31 | 2009-02-05 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8834366B2 (en) | 2007-07-31 | 2014-09-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor calibration |
CA2694931C (en) | 2007-07-31 | 2014-04-29 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9968742B2 (en) | 2007-08-29 | 2018-05-15 | Medtronic Minimed, Inc. | Combined sensor and infusion set using separated sites |
US20090063402A1 (en) | 2007-08-31 | 2009-03-05 | Abbott Diabetes Care, Inc. | Method and System for Providing Medication Level Determination |
CA2700507C (en) | 2007-09-24 | 2018-05-29 | Bayer Healthcare Llc | Multi-region and potential test sensors, methods, and systems |
DE102007047351A1 (en) | 2007-10-02 | 2009-04-09 | B. Braun Melsungen Ag | System and method for monitoring and controlling blood glucose levels |
US20090085768A1 (en) | 2007-10-02 | 2009-04-02 | Medtronic Minimed, Inc. | Glucose sensor transceiver |
US8000918B2 (en) | 2007-10-23 | 2011-08-16 | Edwards Lifesciences Corporation | Monitoring and compensating for temperature-related error in an electrochemical sensor |
US8377031B2 (en) | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7783442B2 (en) | 2007-10-31 | 2010-08-24 | Medtronic Minimed, Inc. | System and methods for calibrating physiological characteristic sensors |
US8290559B2 (en) | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
US20090164251A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Method and apparatus for providing treatment profile management |
DE102008008072A1 (en) | 2008-01-29 | 2009-07-30 | Balluff Gmbh | sensor |
US20090299155A1 (en) | 2008-01-30 | 2009-12-03 | Dexcom, Inc. | Continuous cardiac marker sensor system |
EP2090996A1 (en) | 2008-02-16 | 2009-08-19 | Roche Diagnostics GmbH | Medical device |
WO2009105337A2 (en) | 2008-02-20 | 2009-08-27 | Dexcom, Inc. | Continuous medicament sensor system for in vivo use |
CA2715628A1 (en) | 2008-02-21 | 2009-08-27 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US8317699B2 (en) | 2008-02-29 | 2012-11-27 | Roche Diagnostics Operations, Inc. | Device and method for assessing blood glucose control |
US20090242399A1 (en) | 2008-03-25 | 2009-10-01 | Dexcom, Inc. | Analyte sensor |
US8396528B2 (en) | 2008-03-25 | 2013-03-12 | Dexcom, Inc. | Analyte sensor |
US20090247856A1 (en) | 2008-03-28 | 2009-10-01 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
CN103400028B (en) | 2008-04-04 | 2017-04-12 | 海吉雅有限公司 | Device for optimizing patient's insulin dosage regimen |
US20090267765A1 (en) | 2008-04-29 | 2009-10-29 | Jack Greene | Rfid to prevent reprocessing |
CA2724446C (en) | 2008-05-14 | 2017-04-04 | Espenusa Holding, Llc | Physical activity monitor and data collection unit |
EP2311141B1 (en) | 2008-05-20 | 2018-02-21 | DEKA Products Limited Partnership | Rfid system |
US8394637B2 (en) | 2008-06-02 | 2013-03-12 | Roche Diagnostics Operations, Inc. | Handheld analyzer for testing a sample |
US8432070B2 (en) | 2008-08-25 | 2013-04-30 | Qualcomm Incorporated | Passive receivers for wireless power transmission |
US8734422B2 (en) | 2008-08-31 | 2014-05-27 | Abbott Diabetes Care Inc. | Closed loop control with improved alarm functions |
US20100057040A1 (en) | 2008-08-31 | 2010-03-04 | Abbott Diabetes Care, Inc. | Robust Closed Loop Control And Methods |
US9943644B2 (en) | 2008-08-31 | 2018-04-17 | Abbott Diabetes Care Inc. | Closed loop control with reference measurement and methods thereof |
WO2010033724A2 (en) | 2008-09-19 | 2010-03-25 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US8986208B2 (en) | 2008-09-30 | 2015-03-24 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
JP2012504932A (en) | 2008-10-02 | 2012-02-23 | レイデン エナジー インコーポレイテッド | Electronic current interrupt device for batteries |
CA2753650A1 (en) | 2008-11-26 | 2010-06-03 | University Of Virginia Patent Foundation | Method, system, and computer program product for tracking of blood glucose variability in diabetes |
US8150516B2 (en) | 2008-12-11 | 2012-04-03 | Pacesetter, Inc. | Systems and methods for operating an implantable device for medical procedures |
US20100169035A1 (en) | 2008-12-29 | 2010-07-01 | Medtronic Minimed, Inc. | Methods and systems for observing sensor parameters |
US9320470B2 (en) | 2008-12-31 | 2016-04-26 | Medtronic Minimed, Inc. | Method and/or system for sensor artifact filtering |
CN102300501B (en) | 2009-02-04 | 2015-04-08 | 艾伯特糖尿病护理公司 | Multi-function analyte test device and methods therefor |
US9218453B2 (en) | 2009-06-29 | 2015-12-22 | Roche Diabetes Care, Inc. | Blood glucose management and interface systems and methods |
US20110123971A1 (en) | 2009-11-20 | 2011-05-26 | Medivoce, Inc. | Electronic Medical Voice Instruction System |
US9949672B2 (en) | 2009-12-17 | 2018-04-24 | Ascensia Diabetes Care Holdings Ag | Apparatus, systems and methods for determining and displaying pre-event and post-event analyte concentration levels |
CA2728831A1 (en) | 2010-01-22 | 2011-07-22 | Lifescan, Inc. | Diabetes management unit, method, and system |
WO2011091179A1 (en) | 2010-01-24 | 2011-07-28 | Medtronic, Inc. | Method of making a battery including applying a cathode material slurry to a current collector |
US20110208027A1 (en) | 2010-02-23 | 2011-08-25 | Roche Diagnostics Operations, Inc. | Methods And Systems For Providing Therapeutic Guidelines To A Person Having Diabetes |
-
2008
- 2008-06-20 AU AU2008265542A patent/AU2008265542B2/en active Active
- 2008-06-20 WO PCT/US2008/067793 patent/WO2008157821A1/en active Application Filing
- 2008-06-20 US US12/143,734 patent/US8617069B2/en active Active
- 2008-06-20 EP EP18192278.2A patent/EP3473167A1/en active Pending
- 2008-06-20 EP EP08771682.5A patent/EP2166928B1/en active Active
- 2008-06-20 JP JP2010513477A patent/JP2010531169A/en active Pending
- 2008-06-20 CN CN2008800212991A patent/CN101686804B/en active Active
- 2008-06-20 CA CA2690870A patent/CA2690870C/en active Active
- 2008-06-20 CN CN201310161229.9A patent/CN103251414B/en active Active
-
2009
- 2009-11-24 US US12/625,510 patent/US20100076290A1/en not_active Abandoned
- 2009-11-30 US US12/628,201 patent/US20100076280A1/en not_active Abandoned
- 2009-11-30 US US12/628,210 patent/US20100076293A1/en not_active Abandoned
- 2009-11-30 US US12/628,198 patent/US20100076291A1/en not_active Abandoned
- 2009-11-30 US US12/628,203 patent/US20100076292A1/en not_active Abandoned
- 2009-11-30 US US12/628,177 patent/US20100076289A1/en not_active Abandoned
-
2011
- 2011-11-08 US US13/292,074 patent/US20120053428A1/en not_active Abandoned
-
2013
- 2013-12-18 US US14/133,635 patent/US20140107436A1/en not_active Abandoned
-
2014
- 2014-09-16 JP JP2014187515A patent/JP2015027523A/en active Pending
-
2016
- 2016-11-07 JP JP2016217028A patent/JP2017060795A/en active Pending
-
2018
- 2018-03-05 JP JP2018038519A patent/JP2018118077A/en active Pending
- 2018-05-21 US US15/985,615 patent/US20180271419A1/en not_active Abandoned
Patent Citations (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5289497A (en) * | 1991-05-23 | 1994-02-22 | Interdigital Technology Corporation | Broadcast synchronized communication system |
US5410326A (en) * | 1992-12-04 | 1995-04-25 | Goldstein; Steven W. | Programmable remote control device for interacting with a plurality of remotely controlled devices |
US5499243A (en) * | 1993-01-22 | 1996-03-12 | Hall; Dennis R. | Method and apparatus for coordinating transfer of information between a base station and a plurality of radios |
US5600301A (en) * | 1993-03-11 | 1997-02-04 | Schrader Automotive Inc. | Remote tire pressure monitoring system employing coded tire identification and radio frequency transmission, and enabling recalibration upon tire rotation or replacement |
US5400794A (en) * | 1993-03-19 | 1995-03-28 | Gorman; Peter G. | Biomedical response monitor and technique using error correction |
US5489414A (en) * | 1993-04-23 | 1996-02-06 | Boehringer Mannheim, Gmbh | System for analyzing compounds contained in liquid samples |
US5623933A (en) * | 1993-08-03 | 1997-04-29 | Seiko Epson Corporation | Pulse wave analysis device |
US5891049A (en) * | 1994-09-28 | 1999-04-06 | Heartstream, Inc | Time and data correlated medical display system |
US5601435A (en) * | 1994-11-04 | 1997-02-11 | Intercare | Method and apparatus for interactively monitoring a physiological condition and for interactively providing health related information |
US5735285A (en) * | 1996-06-04 | 1998-04-07 | Data Critical Corp. | Method and hand-held apparatus for demodulating and viewing frequency modulated biomedical signals |
US5707502A (en) * | 1996-07-12 | 1998-01-13 | Chiron Diagnostics Corporation | Sensors for measuring analyte concentrations and methods of making same |
US5856758A (en) * | 1996-11-20 | 1999-01-05 | Adtran, Inc. | Low distortion driver employing positive feedback for reducing power loss in output impedance that effectively matches the impedance of driven line |
US7318816B2 (en) * | 1997-02-05 | 2008-01-15 | Medtronic Minimed, Inc. | Insertion device for an insertion set and method of using the same |
US6028413A (en) * | 1997-09-19 | 2000-02-22 | Perdix Oy | Charging device for batteries in a mobile electrical device |
US20020013538A1 (en) * | 1997-09-30 | 2002-01-31 | David Teller | Method and apparatus for health signs monitoring |
US6348640B1 (en) * | 1997-10-03 | 2002-02-19 | Nir Navot | Tampon detection system |
US20060042080A1 (en) * | 1998-03-04 | 2006-03-02 | Therasense, Inc. | Method of making an electrochemical sensor |
US20030088166A1 (en) * | 1998-03-04 | 2003-05-08 | Therasense, Inc. | Electrochemical analyte sensor |
US6850790B2 (en) * | 1998-05-13 | 2005-02-01 | Cygnus, Inc. | Monitoring of physiological analytes |
US20020013522A1 (en) * | 1998-05-20 | 2002-01-31 | Steffen Lav | Medical apparatus for use by a patient for medical self treatment of diabetes |
US6359270B1 (en) * | 1998-09-04 | 2002-03-19 | Ncr Corporation | Communications module mounting for domestic appliance |
US20040039255A1 (en) * | 1998-11-30 | 2004-02-26 | Simonsen Jan Henning | Medical system and a method of controlling the system for use by a patient for medical self treatment |
US20020023852A1 (en) * | 1999-02-25 | 2002-02-28 | Minimed Inc. | Glucose sensor package system |
US6520326B2 (en) * | 1999-02-25 | 2003-02-18 | Medtronic Minimed, Inc. | Glucose sensor package system |
US8103325B2 (en) * | 1999-03-08 | 2012-01-24 | Tyco Healthcare Group Lp | Method and circuit for storing and providing historical physiological data |
US6514689B2 (en) * | 1999-05-11 | 2003-02-04 | M-Biotech, Inc. | Hydrogel biosensor |
US6359444B1 (en) * | 1999-05-28 | 2002-03-19 | University Of Kentucky Research Foundation | Remote resonant-circuit analyte sensing apparatus with sensing structure and associated method of sensing |
US6203495B1 (en) * | 1999-06-03 | 2001-03-20 | Cardiac Intelligence Corporation | System and method for providing normalized voice feedback from an individual patient in an automated collection and analysis patient care system |
US8116681B2 (en) * | 1999-06-21 | 2012-02-14 | Access Business Group International Llc | Adaptive inductive power supply with communication |
US20090020502A1 (en) * | 1999-10-04 | 2009-01-22 | Bhullar Raghbir S | Biosensor and method of making |
US6522927B1 (en) * | 1999-12-01 | 2003-02-18 | Vertis Neuroscience, Inc. | Electrode assembly for a percutaneous electrical therapy system |
US20040030226A1 (en) * | 1999-12-17 | 2004-02-12 | Quy Roger J. | Method and apparatus for health and disease management combining patient data monitoring with wireless internet connectivity |
US20020065454A1 (en) * | 2000-01-21 | 2002-05-30 | Lebel Ronald J. | Microprocessor controlled ambulatory medical apparatus with hand held communication device |
US20020019584A1 (en) * | 2000-03-01 | 2002-02-14 | Schulze Arthur E. | Wireless internet bio-telemetry monitoring system and interface |
US20020045808A1 (en) * | 2000-08-18 | 2002-04-18 | Russell Ford | Formulation and manipulation of databases of analyte and associated values |
US8131351B2 (en) * | 2000-12-15 | 2012-03-06 | Cardiac Pacemakers, Inc. | System and method for correlation of patient health information and implant device data |
US20030100821A1 (en) * | 2001-01-02 | 2003-05-29 | Therasense, Inc. | Analyte monitoring device and methods of use |
US20030023461A1 (en) * | 2001-03-14 | 2003-01-30 | Dan Quintanilla | Internet based therapy management system |
US20030032867A1 (en) * | 2001-06-21 | 2003-02-13 | Animas Corporation. | System and method for managing diabetes |
US20030060692A1 (en) * | 2001-08-03 | 2003-03-27 | Timothy L. Ruchti | Intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes |
US20040054263A1 (en) * | 2001-08-20 | 2004-03-18 | Piet Moerman | Wireless diabetes management devices and methods for using the same |
US20060040793A1 (en) * | 2001-08-21 | 2006-02-23 | Martens Mark H | Exercise system with graphical feedback and method of gauging fitness progress |
US20050001024A1 (en) * | 2001-12-03 | 2005-01-06 | Yosuke Kusaka | Electronic apparatus, electronic camera, electronic device, image display apparatus, and image transmission system |
US8140160B2 (en) * | 2002-01-29 | 2012-03-20 | Neuropace, Inc. | Systems and methods for interacting with an implantable medical device |
US7668596B2 (en) * | 2002-02-07 | 2010-02-23 | Cardiac Pacemakers, Inc. | Methods and apparatuses for implantable medical device telemetry power management |
US20040030531A1 (en) * | 2002-03-28 | 2004-02-12 | Honeywell International Inc. | System and method for automated monitoring, recognizing, supporting, and responding to the behavior of an actor |
US20040030581A1 (en) * | 2002-06-12 | 2004-02-12 | Samuel Leven | Heart monitoring device |
US20040017300A1 (en) * | 2002-07-25 | 2004-01-29 | Kotzin Michael D. | Portable communication device and corresponding method of operation |
US7020508B2 (en) * | 2002-08-22 | 2006-03-28 | Bodymedia, Inc. | Apparatus for detecting human physiological and contextual information |
US6983861B2 (en) * | 2002-11-05 | 2006-01-10 | Aidox Technology Corporation | Dispensing apparatus |
US8130093B2 (en) * | 2002-12-17 | 2012-03-06 | Cardiac Pacemakers, Inc. | Repeater providing data exchange with a medical device for remote patient care and method thereof |
US20040186365A1 (en) * | 2002-12-31 | 2004-09-23 | Therasense, Inc. | Continuous glucose monitoring system and methods of use |
US8116683B2 (en) * | 2003-02-04 | 2012-02-14 | Access Business Group International Llc | Adaptive inductive power supply with communication |
US20060049359A1 (en) * | 2003-04-01 | 2006-03-09 | Cabot Microelectronics Corporation | Decontamination and sterilization system using large area x-ray source |
US20040225199A1 (en) * | 2003-05-08 | 2004-11-11 | Evanyk Shane Walter | Advanced physiological monitoring systems and methods |
US20050003470A1 (en) * | 2003-06-10 | 2005-01-06 | Therasense, Inc. | Glucose measuring device for use in personal area network |
US8090445B2 (en) * | 2003-06-30 | 2012-01-03 | Codman Neuro Sciences Sárl | System and method for controlling an implantable medical device subject to magnetic field or radio frequency exposure |
US20080060955A1 (en) * | 2003-07-15 | 2008-03-13 | Therasense, Inc. | Glucose measuring device integrated into a holster for a personal area network device |
US20050027463A1 (en) * | 2003-08-01 | 2005-02-03 | Goode Paul V. | System and methods for processing analyte sensor data |
US20050027181A1 (en) * | 2003-08-01 | 2005-02-03 | Goode Paul V. | System and methods for processing analyte sensor data |
US7914450B2 (en) * | 2003-08-01 | 2011-03-29 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8140168B2 (en) * | 2003-10-02 | 2012-03-20 | Medtronic, Inc. | External power source for an implantable medical device having an adjustable carrier frequency and system and method related therefore |
US7492254B2 (en) * | 2003-10-24 | 2009-02-17 | Symbol Technologies, Inc. | Radio frequency identification (RFID) based sensor networks |
US8136735B2 (en) * | 2004-01-23 | 2012-03-20 | Semiconductor Energy Laboratory Co., Ltd. | ID label, ID card, and ID tag |
US20060010098A1 (en) * | 2004-06-04 | 2006-01-12 | Goodnow Timothy T | Diabetes care host-client architecture and data management system |
US7899511B2 (en) * | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US7905833B2 (en) * | 2004-07-13 | 2011-03-15 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7916013B2 (en) * | 2005-03-21 | 2011-03-29 | Greatbatch Ltd. | RFID detection and identification system for implantable medical devices |
US20060264785A1 (en) * | 2005-05-19 | 2006-11-23 | Barton Dring | Monitoring systems and methods |
US20080071580A1 (en) * | 2005-06-03 | 2008-03-20 | Marcus Alan O | System and method for medical evaluation and monitoring |
US7912655B2 (en) * | 2005-08-05 | 2011-03-22 | Bayer Healthcare Llc | Meter having multi-level user interface |
US7882611B2 (en) * | 2005-09-23 | 2011-02-08 | Medtronic Minimed, Inc. | Method of making an analyte sensor |
US8102789B2 (en) * | 2005-12-29 | 2012-01-24 | Medtronic, Inc. | System and method for synchronous wireless communication with a medical device |
US8135352B2 (en) * | 2006-05-02 | 2012-03-13 | 3M Innovative Properties Company | Telecommunication enclosure monitoring system |
US8140299B2 (en) * | 2006-05-17 | 2012-03-20 | Siemens Aktiengesellschaft | Operating method for a sensor and a control facility communicating with the sensor |
US8098208B2 (en) * | 2006-05-30 | 2012-01-17 | Polyic Gmbh & Co. Kg | Antenna configuration and use thereof |
US8098159B2 (en) * | 2006-06-09 | 2012-01-17 | Intelleflex Corporation | RF device comparing DAC output to incoming signal for selectively performing an action |
US20080009304A1 (en) * | 2006-07-06 | 2008-01-10 | Fry Walter G | Electronic device power management system and method |
US8115488B2 (en) * | 2006-08-21 | 2012-02-14 | Abqmr, Inc. | Tuning low-inductance coils at low frequencies |
US20080055070A1 (en) * | 2006-09-01 | 2008-03-06 | Bange Joseph E | Frequency-agile system for telemetry with implantable device |
US20080067627A1 (en) * | 2006-09-15 | 2008-03-20 | Josef Boeck | Fuse Structure and Method for Manufacturing Same |
US8131565B2 (en) * | 2006-10-24 | 2012-03-06 | Medapps, Inc. | System for medical data collection and transmission |
US7912674B2 (en) * | 2006-10-31 | 2011-03-22 | Roche Diagnostics International Ag | Method for processing a chronological sequence of measurements of a time dependent parameter |
US8102263B2 (en) * | 2006-12-08 | 2012-01-24 | Electronics And Telecommunications Research Institute | Passive tag including volatile memory |
US8120493B2 (en) * | 2006-12-20 | 2012-02-21 | Intel Corporation | Direct communication in antenna devices |
US8098160B2 (en) * | 2007-01-22 | 2012-01-17 | Cisco Technology, Inc. | Method and system for remotely provisioning and/or configuring a device |
US7659823B1 (en) * | 2007-03-20 | 2010-02-09 | At&T Intellectual Property Ii, L.P. | Tracking variable conditions using radio frequency identification |
US20090006133A1 (en) * | 2007-06-27 | 2009-01-01 | Roche Diagnostics Operations, Inc. | Patient information input interface for a therapy system |
US20090048503A1 (en) * | 2007-08-16 | 2009-02-19 | Cardiac Pacemakers, Inc. | Glycemic control monitoring using implantable medical device |
US8098201B2 (en) * | 2007-11-29 | 2012-01-17 | Electronics & Telecommunications Research Institute | Radio frequency identification tag and radio frequency identification tag antenna |
US8103241B2 (en) * | 2007-12-07 | 2012-01-24 | Roche Diagnostics Operations, Inc. | Method and system for wireless device communication |
US8138925B2 (en) * | 2008-01-15 | 2012-03-20 | Corning Cable Systems, Llc | RFID systems and methods for automatically detecting and/or directing the physical configuration of a complex system |
US8102021B2 (en) * | 2008-05-12 | 2012-01-24 | Sychip Inc. | RF devices |
US8117481B2 (en) * | 2008-06-06 | 2012-02-14 | Roche Diagnostics International Ag | Apparatus and method for processing wirelessly communicated information within an electronic device |
US8132037B2 (en) * | 2008-06-06 | 2012-03-06 | Roche Diagnostics International Ag | Apparatus and method for processing wirelessly communicated data and clock information within an electronic device |
US8131365B2 (en) * | 2008-07-09 | 2012-03-06 | Cardiac Pacemakers, Inc. | Event-based battery monitor for implantable devices |
US20100025238A1 (en) * | 2008-07-31 | 2010-02-04 | Medtronic Minimed, Inc. | Analyte sensor apparatuses having improved electrode configurations and methods for making and using them |
US8111042B2 (en) * | 2008-08-05 | 2012-02-07 | Broadcom Corporation | Integrated wireless resonant power charging and communication channel |
US8094009B2 (en) * | 2008-08-27 | 2012-01-10 | The Invention Science Fund I, Llc | Health-related signaling via wearable items |
US8102154B2 (en) * | 2008-09-04 | 2012-01-24 | Medtronic Minimed, Inc. | Energy source isolation and protection circuit for an electronic device |
US8098161B2 (en) * | 2008-12-01 | 2012-01-17 | Raytheon Company | Radio frequency identification inlay with improved readability |
US20110004085A1 (en) * | 2009-04-30 | 2011-01-06 | Dexcom, Inc. | Performance reports associated with continuous sensor data from multiple analysis time periods |
US8124452B2 (en) * | 2009-06-14 | 2012-02-28 | Terepac Corporation | Processes and structures for IC fabrication |
US20110004276A1 (en) * | 2009-07-02 | 2011-01-06 | Blair William A | Method and apparatus to detect transponder tagged objects and to communicate with medical telemetry devices, for example during medical procedures |
US8093991B2 (en) * | 2009-09-16 | 2012-01-10 | Greatbatch Ltd. | RFID detection and identification system for implantable medical devices |
US20110077469A1 (en) * | 2009-09-27 | 2011-03-31 | Blocker Richard A | Systems and methods for utilizing prolonged self monitoring in the analysis of chronic ailment treatments |
Non-Patent Citations (1)
Title |
---|
Wireless Access PCI Adapter (June 2002) * |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9561476B2 (en) | 2010-12-15 | 2017-02-07 | Praxair Technology, Inc. | Catalyst containing oxygen transport membrane |
WO2012138431A1 (en) | 2011-04-08 | 2012-10-11 | Praxair Technology, Inc. | Oxygen separation module and apparatus |
US9743224B2 (en) | 2011-04-08 | 2017-08-22 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US8435332B2 (en) | 2011-04-08 | 2013-05-07 | Praxair Technology, Inc. | Oxygen separation module and apparatus |
US8844007B2 (en) | 2011-04-08 | 2014-09-23 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US9028410B2 (en) | 2011-04-08 | 2015-05-12 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US9002390B2 (en) | 2011-04-08 | 2015-04-07 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US9439029B2 (en) | 2011-04-08 | 2016-09-06 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US9980223B2 (en) | 2011-09-23 | 2018-05-22 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US10187850B2 (en) | 2011-09-23 | 2019-01-22 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US9386522B2 (en) | 2011-09-23 | 2016-07-05 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US9730160B2 (en) | 2011-09-23 | 2017-08-08 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US9974018B2 (en) | 2011-09-23 | 2018-05-15 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US10111169B2 (en) | 2011-09-23 | 2018-10-23 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US9492784B2 (en) | 2011-12-15 | 2016-11-15 | Praxair Technology, Inc. | Composite oxygen transport membrane |
US9486735B2 (en) | 2011-12-15 | 2016-11-08 | Praxair Technology, Inc. | Composite oxygen transport membrane |
US8852409B2 (en) | 2012-09-19 | 2014-10-07 | Praxair Technology, Inc. | High purity ceramic oxygen generator |
US9969645B2 (en) | 2012-12-19 | 2018-05-15 | Praxair Technology, Inc. | Method for sealing an oxygen transport membrane assembly |
US9453644B2 (en) | 2012-12-28 | 2016-09-27 | Praxair Technology, Inc. | Oxygen transport membrane based advanced power cycle with low pressure synthesis gas slip stream |
US10005664B2 (en) | 2013-04-26 | 2018-06-26 | Praxair Technology, Inc. | Method and system for producing a synthesis gas using an oxygen transport membrane based reforming system with secondary reforming and auxiliary heat source |
US9611144B2 (en) | 2013-04-26 | 2017-04-04 | Praxair Technology, Inc. | Method and system for producing a synthesis gas in an oxygen transport membrane based reforming system that is free of metal dusting corrosion |
US9839899B2 (en) | 2013-04-26 | 2017-12-12 | Praxair Technology, Inc. | Method and system for producing methanol using an integrated oxygen transport membrane based reforming system |
US9938145B2 (en) | 2013-04-26 | 2018-04-10 | Praxair Technology, Inc. | Method and system for adjusting synthesis gas module in an oxygen transport membrane based reforming system |
US9486765B2 (en) | 2013-10-07 | 2016-11-08 | Praxair Technology, Inc. | Ceramic oxygen transport membrane array reactor and reforming method |
US9776153B2 (en) | 2013-10-07 | 2017-10-03 | Praxair Technology, Inc. | Ceramic oxygen transport membrane array reactor and reforming method |
US9452401B2 (en) | 2013-10-07 | 2016-09-27 | Praxair Technology, Inc. | Ceramic oxygen transport membrane array reactor and reforming method |
US9452388B2 (en) | 2013-10-08 | 2016-09-27 | Praxair Technology, Inc. | System and method for air temperature control in an oxygen transport membrane based reactor |
US9573094B2 (en) | 2013-10-08 | 2017-02-21 | Praxair Technology, Inc. | System and method for temperature control in an oxygen transport membrane based reactor |
US10226205B2 (en) | 2013-11-07 | 2019-03-12 | Dexcom, Inc. | Systems and methods for a continuous monitoring of analyte values |
US10335065B2 (en) | 2013-11-07 | 2019-07-02 | Dexcom, Inc. | Systems and methods for a continuous monitoring of analyte values |
US9974469B2 (en) | 2013-11-07 | 2018-05-22 | Dexcom, Inc. | Systems and methods for a continuous monitoring of analyte values |
US9999379B2 (en) | 2013-11-07 | 2018-06-19 | Dexcom, Inc. | Systems and methods for a continuous monitoring of analyte values |
US9974470B2 (en) | 2013-11-07 | 2018-05-22 | Dexcom, Inc. | Systems and methods for a continuous monitoring of analyte values |
US11730402B2 (en) | 2013-11-07 | 2023-08-22 | Dexcom, Inc. | Systems and methods for a continuous monitoring of analyte values |
US11399742B2 (en) | 2013-11-07 | 2022-08-02 | Dexcom, Inc. | Systems and methods for a continuous monitoring of analyte values |
US10165967B2 (en) | 2013-11-07 | 2019-01-01 | Dexcom, Inc. | Systems and methods for a continuous monitoring of analyte values |
US9901292B2 (en) | 2013-11-07 | 2018-02-27 | Dexcom, Inc. | Systems and methods for a continuous monitoring of analyte values |
US10863931B2 (en) | 2013-11-07 | 2020-12-15 | Dexcom, Inc. | Systems and methods for a continuous monitoring of analyte values |
US9556027B2 (en) | 2013-12-02 | 2017-01-31 | Praxair Technology, Inc. | Method and system for producing hydrogen using an oxygen transport membrane based reforming system with secondary reforming |
US9562472B2 (en) | 2014-02-12 | 2017-02-07 | Praxair Technology, Inc. | Oxygen transport membrane reactor based method and system for generating electric power |
US10822234B2 (en) | 2014-04-16 | 2020-11-03 | Praxair Technology, Inc. | Method and system for oxygen transport membrane enhanced integrated gasifier combined cycle (IGCC) |
US9789445B2 (en) | 2014-10-07 | 2017-10-17 | Praxair Technology, Inc. | Composite oxygen ion transport membrane |
US10441922B2 (en) | 2015-06-29 | 2019-10-15 | Praxair Technology, Inc. | Dual function composite oxygen transport membrane |
US10118823B2 (en) | 2015-12-15 | 2018-11-06 | Praxair Technology, Inc. | Method of thermally-stabilizing an oxygen transport membrane-based reforming system |
US9938146B2 (en) | 2015-12-28 | 2018-04-10 | Praxair Technology, Inc. | High aspect ratio catalytic reactor and catalyst inserts therefor |
US11052353B2 (en) | 2016-04-01 | 2021-07-06 | Praxair Technology, Inc. | Catalyst-containing oxygen transport membrane |
US11136238B2 (en) | 2018-05-21 | 2021-10-05 | Praxair Technology, Inc. | OTM syngas panel with gas heated reformer |
Also Published As
Publication number | Publication date |
---|---|
CN103251414B (en) | 2017-05-24 |
AU2008265542A1 (en) | 2008-12-24 |
US8617069B2 (en) | 2013-12-31 |
US20100076290A1 (en) | 2010-03-25 |
US20100076292A1 (en) | 2010-03-25 |
EP3473167A1 (en) | 2019-04-24 |
US20080319296A1 (en) | 2008-12-25 |
EP2166928A4 (en) | 2012-06-13 |
EP2166928B1 (en) | 2018-09-12 |
JP2017060795A (en) | 2017-03-30 |
CA2690870A1 (en) | 2008-12-24 |
EP2166928A1 (en) | 2010-03-31 |
WO2008157821A1 (en) | 2008-12-24 |
JP2015027523A (en) | 2015-02-12 |
JP2018118077A (en) | 2018-08-02 |
US20180271419A1 (en) | 2018-09-27 |
US20100076291A1 (en) | 2010-03-25 |
US20140107436A1 (en) | 2014-04-17 |
US20100076289A1 (en) | 2010-03-25 |
CA2690870C (en) | 2017-07-11 |
JP2010531169A (en) | 2010-09-24 |
CN101686804A (en) | 2010-03-31 |
CN101686804B (en) | 2013-05-08 |
CN103251414A (en) | 2013-08-21 |
AU2008265542B2 (en) | 2014-07-24 |
US20100076293A1 (en) | 2010-03-25 |
US20120053428A1 (en) | 2012-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11264133B2 (en) | Health management devices and methods | |
US20180271419A1 (en) | Health Monitor | |
AU2015275271B2 (en) | Health monitor | |
AU2013205279B2 (en) | Health monitor | |
AU2016256825B2 (en) | Health management devices and methods | |
AU2014250677B2 (en) | Health management devices and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |